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Summary 
Malaria prevalence estimates in Tanzania have been documented to decline in the recent 
years. National malaria data shows prevalence rates have been reduced by half from 18% in 
2008 to 9% in 2012 (THMIS 2009; 2013). This decline has been attributed to countrywide 
implementation of malaria interventions, including indoor residual spraying (IRS), mass 
distribution of insecticide treated nets (ITNs), long-lasting ITNs and the use of artemisinin 
combination therapy (ACT), which aim at transmission reduction. Monitoring and evaluation 
of malaria interventions requires accurate information on the remaining malaria burden in 
the community. The rapid diagnostic tests (RDTs) and light microscopy (LM) are the 
commonly used diagnostic tools for parasite detection and estimation of parasite prevalence 
rates in many resource-limited areas such as Tanzania. However, owing to the low detection 
limit of LM and RDTs of about 50-100 parasites/µL, their ability to capture low density 
infections is limited (Moody 2002; MalEra 2011). The use of molecular techniques to detect 
malaria parasites has been advocated to improve the accuracy of parasite prevalence 
estimates, especially in moderate to low endemic settings. This is because in areas of 
reduced endemicity, most infections occur at low densities and cannot be detected by the 
routine diagnostic tools. With a detection limit of about 0.034 parasites/µL of blood, 
molecular diagnostics are more reliable for parasite detection. In Tanzania, most of the 
parasites prevalence estimates have been performed by LM and RDTs, hence the most of the 
low density infections may remain undetected. Thus this thesis aimed to assess the 
usefulness of diagnostic methods for epidemiological studies by comparing the performance 
of routine and molecular diagnostics in parasite and gametocytes detection in community 
samples from Tanzania. Furthermore, the thesis investigated the occurrence of 
submicroscopic infections at different endemic sites in Tanzania.  
For the above aims we conducted community surveys at 6 sites in Tanzania between 2011 
and 2013. These sites were classified as low (Iringa), low urban (Dar-Es Salaam), moderate 
(coastal Tanga and Lugoba) and high (Rufiji and Morogoro) endemic sites according to 
district prevalence data recorded by the Tanzania HIV and Malaria indicator surveys of 2008 
(THMIS 2009): A total of 2046 volunteers of all ages with signed consent forms were 
recruited. Finger prick blood was drawn from all individuals for parasite detection by LM, 
vi 
RDT and 18S rRNA qPCR. Gametocytes were detected by both LM and qRT-PCR targeting 
transcripts of the gametocyte specific expressed marker pfs25.  
Generally, high P. falciparum Prevalence rates of 20% (416/2046; 95% CI 18-22%) by 18S 
rRNA qPCR, 17% (349/2046; 95% CI 15.4-18.7%) by RDT and 11% (229/2046; 95% CI 9.8-12%) 
by LM were recorded in Tanzania. A substantial variation in molecular prevalence rates from 
geographically different sites was observed varying from 50% in the high endemic site, Rufiji, 
to 0.6% in the low endemic site, Iringa. These observed differences highlight the 
heterogeneity of transmission patterns in Tanzania attributed to geographical differences. 
Molecular parasite diagnostics unveiled that more than a half, 60% (249/416) of P. 
falciparum positive samples carried submicroscopic infections. Submicroscopic carriage was 
prevalent in all endemic settings. However, very few positive samples from areas of low and 
moderate endemicity impede a firm conclusion on the association of endemicity and 
submicroscopic carriage to be drawn from our samples. Molecularly determined Gametocyte 
prevalence was 15.3% (312/2046; 95% CI 13.6-16.8%) when data from all sites were 
combined. On the other hand, LM detected only 0.88% (18/2046; 95% CI 0.47-1.2%) of all 
samples implying only about 5% of the total gametocytes detected by molecular assay. 
In conclusion molecular parasite detection revealed high parasite prevalence in Tanzania, 
such precise point prevalence molecular data obtained from community sampling may 
provide a more reliable basis of planning new tools of interventions or monitoring and 
evaluating the performance of existing tools in the country. Furthermore, high 
submicroscopic carriage of >50% in Tanzania, particularly in adults is key indicator of 
transmission potential of asymptomatic infections in Tanzania community and thus it is 
relevant for control strategies to focus on identifying submicroscopic carriers in order to 
successfully interrupt transmission. 
vii 
Acknowledgements 
I am ever grateful to the Almighty God for his constant rains of grace and blessings. 
I am highly indebted to my financial sponsors the Dar Es Salaam University College of 
Education (DUCE) through the capacity building project-by the Science and technology  and 
Higher Education project (STHEP) for sponsoring the first three years of my PhD, and the 
Swiss Tropical and Public Health Institute (SwissTPH) through which I was able to obtain 
stipend for the last year of my PhD studies from the Basel stipend commission and most 
importantly, for funding for laboratory analysis and field work during the entire period of my 
PhD. I remain grateful the Ifakara Health Institute (IHI) under the directorship of Dr. Salim 
Abdulla for providing a platform through which, I conducted my field work in Tanzania.  
I recognize and appreciate the invaluable support from my supervisor Dr Ingrid Felger who 
has in special way instil in me her scientific passion and immense experiences, which I will 
cherish throughout my scientific career. I also thank her for being my support system during 
the entire PhD. I also thank, Dr. Steffan Borrmann from the University of Tübingen for being 
my Co-referee and taking his time to provide useful inputs in my study.  
I am profoundly thankful to Professor Marcel Tanner for his patronage and his invaluable 
support in my PhD especially due to facilitating my fieldwork in Tanzania. “ninakushukuru 
sana”. I would like to thank Professor Hans-Peter Beck for his support during my PhD. 
Moreover, I would like to thank his family for the lovely and memorable Christmas parties 
which I always look forward to every time I am in Basel in December.  
I wish to thank the Molecular Parasitology (MolPar) group for their support and 
collaboration particularly previous members such as Dania Müller, Sarah Javati for their 
laboratory technical assistance. I enjoyed the company of my colleagues Rahel Wampler and 
Natalie Hoffmann for their constant encouragement in both academics and social life even 
more during the write up time. I am indebted to Françoise Brand for constantly disturbing 
her with my orders, Sebastian Rusch for his scientific advice, Alex Oberli, Tereza Rezende, 
Beatrice Schibler, Musa Maganga and Pricscilla Rodrigues, Serej Ley, Christian Koepfli 
viii 
Christian, Maira Bholla and Pax Masimba, Daniel Nyogea for the time we shared. I am 
grateful to Amanda Ross for statistical data analysis during my PhD. I must admit she was 
very patient and provided the best advice when needed. I also acknowledge the statistical 
assistance I received from my colleague Ali M. Ali. Furthermore, I would like to thank my 
fellow students with who I shared my Basel experience with them in the course of my 
studies there are too many to mention but I extend my sincere appreciation to all, Special 
thanks to my friend Jennie Jaribu for taking her time to  proof read my work. I am very 
thankful to Christine Mensch and Doris Stamm their colleagues in the training office for 
providing assistance with academic and non-academic issues. Thanks to Margrit Slaoui, 
Christine Walliser, Zsuzsanna Györffy, Maya Zwygart and Dagmar Batra for assisting with 
administrative issues and the IT team for always being available to provide technical 
assistance. 
I am thankful to the staff of Ifakara Health institute (IHI) - Bagamoyo whom I worked with 
during my PhD. Special thanks to Dr. Seif Shekalaghe and Michael Mihayo for their 
supervision during my fieldwork in Tanzania. I would like to thank all the laboratory 
technicians, drivers and fieldworkers from IHI.I also value the participation of all individuals 
who volunteered to be screen for in our surveys in Dar-es Salaam, Coastal Rufiji, Coastal 
Bagamoyo, Tanga, Morogoro and Iringa. I also thank the District Medical Officers (DMOs) of 
all the districts, local government leaders to hamlet leaders for taking their time to not only 
by allowing us to work in their respective communities, but also to mobilise people and 
personally be part of the cohort.   
I acknowledge the encouragement from my friend and husband Ludovic Walter Toto Tarimo, 
to whom this thesis is dedicated. “Nakushukuru kwa upendo wako wa dhati.” I extend my 
sincere gratitude to my family, my mama Esther for her love and constant encouragement 
my sister and confidante Catherine and brother in law Masunga Matondo with their 
beautiful daughter and my best friend (BFF) Ablah Nkwaya Masunga Matondo, my brother 
Walafried James Junior, for their prayers and constant encouragement “ Nawapenda sana 
watu wangu wa nguvu.”.  
ix 
List of abbreviations 
18S SSU rRNA 18S small subunit ribosomal RNA 
DNA   Deoxyribonucleic Acid 
LAMP  loop-mediated isothermal amplification 
LM light microscopy 
LOD  limit of detection 
MDA  mass drug administration 
MGB  minor groove binder 
mRDTs  malaria Rapid Diagnostic Tests 
MSAT  mass screening and treatment 
Msp merozoite surface protein 
PCR Polymerase chain reaction 
PNG  Papua New Guinea 
qPCR  Quantitative polymerase chain reaction  
qRT-PCR  Quantitative reverse transcriptase polymerase chain reaction 
QT-NASBA Quantitative Nucleic Acid sequence Based Amplification 
RNA  Ribonucleic Acid 
SwissTPH Swiss Tropical and Public Health institute 
TARE-2  telomere associated repetitive element 2 
TMHIS  Tanzania Malaria and HIV indicator Survey 
TZ Tanzania 
varATS  var gene acidic terminal sequence 
WBC  White Blood Cells 
WHO  World Health Organization 
MOHSW Ministry of health and social welfare 
 1 
Introduction 
Global malaria burden 
Malaria is one of the major public health concerns due to the high morbidity and mortality 
associated with the disease. A total 104 countries globally are considered to be malaria 
endemic, leaving an estimated 3.4 billion people at risk of contracting the disease (Butler 
2013). More than 207 million cases of malaria were recorded globally in 2012 (uncertainty 
range 135–287 million) and 627 000 deaths, 80% these cases and 90% deaths (occurred in 
Sub Saharan Africa and the highest mortality (77%) occurred among children less than 5 
years old (WHO 2013).  
Malaria is a protozoan infection caused by parasites of the genus Plasmodium of the phylum 
Apicomplexa. Five Plasmodium species are known to infect human namely Plasmodium 
vivax, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale and most recently 
the Plasmodium knowlesii which was identified to infect humans (Singh et al. 2004; Antinori 
et al. 2013). P. falciparum and P. vivax are the most important species. P. falciparum is the 
most virulent due to its ability to attain high levels of parasitemia during in the life cycle. P. 
falciparum is responsible for most (91%) of the morbidity and mortality, due to its 
complications arising from parasite sequestrations in deep tissues.  
Malaria poses a huge burden to humanity not only due to the high morbidity and mortality 
rates but also to huge economic burden. This ranges from poor attendance of school age 
children, reduction of work force and productivity by attending the sick, to cost of treatment 
of the disease. Globally, huge economic burden through the control and treatment of 
malaria has been documented (WHO 2103). For instance, up to 1.84 billion US dollars have 
been distributed to fight malaria in endemic countries of SSA alone in the last year (WHO 
2013). 
2 
Figure 1: World map showing the spatial distribution of P. falciparum malaria endemicity in 
2010 (blue indicates PfPR = 0% and red is PfPR = 70% (Gething et al. 2011). 
http://www.map.ox.ac.uk/browseresources/endemicity/Pf_mean/world 
Malaria varies widely in epidemiology and clinical manifestation in different parts of the 
world. This variability depends on the species of malaria parasites that occur in a given area, 
the susceptibility to commonly used or available antimalarial drugs, the distribution and 
efficiency of mosquito vectors, climate and other environmental conditions, the behaviour 
and level of acquired immunity of the exposed human populations (Bloland 2001) and most 
importantly is the malaria control strategies in a given area. 
Malaria Transmission-P. falciparum life cycle and gametocyte development 
Malaria infection begins when a malaria-infected female mosquito genus Anopheles S.L. 
inoculates sporozoites into the bloodstream of a human host during a blood meal. 
Sporozoites migrate and infect liver cells and mature into schizonts. This cycle is known as 
the exo-erythrocytic schizogony cycle. Schizonts then rupture and release merozoites into 
the blood. The merozoites infect red blood cells where they undergo asexual multiplication 
resulting in the ring stage, trophozoites and finally produce schizonts which on rupture 
release more merozoites that continue to infect other red blood cells. This erythrocytic 
schizogony cycle occurs in the first 48 hours. On average, parasitemia of 50,000-500,000 per 
mm3 blood and maximum parasitemia of 2.5 million per mm3 blood can be produced; these 
blood stage parasites are responsible for clinical manifestations of the disease.   
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A small proportion about 1% of the asexual parasites differentiates into sexual stages 
(gametocytes) by a process called gametocytogenesis (Taylor and Read 1997). The 
mechanism that triggers this route is still debatable and is not limited to parasite intrinsic 
factors, chemical stress induced by the use of antimalarial drugs, fever and hematological 
disruptions (Drakeley et al. 2006; Ouédraogo et al. 2010). Commitment to the sexual 
pathway is believed to occur prior to the formation of the Schizont; descendants of a 
committed Schizont will develop into gametocytes and gametocytes produced from one 
sexually committed Schizont are of the same sex. P. falciparum gametocytes undergo five 
developmental stages of maturation. While stage I-IV gametocytes remain sequestered in 
deep tissues, only stage V is found in circulation. The mature stage V is the infectious stage 
(Babicker and Schneider 2008). Earlier stages I-II resembles the asexual stages, stage III-V 
shows distinct morphological changes and female and male gametocytes can easily be 
distinguished. During gametocytogenesis, molecular and biochemical levels are altered on 
protein level and several gametocytes specific mRNA are transcribed to enable the survival 
of gametocytes in once in the mosquitoes midgut. These transcribed gametocyte-specific 
mRNA include the pfs16, pfg37, pfs25 and pfs48/45 (Talman et al. 2004; Young et al. 2005; 
Drakeley et al. 2006 and Alano 2007).  
Gametocytes are responsible for propagating transmission when ingested by an Anopheles 
mosquito during a blood meal. Male and female gametocytes develop into gametes, fuse 
and generate zygotes in mosquito's midgut. The motile zygotes (ookinetes) migrate to the 
midgut wall of the mosquito where they develop into oocysts. These grow, rupture, and 
release sporozoites which make their way to the mosquito's salivary glands. Inoculation of 
the sporozoites into a new human host perpetuates the malaria life cycle. Gametocytes are 
important for perpetuating the transmission cycle. Therefore identifying and targeting 
gametocytes is of empirical importance for successful malaria control and elimination efforts 
(Babiker et al. 2008, Ouédraogo et al. 2009). Gametocytes naturally occur in lower densities 
under the limit of light microscopy (LM). The limit of detection of LM is roughly, 50 
gametocytes / µL blood (Moody et al. 2002) and is most likely not to detect low gametocyte 
densities. Prevailing submicroscopic gametocytemia may contribute to transmission since 
they are known to also infect mosquitoes (Schneider et al. 2007). Other studies showed the 
submicroscopic gametocytemia showed a more than 10-fold lower infection rates in 
mosquito feeding experiments compared to gametocyte positive blood samples by LM and 
4 
thus able to propagate transmission (Coleman et al. 2004; Lin et al. 2014). Gametocyte 
identification and quantification in Tanzania in the past years was performed by light 
microscopy, a less sensitive tool compared to molecular detection (Drakeley 2000). Currently 
more sensitive assays have been developed for gametocyte detection by QT-NASBA and 
qRT-PCR which are able to detect less than 1 gametocyte/µL of blood (Babicker et al. 2008, 
Schneider et al. 2004). In recent years, a study was conducted in North Tanzania to assess 
gametocyte prevalence by molecular techniques (Shekalaghe et al. 2007); in this study, low 
gametocyte prevalence was in line with the low endemicity. Thus this thesis embarked to 
determine molecular –based gametocyte prevalence in crossectional survey in 6 regions of 
different endemic settings in Tanzania.  
Malaria Burden in Tanzania 
Malaria is transmitted by female mosquitoes of the genus Anopheles. In Africa the Anopheles 
gambiae S.L is the most important vector (WHO 2006; Hay et al. 2009). A. Arabiensis and A. 
fenestus are becoming increasingly efficient in various parts of Tanzania (Killeen at el. 2006; 
Lwetoijera et al. 2014). P. falciparum is the most prevalent species in Tanzania accounting to 
98% of malaria cases in the country the rest of malaria burden is due to P. malariae and P. 
ovale species which are less than 0.5% of the cases (Tarimo et al. 2001; Mboera et al. 2008) 
and are hardly ever documented in most cases.  
More than 90% of the 44 million people are at risk of contracting malaria in Tanzania. It is 
still the major cause of morbidity and mortality among outpatient and inpatient admissions 
especially children under five years and pregnant women (MOHSW 2010). Malaria 
transmission is reported in many parts of the country throughout the year although it is 
more frequent during and after the rainy season (April to June) (Figure 2).  
A review of entomological inoculation rate (EIR) in Africa showed Tanzania had a mean EIR of 
367 ranging (94-667) (Hay et al. 2000). Individual studies in various parts of Tanzania 
recorded, EIR ranges of 3-4 infectious bites per year in a low endemic area of the Usambara 
highlands (Oesterholt et al. 2006), a range of 29-78 in Ifakara (Drakeley et al. 2003; Russell et 
al. 2010). Moreover, a review of EIR recorded mean EIR of 285 in Tanzania as among the 
highest in sub-Saharan Africa (Kelly-Hope and Mackenzie 2009). These high EIR indicate high 
malaria burden in various areas of Tanzania.   
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Tanzania records a decline of malaria prevalence rates through national malaria indicator 
surveys conducted every four years. For instance, the national average malaria prevalence 
rate declined from 21% in 2006 to 18% by 2008. A further 50% decline was observed in the 
latest surveys to a national average prevalence of 9% in 2012 (MOHSW 2006; THMIS 2009; 
2013). This decline in malaria burden is attributed to countrywide malaria interventions 
including insecticide residual spraying, mass distribution of both, insecticide treated nets 
(ITNs) and long lasting ITNs. In addition, the change in malaria policy to introduce the 
Artemisinin-based Combination Therapy (ACTs) as the first line drug in the treatment of 
malaria occurred in 2006. ACTs affect the asexual stage parasites and young gametocytes 
and hence contribute towards transmission reduction (Bousema et al. 2010; Sawa et al. 
2013). The data from national malaria indicator survey show huge differences in malaria 
endemicity of about 80-fold differences ranging from 0.4% to 32% within regions of Tanzania 
(Figure 2). The different endemic settings are mainly due to geographical and environmental 
conditions. Regions with high altitudes and cooler temperatures (Iringa, Njombe and 
Mbeya), semi-arid areas such as (Singida and Dodoma) which do not favour the survival of 
the mosquitoes have lower malaria prevalence rates compared to warmer areas (Lindi, 
Mtwara and Mara) (Figure 2).  
Malaria Prevalence in Tanzania is mostly measured by classical light microscopy (LM) 
(Drakeley et al. 2000; THMIS 2008; Mmbando et al. 2010; Ishengoma et al. 2013). Recently 
LM has been complemented by malaria rapid diagnostic tests (mRDTs) (THMIS 2013). RDTs 
are currently being scale-up for parasite confirmation in all health centres. However the 
supply chain of RDT to peripheral health facilities is still a challenge.  
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Figure 2: Malaria prevalence rates in children under five years in Tanzania national malaria 
indicator survey of 2011/12 (THMIS 2012) 
Malaria Diagnosis and challenges 
Early diagnosis and prompt treatment are essential for malaria management. LM is the 
standard diagnostic method of choice in many resource constrained areas in Sub-Saharan 
Africa. In the absence of such classical technique, diagnosis based on signs and symptoms of 
malaria is performed. The diagnosis based on signs and symptoms of malaria is presumptive 
and recommendation of parasite confirmation by laboratory diagnosis is advocated 
(Penhabel et al, 2005; MalEra 2011, WHO 2013).  
LM is limited by a low detection the limit of detection (LOD) of LM is estimated at 50-100 
parasite /µl blood hence low density infections are likely not detected (MalEra 2011). In fact 
the sensitivity of any diagnostic method is dependent on the volume of blood and 
parasitemia (Wampfler et al. 2013). LM uses a volume of blood of about 0.025 to 0.2 µl 
(Okell et al. 2009) which limits it`s sensitivity. Several other shortcomings of LM have been 
documented including the incorrect interpretation of blood films (Kahama - Maro et al. 
2011), lack of expertise and inadequate quality control (Molyneux et al, 1993; WHO 1996).  
7 
In recent years, rapid diagnostic tests (RDT), which target specific Plasmodium antigens 
mainly the histidine rich proteins (HRP), Plasmodium lactate dehydrogenase (pLDH) and 
Aldolase enzyme in blood of infected humans, have been introduced. The RDTs are easier to 
use and their sensitivity and specificity in field settings have been established in many 
studies (Craig et al, 1997; Moody et al, 2002; Mueller et al, 2006). Similar to LM, RDT attains 
a limit of detection (LOD) of 50-100 parasites/µL blood (WHO 1996; Moody et al. 2000). The 
RDTs have been integrated in many health systems and used for malaria parasite detection 
at health care facilities for parasite confirmation prior to malaria treatment as 
recommended by WHO (WHO 2008, WHO 2013). Currently, RDTs are widely used in 
community surveys; however, due to their low LOD their performance in low endemic field 
settings is debatable (WHO 2000). Shortcoming of RDTs lies in its inability to quantify the 
parasite load, the ability of pLDH based- RDT to detect gametocytes confound treatment 
outcomes (Mueller et al, 2006) and generation of false positives due to residual HRP antigen 
even after parasite clearance (Bell et al. 2005; Batwala et al. 2010).  
Low sensitivity both LM and RDTs can underestimate the malaria burden especially in areas 
of declining transmission. In order to precisely estimate malaria burden in Tanzania, this PhD 
thesis embarked on using highly sensitive molecular assays for parasite detection in order to 
obtain more precise estimates of malaria burden in Tanzania. 
Molecular detection of P. falciparum parasite infections and gametocytes 
Molecular assays for parasite and gametocyte detection have been introduced to several 
laboratories in endemic countries and are increasingly applied in interventions and 
epidemiological field surveys (Andrade et al. 2010; Kamau et al. 2011; Mosha et al. 2013).  
These include the DNA based quantitative polymerase chain reaction (qPCR) and the RNA 
based quantitative reverse transcriptase PCR (qRT-PCR). RT-PCR involves the reverse 
transcription of RNA into cDNA and further amplifies the cDNA. The qRT-PCR uses Taqman® 
or SYBR® chemistry. The assay uses two primers and a minor grove binder (mgb) labeled 
probe. The reverse transcription makes use of the reverse primer, further a combination of 
both reverse and forward primers are used in the proceeding cDNA amplification. The 
reaction is prone to gDNA contamination hence it requires that the RNA is treated by and 
RNase free DNase before amplification. The qPCR and qRT-PCR are sensitive assays with 
ability to detect between 0.1 -0.034parasites/μL blood (Babicker et al. 1999; Abel-Wahab et 
al. 2002; Babicker et al. 2008; Schneider et al. 2007; Rosanas-Urgell et al. 2010; Bousema et 
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al. 2011; Kamau et al 2011; Wampfler et al. 2013 and Hofmann et al. 2014). The high 
sensitivity of molecular assays makes these assays more reliable for parasite detection 
(Maeno et al. 2008).  
Other molecular assays include the quantitative nucleic acid sequenced based amplification 
(QT-NASBA) is the most sensitive assay in RNA detection and amplification compared to the 
qRT-PCR assay (Schneider et al. 2004). The QT-NASBA is an isothermal process at 41°C 
allowing a specific amplification RNA only even in the presence of DNA double strand which 
does not denature at 41°C. The amplification of single–strand sequences uses three enzymes 
namely the virus based AMV- Reverse transcriptase, RNaseH and T7 polymerase. One of the 
two primers carries the T7 promoter sequence. Using fluorescent probe the amplification 
data is collected in real time. The LOD of QT-NASBA is 0.02parasites/μL blood (Schneider et 
al. 2004; Mens et al. 2006) and its advantage over qRT-PCR is that it is affected by genomic 
DNA (gDNA) contamination in RNA. 
Recently, the Loop-isothermal mediated DNA amplification (LAMP) molecular assay was 
introduced in the market (www.finddiagnostics.org). It is increasingly advocated to be used 
as point of care molecular malaria diagnostic tool. The performance of LAMP technique has 
already been tested in field surveys such as in Zanzibar-Tanzania and has shown to perform 
better than LM in the field (Aydin-Schmidt et al. 2014). LAMP has a detection limit of > 
5parasites/μL blood. To increase sensitivity LAMP uses four primers; two outer and inner 
forward primers and two outer reverse primers. LAMP is isothermal operating at 65°C and 
has a shorter turn over time of about 15- 20 minutes. However, its inability to quantify 
parasites giving results by turbidity or fluorescent is a major setback of LAMP technique. 
Furthermore, the sensitivity of LAMP is the field in areas with low parasitemia is still 
debatable.  
In light of the merits of molecular diagnostic tools, our study was designed to compare P. 
falciparum parasite and gametocyte carriage prevalence rates determined by LM and RDT 
with molecular tools in community samples in Tanzania. The higher sensitivity of PCR-based 
techniques can be used to assess the extent of underestimation of parasite prevalence rates.  
9 
Context of the Study 
This study was conducted within the framework of two projects within the Ifakara Health 
Institute (IHI) (i) Artemether Lumefantrine In Vulnerable patients: Exploring health impacts 
(ALIVE) that have been going on for about 8 years in Kilombero and Ulanga (K-U) Districts in 
Morogoro and (ii) Sentinel Panel District (SPD) initiated in 2009 in 27 districts in Tanzania. 
This research was designed to answer very important questions that arose in the course of 
these on-going projects. Protocols amendments to enable blood sampling for molecular 
diagnosis within established in the projects were reviewed and approved by the Ifakara 
Health institute -ethical review board. 
ALIVE project 
The Ifakara Health Demographic Surveillance system (IHDSS) covers a rural population of 
about 84,000 people in 22,000 scattered rural households (Figure 3). Household surveys are 
conducted every 4 months and data on pregnancies, births, deaths, in and out migrations 
are recorded. The ALIVE project had over 800 households under surveillance within the 
IHDSS from K-U districts. Primary aim of the ALIVE project was to assess the impact on all-
cause mortality in infants/children below 5 years, 
Malaria prevalence in the K-U district was 25% during the first round of ALIVE study in 2005. 
By 2006 malaria prevalence assessed by LM had declined to 13.4%. This decline coincided 
with the national change on malaria policy which introduced Antimalarial combination 
therapy (ACTs) as first line drugs for malaria treatment. In the following years of survey RDTs 
were used alongside LM in the surveys. Malaria prevalence in 2007 was 11.1% by LM and 
12% by RDT. A further decline to prevalence rates of 4.7% by LM and 3.9% by RDT in 2010 
was observed. This decline of transmission was partly attributed to the use of ACT – 
Artemisin based antimalarial which has some gametocidal effects (Kabanywanyi PhD thesis 
2012). However, in the entire 7 years of surveys (2004-2010) in the K-U districts molecular 
detection of parasitemia was not applied alongside the classical LM and RDT. 
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Figure 3: Map of Tanzania showing the K-U districts and the IHDSS shown in red. 
Courtesy of the Ifakara Health Demographic Surveillance System www.ihi.eprints.org 
Sentinel District Panel 
The SPD initiative was newly established in 2009 by the IHI in collaboration with National 
Bureau of Statics (NBS), National Institute of Medical Research (NIMR) and Ministry Of 
Health and Social Welfare (MoHSW). The over-arching goal of SPD is to provide a sustainable 
source of reliable, national data to meet the monitoring needs of program managers, policy-
makers and funding partners. In addition, it offers a national, integrated platform for impact 
evaluation and research. The panel comprises 23 districts (Figure 4), sampled to represent 
Tanzania Mainland, plus the 4 districts (Kilombero, Ulanga, Rufiji, Kigoma Urban), where IHI 
already operates demographic surveillance (Figure 3). 
The SPD project covers a population of around 800,000 people in 167,000 households 
(Figure 4). The study collects birth and death registers and verbal autopsy by questionnaires 
in order to produce annual estimates of age- and cause-specific mortality. Field work of this 
PhD project was carried out in selected 6 SPD districts with different malaria endemicity 
(Table 1).  
11 
Figure 4: The Sentinel Panel Districts of– Tanzania. Courtesy of Ifakara Health Institute (IHI) 
spotlight issue No. 8.  
12 
Figure 5: Map of Tanzania showing 6 selected regions within the SPD for this study with 
sample size from each region. Grey depicts low, Yellow -moderate and Orange depicts high 
endemic sites. 
Table 1: The 6 selected regions from the SPD categorized into settings of different malaria 
endemicity using previously available prevalence data from national malaria indicator 










1 Dar es salaam 1.2% 2013 440 
Low 2 Iringa 3% 2013 329 
3 Coastal Lugoba 10% 2013 316 
Medium 4 Tanga 14% 2013 235 
5 Morogoro 16% 2011 330 
High 6 Coastal Rufiji 21% 2013 500 
13 
Study Goal, Aims and Objectives 
I. The main goal of this thesis was to evaluate the extent of underestimation of P. 
falciparum infection and gametocyte prevalence by the routine diagnostic tools in 
Tanzania (RDT and LM). For this evaluation molecular diagnostic assays were used 
as a gold standard.  
In the course of optimizing parasite diagnostics  we aimed at exploring parasite 
infections of very low density that are missed by most techniques, even by PCR. A 
novel approach to increase test sensitivity even beyond classical PCR was 
validated in a subset of the field samples collected. Parasite positivity results from 
two new highly sensitive P. falciparum parasite detection assays were compared 
to both, classical and standard molecular diagnosis.  
II. Secondary objective was to identify how the diagnostic methods perform in
various endemic settings in Tanzania. For this, parasites were detected in 5
selected regions: Dar es Salaam (Urban), Iringa (Low) Coastal Bagamoyo and
Tanga (Moderate), Coastal Rufiji (High).
III. A further objective was to evaluate various methods of RNA sampling strategies
for gametocyte detection. For this, samples from a pilot project cross sectional
survey of mostly asymptomatic children (5-9) years in Papua New Guinea (PNG)
were used.
The relevance and impact of this work consists in the provision of accurate prevalence 
estimates for evaluating and improving existing malaria interventions and to plan for new 
intervention strategies in the ongoing elimination attempts in Tanzania.  
14 
Research questions and rationale for specific research objectives 
I. Assessment of P. falciparum parasite prevalence and density by classical and 
molecular diagnosis 
Qn: How useful are classical tools for malaria diagnosis? 
Most epidemiological surveys in Tanzania are performed by routine diagnostic tools LM and 
RDT, owing to their easy use and cheap costs. Prevalence data from RDT and LM will enable 
comparison with previous available data for instance, the national malaria indicator surveys 
and other epidemiological studies.  We aimed to describe the malaria burden in Tanzania in 
2012-13, a total of 2893 samples were collected in all 6 regions in Tanzania in the course of 
this study. Routine diagnostics was applied establish parasite prevalence rates in these 
regions of different malaria endemicity. LM provides asexual parasite densities which can 
serve to describe the age trends in parasite burden. 
Qn: What are advantages offered by molecular diagnosis? 
It is well established that routine diagnostic tools tend to underestimate the true prevalence 
rates, due to their inability to detect lower parasitemia. Lower parasitemia is characteristic 
in populations with acquired immunity as a result of frequent exposure to infection in 
endemic areas. Moreover, in areas of with interrupted transmission and declining 
endemicity parasitemia tends to be maintained at lower levels. Such low parasitemia remain 
undetected by LM and RDT.  Therefore, we aimed to quantify the extent of underestimation 
of parasite prevalence, by determining P. falciparum parasite prevalence by molecular–
based quantitative polymerase reaction (qPCR) targeting the P. falciparum S- type 18S rRNA 
gene. 
Qn: Why is sensitive detection of gametocytes important? 
Gametocytes usually persist in low densities to ensure transmission success. These low 
densities are likely to be missed by classical LM. Moreover studies have shown that even LM 
negative individuals are able to infect mosquitoes. Therefore, in order accurately estimate 
the gametocytemic proportions of individuals in the community all samples were further 
analyzed for gametocyte by LM and molecular detection targeting gametocytes - specific 
marker pfs25. Our aim was to establish and compare gametocyte prevalence rates in 
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Tanzania. Moreover, the improved gametocyte prevalence rates by molecular diagnosis 
enabled to us to identify the proportion of submicroscopic gametocytemia in different 
endemic settings in Tanzania. The submicroscopic gametocytemia may substantially 
contribute the infective reservoir.  
 
Qn: can we further improve malaria diagnosis? 
Moreover, in the course of the PhD thesis development, novel ultra-sensitive assays for P. 
falciparum parasite detection were developed targeting high-copy subtelomeric sequences 
of P. falciparum the Telomere Associated Repeat Element 2 (TARE-2), and the var gene 
Acidic Terminal Sequence (varATS). These ultra-sensitive assays had a LOD 10-times higher 
than the 18s rRNA gene qPCR assay we routinely used in the laboratory. We compared these 
assays to a standard P. falciparum detection qPCR amplifying the S18S rRNA gene. We aimed 
to increase diagnostic sensitivity in field samples. 
  
II. Comparison of malaria endemic sites in Tanzania 
Qn: Does endemicity impact malaria prevalence rates? 
Parasite prevalence and density are known to increase with transmission intensity. Imperfect 
diagnostic tools (LM) are likely not to detect lower parasitemia resulting in large proportion 
of submicroscopic infections in low endemic settings. Using highly sensitive molecular tools  
(quantitative polymerase chain reaction (qRT-PCR) & quantitative PCR (qPCR) and light 
microscopy (LM), we aimed to establish the proportion of submicroscopic infections 
(parasitemia and gametocytemia) in areas of varying endemic settings:  Dar Es Salaam 
(Urban), Iringa (Low) Coastal Bagamoyo and Tanga (Moderate), Coastal Rufiji and Morogoro 
(High) in Tanzania. 
 
 
III. Molecular detection of  gametocytes in community samples 
Qn: Do RNA sampling methods and storage conditions affect gametocyte detection?  
RNA sampling, extraction and storage is difficult because RNA is unstable and easily 
degraded by RNases resulting into low integrity RNA. In a pilot project, we compared 
different blood sampling methods and storage conditions of whole blood for later 
gametocyte detection by qRT-PCR.  Blood samples from a cross sectional survey of children 
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This thesis consists of 6 chapters.  
Chapter 2 discusses the comparison the various P. falciparum parasites and gametocytes 
detection in community samples in the Kilombero and Ulanga districts in Tanzania.  
Chapter 3 focuses on the prevalence of submicroscopic infections in a community surveys in 
5 regions of varying malaria endemicity in Tanzania. In light of increasing sensitivity in 
parasite detection  
Chapter 4 discusses on the ultrasensitive P. falciparum parasites from field samples. 
 Chapter 5 introduces the various strategies for RNA sampling methods and gametocyte 
detection in field samples.  
Chapter 6: Summarizes, discusses, and concludes the study presented in the thesis and 
suggests directions for future work.  
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The use of molecular techniques to detect malaria parasites has been advocated to improve 
the accuracy of parasite prevalence estimates, especially in moderate to low endemic 
settings. Molecular work is time-consuming and costly, thus the effective gains of this 
technique need to be carefully evaluated. Light microscopy (LM) and malaria rapid 
diagnostic tests (mRDT) are commonly used to detect malaria infection in resource 
constrained areas, but their limited sensitivity results in underestimation of the proportion 
of people infected with Plasmodium falciparum. We aimed to evaluate the extent of missed 
infections via a community survey in Tanzania, using polymerase chain reaction (PCR) to 
detect P. falciparum parasites and gametocytes. 
 
Methods 
We enrolled 330 individuals of all ages from the Kilombero and Ulanga districts (Tanzania) in 
a cross-sectional survey. Finger prick blood samples were collected for parasite detection by 
mRDT, LM and molecular diagnosis using quantitative 18S rRNA PCR and msp2 nPCR. 
Gametocytes were detected by LM and molecularly by amplifying transcripts of the 
gametocyte-specific marker pfs25.  
 
Results 
Results from all three diagnostic methods were available for a subset of 226 individuals. 
Prevalence of P. falciparum was 38% (86/226; 95% CI 31.9 - 44.4%) by qPCR, 15.9% (36/226; 
95% CI 11.1 – 20.7%) by mRDT and 5.8% (13/226; 95% CI 2.69- 8.81%) by LM. qPCR was 
positive for 72% (26/36) of the mRDT-positive samples. Gametocyte prevalence was 10.6% 
(24/226) by pfs25-qRT-PCR and 1.2% by LM.  
 
Conclusions 
LM showed the poorest performance, detecting only 15% of P. falciparum parasite carriers 
identified by PCR. Thus, LM is not a sufficiently accurate technique from which to inform 
policies and malaria control or elimination efforts. The diagnostic performance of mRDT was 
superior to that of LM in our survey. However, it is also insufficient when precise prevalence 
data are needed for monitoring intervention success or for determining point prevalence 
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rates in countrywide surveillance. Detection of gametocytes by PCR was 10 times more 
sensitive than by LM. These findings support the need for molecular techniques to 
accurately estimate the human infectious reservoir and hence the transmission potential in a 
population.  
  




Records of Tanzanian malaria indicator surveys show a general decline in malaria prevalence 
among children under 5 years, from 18% in 2008 to 9% in 2012 [1, 2]. This decline has been 
attributed to countrywide implementation of malaria interventions, including indoor 
residual spraying (IRS), mass distribution of insecticide treated nets (ITNs), long-lasting ITNs 
and the use of artemisinin combination therapy (ACT), which effectively kills both asexual 
blood stage parasites and immature gametocytes, thereby reducing transmission [3, 4].  
 
Early diagnosis and prompt treatment are essential for appropriate malaria management. 
The World Health Organization (WHO) recommends laboratory confirmation of malaria 
before treatment, either by microscopy or by immuno-chromatographic malaria rapid 
diagnostic test (mRDT) [5]. Accurate malaria diagnosis is not only important for case 
management but also for estimating parasite prevalence in community surveys. Light 
microscopy (LM) is a standard tool for malaria diagnosis in resource constrained areas such 
as Tanzania. However, its performance is limited due to a lack of expertise and its low limit 
of detection (LOD) of about 50 parasites/µL of blood, which does not allow detection of low 
parasite densities [6, 7]. Although expert microscopists can attain a LOD of around 20 
parasites/µL of blood [8], such high sensitivity is hardly ever achieved in field settings. 
mRDTs are easier to use and their sensitivity is comparable to that of LM in the field [9, 10]. 
Currently, mRDTs are widely used in community surveys but, owing to a low LOD, their 
performance in low endemic field settings is limited [11]. 
 
Recently, molecular tools for parasite detection have been introduced in many laboratories 
in endemic countries and are increasingly applied in monitoring interventions and 
epidemiological field surveys [12, 13, 14, 15]. These molecular assays have LODs between 
0.34-0.002 parasites/µL of blood, which results in more sensitive and reliable parasite 
detection. Due to their higher sensitivity, PCR-based techniques can be used to assess the 
extent to which parasite prevalence has been underestimated in endemic settings such as 
Tanzania, where malaria prevalence is routinely measured by classical LM [1, 16, 17, 18], 
complemented in recent years by mRDTs [2]. So far, only a few studies in Tanzania have 
applied molecular techniques for blood stage parasite detection and even fewer for 
gametocyte detection [19, 20, 21, 22]. Therefore, we aimed to compare P. falciparum 
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parasite and sexual stage prevalence rates as determined by LM and mRDT with those 
obtained using molecular techniques, thereby assessing the usefulness of these different 
methods for epidemiological studies in Tanzania. 
 
Methodology 
Study site and design 
The study was conducted in the Kilombero and Ulanga (K-U) districts in Morogoro region in 
southeast Tanzania. The Ifakara Demographic Surveillance System (IHDSS) covers the study 
area [23]. The districts are primarily rural. Transmission of malaria is perennial with two 
rainy periods: from October to December and from March to May. The K-U districts were 
among the first areas in Tanzania to implement several malaria intervention strategies. The 
Kilombero Net project (KINET) successfully distributed ITNs, attaining 91% coverage by late 
2000 [24]. This programme led to a fourfold reduction in entomological inoculation rates 
(EIR) [25] to about 78 infectious bites per year [26]. 
 
Our study was conducted as an extension of the Artemether-Lumefantrine In Vulnerable 
Patients: Exploring Health Impacts (ALIVE) project. Its main aim was to assess the impact of 
introducing ACT as a first line antimalarial treatment on all-cause mortality in 
infants/children under 5 years of age in the K-U districts.  
A cross-sectional survey was performed between May and August 2011. Randomly selected 
households within the IHDSS were surveyed. A subset of 330 randomly selected individuals 
of all ages was included in the molecular analysis. The study was granted ethical clearance by 
the Ifakara Health Institute (IHI) and by the National Institute for Medical Research Tanzania. 
 
Blood collection and sample storage 
Finger prick blood was used to diagnose malaria positivity by (i) mRDT SD Bioline Pan-
pLDH/Pf-HRP2, (ii) blood smear and LM and (iii) PCR-based molecular diagnosis. 
Approximately 50μL of whole blood were collected on Whatman® grade-3 filter paper, air 
dried in the field and stored at ambient temperature in separate sealed plastic bags with 
desiccant. Two blood spots on filter paper were prepared per individual, one of which was 
put in 300μL TRIzol® (Invitrogen) to stabilize RNA and stored at -80°C. Samples in TRIzol® 
were shipped by air on refrigerant gel packs to the laboratory responsible for DNA and RNA 
extraction. RNA was extracted from 330 samples using the Qiagen RNeasy Plus ® protocol 
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with on-column DNase digestion, to ensure removal of genomic DNA (gDNA) as described 
elsewhere [14]. RNA was stored at -20°C for a maximum of two weeks prior to cDNA 
synthesis and amplification. One additional blood spot per patient was air-dried and 
preserved in a sealed plastic bag with desiccant at -20°C until shipped at room temperature. 
DNA was extracted from 226 dried blood spots using the Chelex protocol [27]. DNA was 
stored at -20°C for one to two weeks until used in PCR.  
 
Microscopy blood smear reading 
Thick and thin blood films were prepared in the field, air dried, Giemsa stained and read for 
detection and quantification of malaria parasites according to Standard Operating 
Procedures at the IHI laboratory. Asexual parasites were reported out of 200 leukocytes. 
Gametocyte detection by LM was based on a volume of blood corresponding to 500 
leucocytes. Assuming 8,000 leucocytes/μL blood, parasite density (expressed/ as parasites 
per μL blood) was calculated by multiplying LM counts by a factor of 40 if parasites were 
reported out of 200 leukocytes or by 16 for 500 leukocytes. Two independent qualified 
technicians read all slides. In case of discrepancy between two readers, a third reader was 
requested. The final result was the mean of the two closest readings out of three. For cases 
of positive/negative discrepancy the majority decision was adopted.  
 
Molecular assays 
A qPCR targeting the P. falciparum S-type 18S rRNA genes was performed on all DNA 
samples to determine parasite prevalence [28]. As a reference, a nested PCR (nPCR) 
targeting the merozoite surface protein 2 (msp2) was performed on all DNA samples [29]. 
Gametocytes were detected by amplifying transcripts of the gametocyte-specific expressed 
marker pfs25 [14]. pfs25 transcripts were reverse transcribed and the resulting pfs25 cDNA 
was amplified by qPCR. The RNA-based quantitative reverse transcriptase PCR (qRT-PCR) 
assay was performed on all extracted RNA samples after complete gDNA removal had been 
confirmed by a qPCR assay targeting 18S rRNA genes of all Plasmodium species [14]. To 
quantify P. falciparum parasites and gametocytes, copy numbers of the respective template 
per μL blood were calculated using standard curves obtained from assay-specific plasmids 
routinely included on each 96-well qPCR plate.  
 
 





All data was entered and analyzed by STATA® version 13, Texas, USA. To compare the 
performance of different diagnostic tests, concordance of results was recorded. Parasite 




This community survey included 330 individuals, the mean age was 18 years with an age 
range of 1 – 81 years.  Of these, 21% were children <5 years, 44% were between 5-19 years. 
Individuals between 20-59 years and adults >60 years accounted for 30% and 4.5% of 
recruited individuals, respectively. A complete dataset including all four diagnostic methods 
was obtained for 226 participants and used to compare test performance.  
 
P. falciparum prevalence and density  
Prevalence of P. falciparum blood stages in the K-U districts was 38% (86/226; 95% CI 31.9-
44.4%) by Pf18S rRNA qPCR. A lower parasite prevalence of 26.6% (60/226; 95% CI 19–
31.2%) was observed when msp2 nPCR was performed. Of msp2 positive samples, 83.3% 
(50/60) were confirmed by Pf18S rRNA qPCR. Only 58% (50/86) of Pf18S rRNA qPCR-positive 
samples were positive by msp2 nPCR (Table 1). Thus, sensitivity of qPCR was superior to that 
of standard nPCR. 
 
P. falciparum prevalence was 15.9% (36/226; 95% CI 11.1 – 20.7%) by mRDT and 5.8% 
(13/226; 95% CI 2.69- 8.81%) by LM. mRDT was positive for 8/13 (61.5%) and qPCR for 11/13 
(84.6%) of LM positive samples. Only 2/13 (15.4%) LM-positive samples were unidentified by 
both mRDT and qPCR, suggesting that these two LM results were false positives (Table 2). Of 
36 mRDT-positive samples, 24 (66.7%) were also positive by qPCR, whereas the remaining 
30% of mRDT-positive samples were negative by qPCR and LM.  
 
LM recorded a mean of 13,483 parasites/µL (range 80 to 64,640). Pf18S rRNA qPCR detected 
a mean of 6,524 18S rRNA gene copies/μL (range 0.9 to 155,293). 18S rRNA copy numbers 
were not converted into parasite counts because trend-line experiments using ring stage 
parasites were not performed for filter paper blood spots with similar storage conditions. 
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Moreover, original blood spots varied in size and thus whole blood content also varied. A 
non-linear correlation was observed between log10 parasite density by LM and log10 18S 
rRNA gene copy numbers/µL of blood for all microscopy positive samples (Figure 2).  
 
Gametocyte prevalence  
Gametocyte prevalence was determined by LM and qRT-PCR in 226 samples. Gametocyte 
carriage in our study population was 10.6% (24/226; 95% CI 6.6-14.7%) by qRT-PCR and 1.2% 
(3/226; 95% CI 0.2-2.8%) by LM. Two of the three gametocyte carriers identified by LM were 
confirmed by molecular gametocyte detection. A large proportion of gametocytemia (87.5%; 
21/24) was submicroscopic. 
 
The proportion of molecularly identified gametocyte carriers among P. falciparum positive 
individuals is listed in table 3 for all four independent diagnostic tests (LM, mRDT, msp2 
nPCR and 18S rRNA qPCR). In total, 3/13(23%) LM-positive and 9/36 (25%) mRDT-positive P. 
falciparum infections harbored gametocytes detected by pfs25 qRT-PCR. In individuals 
deemed positive by msp2, we detected 12/60 (20%) gametocyte carriers. This proportion 
was slightly higher than in individuals deemed positive by the more sensitive 18S rRNA qPCR, 
with only 16.2% (14/86) of infections harboring gametocytes.  
 
Discussion  
Accurate estimation of malaria burden after implementation of effective malaria control 
programmes is of particular importance for evaluating and planning further intervention 
strategies. Accuracy of the diagnostic tests applied and knowledge of their limitations are 
essential. Therefore, we evaluated the performance of LM and mRDT, the routinely used 
methods for estimating P. falciparum prevalence in the community, and compared it with 
that of qPCR for determining parasite positivity. Our results highlight the poor sensitivity of 
LM and the high prevalence of submicroscopic infections. Malaria prevalence in the K-U 
districts is vastly underestimated, if detection is based on LM only.  
 
In many parts of Tanzania, LM is still widely used as the standard parasite confirmation 
method because supply of mRDTs is unreliable owing to stock-outs. With the increasing 
success of interventions and as a consequence of reduced clinical malaria, it becomes 
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increasingly important to determine prevalence rates in the community to estimate the 
remaining malaria burden and to monitor the effect of sustained control measures. In this 
context, the sensitivity of the diagnostic method, which greatly influences prevalence 
determination, becomes increasingly important.  
 
We observed a sevenfold difference between parasite prevalence estimated by qPCR and 
that estimated by LM. Other studies in Thailand, Myanmar [30, 31] and Malawi [32], as well 
as a systematic review [33] have also reported more than two- to fivefold difference in 
asexual stage parasite prevalence estimates between classical LM and molecular detection. 
Several limitations of LM have been documented [34], such as its dependency on the 
expertise of the reader, the method of slide preparation, staining and reading, and last but 
not least, it’s LOD of about 50 parasites/µL of blood. The LOD ranges from 20-100 
parasites/µL between expert and field microscopists. Thus, the high prevalence of 
submicroscopic infections in the K-U districts is not surprising, and even slightly higher than 
in studies done elsewhere. Such an abundance of submicroscopic infections is expected in 
areas where malaria transmission has recently been reduced successfully because parasite 
densities are controlled by acquired immunity of previously exposed individuals [35].  
 
Our study revealed that two of the 13 LM-positive samples were negative by mRDT and by 
both molecular assays. These LM-positive samples were likely false positives that may have 
resulted from erroneous thick smear reads, as has been documented in other studies [36]. 
Massive over-diagnosis of more than twenty-fivefold difference in the prevalence rates (i.e. 
53% versus 2% prevalence) has been reported in a comparative study of routine and expert 
LM in Tanzania [6].  
 
Molecular methods (nPCR and qPCR) applied in the study were slightly discordant in parasite 
detection. This difference can be explained by a lower sensitivity of msp2 nPCR compared to 
the 18S rRNA qPCR, which is likely due to its greater amplicon size and thus less efficient 
amplification. Moreover, compromised integrity of parasite DNA could also lead to more 
efficient amplification of the shorter 18S rRNA amplicon. However, some samples which 
were positive using the marker msp2 were negative by qPCR. In samples with very low 
parasite densities, a chance effect in the template distribution to one reaction but not to the 
other could account for such discrepant results. Alternatively, PCR inhibitors could 
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potentially be present in a sample, which may affect the qPCR assay more than the nested 
PCR assay. 
 
Our PCR data help to understand the difference between LM and mRDT results in this study. 
The discrepancies are likely due to the low sensitivity of LM as well as to the residual HRP 
antigen that remains after a cleared infection [37, 38]. The LOD of mRDTs is roughly 
comparable to LM in the field, although the last generation of mRDTs showed a higher 
sensitivity than previous ones [39]. Moreover, mRDTs performed better than LM in 
community surveys [12, 40]. To estimate the proportion of parasite infections undetected by 
LM and mRDT, we applied qPCR with a substantially higher sensitivity of up to 0.34 
parasites/μL blood [15]. The use of qPCR in our study increased malaria prevalence twofold, 
which is similar to differences between PCR- and mRDT-detected prevalence reported 
elsewhere [12, 36, 40, 41]. About 30% of mRDT positive samples were negative by our most 
sensitive qPCR assay. Variability in the interpretation of mRDT results may have contributed 
to the discordance between mRDT and PCR. A direct comparison between the results of 
qPCR and mRDT is generally problematic because these two tests do not detect the same 
target molecule: while qPCR detects DNA from circulating parasites, mRDT detects 
circulating antigens; hence a 100% concordant result is not expected.  
 
Another explanation for the discrepancies between mRDT, LM and PCR results could be that 
mRDTs are actually capturing gametocytes in the absence of asexual forms. pLDH is 
produced by live parasites including gametocytes [42]. In confirmed samples containing only 
P. falciparum gametocytes, mRDT was positive in 72% of samples with high gametocyte 
density (>500 gametocytes/µL of blood) compared to only 20.5% mRDT positives in samples 
with low gametocytemia(>200 gametocytes/µL of blood) , suggesting that the presence of 
gametocytes can compromise RDT results [43]. Similarly, among the three samples in our 
study that were mRDT positive but qPCR negative, all harbored gametocytes by pfs25 qRT-
PCR. This could indicate the presence of gametocytes in the absence of asexual forms. 
Negativity by qPCR in a gametocyte-positive sample could be explained by the presence of 
only three 18S rRNA gene copies per parasite genome, whereas the numbers of pfs25 
transcripts are much higher [14]. Other molecular markers, specific for asexual parasite 
stages, would be needed to prove the absence of any asexual parasite.  
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In our study, the prevalence of gametocytes by pfs25 qRT-PCR was ten times higher than 
that by LM, indicating a high proportion of submicroscopic gametocytemia in the 
community. Based on the low gametocyte prevalence by LM in previous years and in the 
same population [44], much higher gametocyte prevalence had been anticipated, but was 
not confirmed until now. An even greater difference in gametocyte detection between LM 
and molecular analysis by Quantitative Nucleic Acid Sequenced-based Amplification (QT-
NASBA) has been observed in a community survey in Tanzania (0.4% and 15% positivity, 
respectively) [45]. In malaria epidemiology, submicroscopic gametocytemia is important. It 
has been shown that submicroscopic gametocyte carriage substantially contributes to the 
human infective reservoir for onward transmission to mosquitoes. These studies have shown 
that even microscopy negative individuals can infect mosquitoes [46, 47]. Therefore, the 
observed 10.6% gametocyte prevalence in our study population is likely to sustain malaria 
transmission in the presence of an efficient vector.  
 
Over the seven-year course of malaria community surveys in the K-U districts, molecular 
data were generated only during the 2011 survey. Therefore, the longitudinal effect of 
interventions in the study area on P. falciparum prevalence rates can only be analyzed by 
classical diagnostic means. Previous LM data from the IHDSS recorded declining malaria 
prevalence within the K-U districts, from 25% in 2004 to 4.6% in 2009 [23, 46]. The qPCR-
based prevalence rates obtained from the 2011 survey now provide a more precise picture 
of the malaria prevalence in the K-U districts and put the very low prevalence rate by LM 
into a new perspective. LM seems inadequate as a diagnostic tool for surveillance of parasite 
infections in Tanzania at a point when transmission intensity is shifting from high to low. The 
question remains whether mRDT diagnosis should be considered a suitable alternative. This 
test has the advantage of allowing on-site treatment for symptomatic or asymptomatic 
individuals with positive mRDT results. It also allows comparison of data from different areas 
and countries that still use conventional techniques. Lastly mRDT is quite cheap. The future 
might be to use both, mRDT for all individuals and PCR in a subsample, to better gauge the 
magnitude of underestimation of the parasite prevalence. Molecular techniques should be 
used especially in areas of very low endemicity, where elimination is the prime objective. 
 




Light microscopy showed the poorest performance for detecting both P. falciparum asexual 
parasites and gametocytes. This implies the presence of a large proportion of 
submicroscopic parasitemia and gametocytemia in the K-U districts, a phenomenon that is 
common in areas of recently declining transmission. mRDT performed better than LM, as it 
detected almost half of the P. falciparum carriers identified by molecular tools. However, in 
light of our PCR results, the gain in sensitivity of mRDT over LM was still modest. However, 
the use of mRDT adds to our understanding of the real transmission level, in the sense that it 
can also detect recently cleared infections (treated or not) that are no more detectable by 
LM or PCR. Thus, using both tools, PCR and mRDT, which together are able to detect actual 
parasitemia plus recent infections, may provide the most precise information by which to 
assess the impact of interventions and to decide on the best control strategies. To reliably 
estimate the malaria reservoir in areas of high submicroscopic parasitemia, molecular tools 
are clearly justified.  
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List of tables  
Table 1: Comparison of the two molecular methods Pf18S rRNA qPCR and msp2 nested PCR 
for P. falciparum parasite detection 
 msp2 
18S rRNA qPCR  Positive Negative Total 
Positive 50 36 86 
Negative 10 130 140 
Total 60 166 226 
  Pearson chi2 (1) = 71.0492  Pr = 0.000 
 
Table 2: Concordance among three different diagnostic methods for detecting P. falciparum 
positivity  
Patterns of test positivity by three diagnostic methods  
18S rRNA qPCR 
(Npos = 86) 
mRDT 
(Npos = 36) 
LM 




+ - - 57 
+ + - 18 
- + - 10 
+ + + 8 
+ - + 3 
- - + 2 
 
Table 3: Proportion of P. falciparum gametocyte carriers among individuals deemed positive 




among Pf. positive 
samples  
(% Gametocyte carriage 
among Pf. positives ) 





LM 3/13 (23%) 3 10 
mRDT 9/36 (25%)  9 27 
msp2 nPCR 12/60 (20%) 12 48 
18S rRNA qPCR 14/86 (16%) 14 72 
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List of figures 
 
Figure 1: P. falciparum prevalence rates by LM, mRDT, msp2 nested PCR and 18S rRNA qPCR 
performed in N=226 samples from the Kilombero-Ulanga districts in Tanzania. 
  




Figure 2: Comparison of log10 P. falciparum 18S rRNA gene copy numbers /µL blood by qPCR 
and log10 parasite counts /µL blood by LM. *Two LM-positive samples were negative by 
mRDT and molecular assays and likely represent false positive microscopy results. 
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Prevalence of Plasmodium falciparum in community samples is one of the cornerstones for 
describing malaria transmission in the area. Measurements of parasite prevalence greatly 
depend on the diagnostic techniques applied and can lack precision in case of low parasite 
densities, which often remain undetected by the routinely used diagnostic tool, light 
microscopy (LM). Highly sensitive molecular tools are able to detect submicroscopic 
infections and can serve to evaluate the performance of diagnostic tools used in the field 
surveys. We aimed to investigate local differences in the prevalence of submicroscopic 
infections and gametocyte carriage at different sites of varying endemicity and to investigate 




In community surveys 1820 individuals were recruited from 5 sites of greatly varying of 
endemicity. Finger prick blood was collected for parasite detection by LM, RDT and 18S rRNA 
qPCR. Gametocytes were detected by both LM and qRT-PCR targeting transcripts of the 
gametocyte-specific expressed marker pfs25. Submicroscopic infections were those positive 
by qPCR but not by LM.  
 
Results 
P. falciparum prevalence by qPCR varied from 50% at the site of high endemicity to 0.6% in 
low endemicity. 52.7% (174/330) of qPCR positive samples were submicroscopic. At the site 
of lowest endemicity only 2 samples were positive by qPCR and both were negative by LM.  
Submicroscopic carriage did not show a clear relationship with endemicity patterns and was 
73% (11/15) in low, 34% (19/56) and 63% (5/8), in moderate and 55% (137/249) in high 
endemicity. Molecularly determined gametocyte prevalence at each location closely 
followed the parasite prevalence of this site. But the vast majority (96%; 277/288) of all 
gametocytemia was submicroscopic. 
 




Molecular parasite detection revealed high prevalence of submicroscopic carriage in 
Tanzania particularly in adults. Submicroscopic infections were prevalent in all endemic 
settings, even in areas of high transmission intensity. Highly standardized and comparable 
data on submicroscopic parasitemia and gametocytemia from multiple sites within a country 
can help to better assess the human infective reservoir for onwards transmission and the 
relative contribution of asymptomatic infections. Identifying the extent of submicroscopic 













Measurement of parasite prevalence in communities from endemic areas is one of the most 
important metrics for describing levels of malaria endemicity. Prevalence rates complement 
entomological measures of transmission that are much more difficult to obtain, particularly 
in low transmission settings. Monitoring changes in prevalence rates is useful for measuring 
outcomes of antimalarial interventions or for informing control strategies. In particular 
molecular diagnosis is gaining increasing importance in the context of current efforts to scale 
up malaria control and to move towards malaria elimination in many countries (MalEra 
2011). The merits of molecular malaria diagnostics are owing to a higher precision compared 
to the traditional malaria diagnostics tools, light microscopy (LM) and rapid diagnostic test 
(RDT), which are still widely used in all malaria endemic countries.  
As a consequence of intensified malaria interventions a major decline in malaria prevalence 
has been observed in many areas, including highly endemic regions in sub Saharan Africa 
(WHO 2013) (Tanner and Hommel, 2010). Also in Tanzania the national average of malaria 
prevalence has halved from 18% in 2008 to 9% in 2012 (THMIS 2009, THMIS 2013). Studies 
conducted in various regions in Tanzania recorded intense reductions in malaria 
transmission (Mmbando et al. 2010; Khatib et al.2012 and Ishengoma et al. 2013).  
A decline in prevalence and thus in exposure to P. falciparum could affect the overall 
parasite densities in the population and may affect the sensitivity of the commonly used 
diagnostic tools. In view of a worldwide malaria reduction it seems of paramount 
importance to investigate potential changes in the performance of LM, the main diagnostic 
tool. A meta-analysis using data from varying transmission intensities had indicated that in 
low-endemic areas submicroscopic parasite carriage was very frequent, whereas in high 
endemicity, 80 % of infections were detectable by LM (Okell et al. 2012). This suggests that 
low parasite densities could account for the low positivity by LM in community samples from 
low transmission settings. Such a relationship would imply that LM, the primarily used 
detection method, would provide insufficient sensitivity for malaria surveillance if the 
malaria prevalence further declines in future.  
Several recent molecular-epidemiological studies in Tanzania did not conform to the results 
of the meta-analysis of Okell and co-workers (2012).  An earlier study performed in Tanzania 
in an area of declining endemicity reported a large proportion of submicroscopic infections 
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(Shekalaghe et al. 2007). Prevalence rates in that study were 1.9% by LM and 33% by 
quantitative nucleic acid sequence based amplification (QT-NASBA). Submicroscopic carriage 
in that study did not vary by age or season, in contrast to the determinants for 
submicroscopic infections formulated by Okell and co-workers (2012). A further study was 
conducted at several Tanzanian sites of different altitude (Manjurano et al. 2011). 
Prevalence was found to decline with increasing altitude (and thus lesser transmission). LM 
detected only 50% of all infections identified by PCR and this submicroscopic carriage was 
similar at all altitudes.  For other Tanzanian regions, in particular for settings of moderate 
and high malaria transmission, the prevalence of submicroscopic infections has not been 
investigated so far. Our comparative analysis of 5 Tanzanian sites of greatly differing malaria 
endemicity aimed at filling this gap. 
 
In parallel to investigating P. falciparum prevalence across Tanzania, we also assessed 
prevalence of gametocytes, the stages solely responsible for onward transmission to 
mosquitoes. Again we aimed at comparing LM-based gametocyte prevalence with positivity 
by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Because the 
commitment of P. falciparum to sexual development is considered to be rare (about 1/100 
parasites) (Bousema and Drakeley, 2011), gametocyte densities are generally much lower 
than those of asexual stages, and very few individuals harbour gametocytemia detectable by 
LM (Taylor et al 1997). Importantly, also gametocytemia at submicroscopic levels contributes 
to transmission of the parasite (Schneider et al. 2007). Mosquito membrane feeding 
experiments revealed that blood samples with submicroscopic gametocytemia could infect 
mosquitoes, but the mosquito infection rate was 10-fold lower compared to the rate 
observed for blood samples that were gametocyte-positive by LM (Coleman et al. 2004; Lin 
et al. 2014). Quantification of submicroscopic gametocytes by qRT-PCR or NASBA and their 
contribution to transmission has been investigated in several studies (Schneider et al 2006; 
Shekalaghe et al 2007; Ouédraogo et al 2009; Harris et al.2010; Manjurano et al 2011; 
Mosha et al 2013; Lin et al 2014). In an attempt to define the relationship between 
gametocyte density and mosquito infection rate, Churcher and co-workers (2013) showed 
that this relationship was complex and non-linear. These results indicated that molecularly 
determined gametocyte densities cannot be used as a surrogate for a simple prediction of 
the impact of transmission reducing interventions, other factors such as host age, asexual 
parasite densities and gametocyte maturity also seem to play a role (Churcher et al. 2013). 
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However, gametocyte quantification is useful for describing the human infectious reservoir 
to mosquitoes.  
The aim of our multi-site study was to identify local differences in the proportion of 
submicroscopic parasitemia and to investigate how well LM performs in malaria surveillance 
over the full range of local transmission intensities. This also provides a useful and precise 
description of malaria prevalence in the country. By determining the extent of 
submicroscopic parasitemia particularly in areas of very low transmission and urban areas in 
Tanzania we aimed to test the hypothesis that such settings most P. falciparum infections 
are detectable only by molecular methods. Secondary objective was to document the 
molecular gametocyte prevalence in the different transmission settings and to confirm their 
presence also in samples of very low or urban transmission, despite their apparent absence 
by LM.  
Methods and study design 
Study sites 
The study was conducted at 5 sites in Tanzania, which were classified in urban, low, medium 
and high endemic settings according to district prevalence data recorded by the Tanzania 
HIV and Malaria indicator surveys of 2008 (THMIS 2009): Dar Es Salaam (urban), coastal Rufiji 
(high), coastal Bagamoyo and Tanga (Moderate) and Iringa (very low). The prevalence rates 
reported in the THMIS surveys and our classification of endemicity levels for the 5 study sites 
are listed in supplementary Table S1.  
 
Study Design 
Cross-sectional surveys were conducted at all study sites between May and August 2013. 
1820 individuals of all ages (>6 months to 90 years) with signed consent forms were 
enrolled. Finger prick blood was collected and malaria screening was performed by Pan 
PLDH/Pf (HRP2) SD Bioline® rapid diagnostic tests (RDT). All individuals positive by RDT were 
treated at the time of blood sampling with a recommended full dose of ACT (Coartem®). 
Thick blood smears were made for parasite diagnosis by LM. In the first survey conducted in 
Dar Es Salaam approximately 50μL blood were spotted onto Whatman® grade 3 filter paper, 
air dried and transferred into 300μL of TRIzol® RNA stabilate within 1-7 days as described 
elsewhere (Wampfler et al. 2013). At 4 of our study sites about 100-150µL whole blood from 
finger prick were collected in EDTA tubes and kept at ambient temperature until later that 
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same day 100µL EDTA blood were transferred to microtubes containing 500µL RNA Protect® 
reagent and mixed. Both types of samples for RNA extraction were stored at -20°C until 
shipped on ice packs to the molecular laboratory. RNA and DNA were co-extracted in a 96-
well plate format, RNA was extracted using the Qiagen RNeasy® plus extraction kit. DNA was 
obtained by washing gDNA eliminator columns from the RNA extraction using buffers from 
the modified protocols in the QiAmp® DNA mini kit. The obtained nucleic acids were stored 
temporarily at 20°C storage prior to analysis by PCR. Details of nucleic acid (RNA and DNA) 




Approval for the TZ cross-sectional study was obtained from the Institutional Review Board 
of the Ifakara Health Institute (IHI), Dar Es Salaam (no. 13-2013). This study was carried out 
within the framework of the Sentinel Panel District Project of IHI (IRB and NIMRI clearance).  
Approval was also sought from the District Medical Officers and from the local governing 
bodies of respective administrative wards, streets and hamlet level. Before blood sampling 
an informed written consent was obtained from all participants or parents/guardians of all 
children. 
 
Light microscopy  
Thick films were made from finger prick blood, air dried in the field and stained with 10% 
Giemsa in the IHI laboratory. Gametocytes were read separately from asexual blood stage 
forms. Parasite densities were quantified by counting the number of asexual and 
gametocytes per 200 and 500 leucocytes respectively. The results were converted to 
parasites/µL assuming a total of 8000 WBC/µL blood.  
 
P. falciparum detection 
P. falciparum asexual stages were analyzed by a DNA-based P. falciparum 18S rRNA qPCR 








P. falciparum gametocyte detection was performed on RNA from all samples irrespective of 
their DNA-based positivity but only after confirming the presence of parasite RNA in the 
sample. Transcripts of the pfs25 mRNA gene, a gametocyte-specifically expressed gene, were 
reverse transcribed and the resulting pfs25 cDNA was amplified by qPCR in a single reaction. 
Details of this assay have been described previously (Wampfler et al. 2013). Standard curves 
of assay-specific plasmids in triplicates were analysed on each plate together with the test 
samples to enable conversion of Ct values into template copy numbers/µL blood. No further 
conversion of the copy numbers/µL blood was done.   
Data analysis 
Data were entered and analysed by STATA® version 13, Texas USA. Prevalence rates by LM, 
RDT and qPCR were determined and compared between 4 endemic settings. Marker-specific 
transcript copy numbers/μL blood were converted to log10. Age of participants was 
categorized in 8 groups as follows: <1, 1-2, 3-4, 5-9, 10-19, 20-39,40-59, 60+ years. Samples 
with missing age data were excluded from the analysis. 
 
Results 
P. falciparum prevalence and density at 5 study sites  
Our study included 1820 participants from 5 sites in Tanzania, numbers of participants by 
study site and the endemicity classification of sites are shown in Supplementary Table S1.  
 
The P. falciparum parasite prevalence rates determined by the 3 diagnostic tests for all sites 
combined were 18.1% (330/1820; 95% CI 16.3-19.9%) by 18S rRNA qPCR, 17.2% (313/1820; 
95% CI 15.5-18.9%) by RDT and 11.8% (216/1820; 95% CI 10.3-13.3%) by LM. The molecular 
prevalence rates varied substantially between geographic sites and ranged roughly 50% in 
Rufiji, the site of highest endemicity, to 0.6% in Iringa, the site of lowest endemicity 
(Supplementary Table S2). These figures highlight the variation of malariometric indices in 
Tanzania.  As expected, the regions in the moderate and high endemic sites according to the 
THMIS classification showed higher molecular prevalence rates than sites in low and urban 
endemicity (Figure 1 and Supplementary Table S2). LM and RDT mirrored the molecular 
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findings (Figure 1). The discrepancy between molecular and LM prevalence rates was large at 
the highly endemic site, whereby about 50% of total parasite infections remained 
undetected by LM. An exception to the poor performance of LM was observed at the urban 
site Dar Es Salaam, where LM recorded a prevalence of 6.6% (29/440), which was 4-fold 
higher than the prevalence by RDT (7/440) and 2-fold higher than that by qPCR (15/440). 
Yet, these differences in parasite detection by the three methods LM, RDT and qPCR at the 
urban endemic site were not significant. The three diagnostic methods differed only 
marginally in prevalence rates recorded in Iringa (low endemicity), Tanga and Bagamoyo 
(both low and moderate endemicity). This implies that submicroscopic infections prevail at 
high endemic sites but are rare in low and moderate transmission sites, where LM 
performed more or less similar to RDT and molecular assays. 
 
To investigate whether higher parasite densities in areas of low and moderate transmission 
could account for the good LM diagnosis observed, we analysed parasite counts by LM 
(Figure 2). The geometric mean parasite density by LM was 4407 parasites/µL blood 95% CI: 
3131-6203 parasites/µL blood in Rufiji, the highly endemic site, while the urban low endemic 
site, Dar recorded a mean parasite density of 317 parasites/µL blood 95% CI: 269-374 
parasites/µL blood (Figure 2). The difference in mean density by LM between the sites of 
highest and lowest endemicity was 14-fold. However, we obtained very low numbers of P. 
falciparum positive samples in the low and moderate endemic settings, thus the estimates of 
mean parasite load at these sites may not be very robust. 
Submicroscopic infections in different endemic sites  
Submicroscopic parasitemia was defined as samples that were parasite positive only by 
molecular detection but not by LM. Overall, 52.7% (174/330) of samples positive for P. 
falciparum were submicroscopic according to the above definition. At our site of lowest 
endemicity (Iringa), LM did not detect any positive sample, whereas 2 P. falciparum positive 
samples were found by qPCR and confirmed by RDT. The very low numbers of positive 
samples precludes any firm conclusion on submicroscopic prevalence in the two low 
endemicity sites. In contrast, high numbers of submicroscopic carriers (55%; 137/249) were 
observed in Rufiji. No clear trend in the relationship between submicroscopic carriage and 
endemicity was observed (Table 1).  
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Prevalence and submicroscopic carriage of gametocytes 
Gametocytes were diagnosed in all samples by LM and qRT-PCR. The molecular gametocyte 
prevalence in all community samples from the 5 sites was 15.8% (288/1820; 95% CI 14.1-
17.5%). When only P. falciparum positive samples were considered, 87.2% (288/330) carried 
gametocytes by qRT-PCR. By LM the overall gametocyte prevalence was 0.82% (15/1820; 
95% CI 0.47-1.2%). Thus, LM identified only 5.2% (15/288) of all gametocyte carriers 
identified by qRT-PCR.  When only slide reading results were considered, 4.5% (15/330) of 
the P. falciparum positive individuals would be gametocyte carriers.  
 
The lowest molecular gametocyte prevalence of <1% was observed in Iringa and Dar Es 
Salaam (Supplementary Table S2). This sharply contrasts with findings from the high 
endemic site Rufiji, where 43.6% of the population carried gametocytes. In high endemicity 
LM-based gametocyte detection was 15-fold lower compared to molecular diagnosis. In 
most areas of low and moderate endemicity (Iringa, Tanga and Bagamoyo) LM did not detect 
any gametocytes, while qRT-PCR had detected gametocytes at all sites. When all data was 
combined, 96% (277/288) of all P. falciparum gametocyte positive samples were 
submicroscopic. Endemicity did not seem to affect the prevalence submicroscopic 
gametocytemia in a major way (Table 2). 
Comparison of parasite and gametocyte load 
The molecular gametocyte load in the high endemic site, Rufiji, had geometric mean of 86.8 
pfs25 transcripts/µL blood (95% CI 63.2-119.1 pfs25 transcripts/µL blood). Only one of the 
two parasite positive samples in the lowest endemic site, Iringa, carried gametocytes with 16 
pfs25 transcripts/µL blood. By LM the overall mean gametocyte density was 52 
gametocytes/µL blood, ranging from 30-90 gametocytes/µL blood. Rufiji, the high endemic 
site displayed a geometric mean of 54 gametocytes/ µL blood, while only one positive 
samples in Dar, urban low endemic had a geometric mean of 32 gametocytes/µL blood.  We 
observed a positive linear correlation (r2=0.47) between P. falciparum parasite load depicted 
by the log transformed 18S rRNA copies/µL blood and the gametocyte load in the same 
sample (Figure 3). 
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Age trends in prevalence and submicroscopic carriage of P. falciparum parasites and 
gametocytes 
To investigate age trends in parasite load, prevalence and submicroscopic carriage we 
combined the molecular data from all sites. In age groups 1-2, 3-4, and 5-9 years both high 
prevalence rates and high densities were observed (Figure 4 and Supplementary Figure S1). 
The highest prevalence rate by qPCR peaked at 5-9 yrs. Similarly observation was shown by 
LM. Parasite density by LM and PCR was highest at 3-4 yrs followed closely by age groups 1-2 
yrs and 5-9 yrs). A decline of both prevalence rates and parasite load by LM and qPCR was 
observed in children older than 10 yrs and adults. The prevalence of submicroscopic 
infections increased steadily over the younger age groups and peaked at 20-39 yrs followed 
by a decline in the oldest age groups (Supplementary Figure S2). Thus, the age trend in 
submicroscopic infections was non-monotonous with a clear increase over the younger age 
groups.    
  




Our comparison of 5 sites in Tanzania revealed huge variations in P. falciparum parasite and 
gametocyte prevalence rates across the varying endemic sites. The strength of this study 
consisted in a good comparability of the data generated at each site. Parasite detection by 
LM, RDT and qPCR was performed for the entire data set by the same field and laboratory 
team using a generalized protocol. This approach minimized the technical variability and has 
major advantages over a comparison of data from unrelated studies performed with 
different techniques. The observed differences between the study sites should thus be 
attributed to geographical factors, particularly those that favour the development and 
survival of the mosquito vectors. Highland areas, such as rural Iringa with low temperatures 
of about 15°C and an altitude >1600m, are known to have low or no malaria transmission 
(Mboera et al. 2008; Talundzic et al. 2014). Urban areas of Dar Es Salaam have much less 
malaria (Strøm et al. 2013a) compared to the rural areas of Tanga (Mmbando et al. 2010), 
Rufiji (Khatib et al. 2012) that are well documented and known to be highly endemic (THMIS 
2013).  
In our low and moderate endemic areas the prevalence rates obtained by the 3 independent 
diagnostic tools did not differ substantially. This implies that most infections were captured 
even by LM and RDTs. In contrast, major discrepancies between LM and qPCR were 
observed at the high endemicity site Rufiji. Because the highly sensitive detection of 0.34 
parasites/µL by our 18S rRNA qPCR (Hofmann et al. 2014) massively exceeds the limit of 
detection of LM of around 50-100 parasites/µL (Wongsrichanalai et al. 2007), we expected 
and confirmed that molecular detection yielded the highest prevalence rates at all sites 
except Dar Es Salaam, where LM outperformed both RDT and PCR. We assume that the 
14/440 samples that were positive only by LM could represent technical problems at this site 
or due to erroneous reading of thick smears. Under the condition of low endemicity LM 
sometimes creates false positives. High levels of false positivity by LM have been reported 
from other areas of low endemicity (Wongsrichanalai et al. 2007; Kahama-Maro et al. 2011; 
Fançony et al. 2013; Strøm et al. 2013 b).  
 
This study confirms the predominance of submicroscopic P. falciparum infections in Tanzania 
with 52.7% of all molecularly detected infections being submicroscopic. This is consistent 
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with data from the Usambara and Kilimanjaro areas in Tanzania where, 50% and 33% of the 
total infections were submicroscopic (Manjurano et al. 2011; Shekalaghe et al. 2007). Our 
results also agree with an earlier meta-analysis that had indicated that LM detects on 
average only 50% of total infections determined by PCR (Okell et al. 2009).  Submicroscopic 
infections in our study were more prevalent in older children and adults with peak 
prevalence at 20-39 yrs. A similar observation was reported from north-east Tanzania, where 
older children were 3-times more likely to carry submicroscopic infections compared to 
younger children (Manjurano et al. 2011). Similarly, a meta-analysis by Okell and co-workers 
(2012) had shown that submicroscopic infections were common in adults, owing to the 
ability of acquired immunity to control parasite densities to levels under the detection limit 
of LM.  In contrast to this meta-analysis we did not observe an increase of submicroscopic 
carriage with decreasing endemicity.  Our data of submicroscopic carriage did not show 
substantial differences between the sites of different endemicity. 
 
The detection limit of LM very often does not permit to diagnose low density infections, and 
thus prevalence estimates generated by LM will depend greatly on the average parasite 
density of the population studied.  In our study we did not detect significant differences in 
parasite densities nor in the prevalence of submicroscopic carriage. This indicates that at our 
sites parasite densities in high as well as low endemic settings might be well controlled by 
acquired immunity as a consequence of previous exposure to malaria parasites (Alves et al. 
2002; Proietti et al. 2011; Okell et al. 2012; Harris et al. 2010; Sturrock et al. 2013 and 
Lindblade et al. 2013). It has been argued that a recent decline in transmission in formerly 
highly endemic areas keeps parasite densities low despite reduced transmission (Gatton et 
al. 2010; Golassa et al 2013). Similarly, a study in Tanzania indicated an inverse relation 
between parasite densities and endemicity, suggesting that submicroscopic infections are 
likely to occur in high endemic areas where exposure to infection is more frequent and 
densities are low (Mosha et al. 2013). That study and our own data are inconsistent with the 
meta-analysis by Okell et al. (2012), which had indicated that in low endemic settings with a 
P. falciparum prevalence of <10% the great majority of infections (88%) should be 
submicroscopic, while in high endemic settings with a prevalence >75% the submicroscopic 
carriage was estimated to be as low as 25%. A major problem for this kind of comparison is 
that the positive cases in low endemicity settings are very few (e.g. we observed only 2 
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infections by qPCR at our lowest endemicity site), thus, not sufficient data is generated to 
draw firm conclusions on submicroscopic carriage. These limitations became clear in view of 
the very few qPCR-positive samples even in low (positivity: 2/329 and 15/440) and moderate 
(positivity: 8/235 and 56/316) transmission settings. We observed high P. falciparum 
prevalence rates by both LM and qPCR in young children with a peak at age 5-9 yrs. This was 
expected as high incidence rates for clinical malaria and infections of high parasite densities 
mainly occur in children. Similar studies in Ghana and Tanzania have also recorded a peak in 
malaria prevalence at 5-9 yrs (Owusu-Agyei et al. 2002; Drakeley et al. 2006; Mosha, et al. 
2013). 
An additional objective of this study was to investigate whether malaria endemicity affects 
the prevalence of submicroscopic gametocyte carriers. As expected, applying molecular 
tools for gametocyte detection was far better than LM. The molecular assay detected 15.8% 
gametocyte carriers compared to <1% by LM and 96% of the gametocyte positive samples 
were submicroscopic. The occurrence of a high proportion of submicroscopic 
gametocytemia (95-100% at all sites) irrespective of endemicity is alarming, since several 
studies involving mosquito feeding experiments had indicated a substantial contribution of 
submicroscopic gametocyte carriage to transmission (Coleman et al. 2004; Schneider et al. 
2006; Churcher et al. 2013; Lin et al.2014). 
Despite great benefits of molecular tools for parasite detection, PCR will unlikely replace the 
two standard diagnostic tools in the field, LM and RDT, which will continue to be heavily 
used in resource limited settings (Mwingira et al. manuscript under review). However, PCR 
can play an essential role in assessing the quality of LM. By routinely conducting PCR-based 
studies in parallel to LM diagnosis in some malariological surveys, valuable estimates of this 
otherwise undetected parasite burden can be generated. With a country-wide cross 
sectional surveys combined with PCR diagnosis we were able to provide an assessment of 
the LM quality for the widely differing transmission intensities in Tanzania.  
 
Conclusions 
Our study confirms a high prevalence of submicroscopic parasitemia and gametocytemia in 
Tanzania. Submicroscopic infections were observed in all endemic settings and did not show 
a specified trend with decreasing endemicity. Our results can inform control strategies by 
drawing attention to asymptomatic individuals, mostly adults with primarily submicroscopic 
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infections, whose contribution to onwards transmission should not be ignored. Our 
molecular parasite detection assays unveiled 52% of infections and 96% of gametocyte 
carriers that would have been missed if the survey had relied on LM alone. Imperfect 
diagnosis will likely jeopardize malaria control efforts. Thus our qPCR-based point prevalence 
rates for areas of different endemicity contribute to a solid basis for planning and monitoring 
elimination efforts in Tanzania. 
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List of tables 
Table 1: Proportion of submicroscopic parasitemia in 5 areas of different endemicity in 
Tanzania 
Region qPCR positives  
 
 
%      (n/N) 
LM positives in 
qPCR positives  














Iringa 0.6   (2/329) 0 2/2    2/329 n.a.1) 
Dar 3.4   (15/440) 26.7   (4/15) 11/15 11/440 73 
Tanga 3.4   (8/235) 37.5   (3/8) 5/8   5/235 63 
Bagamoyo 17.7 (56/316) 66.1   (37/56) 19/56 19/316 34 
Rufiji 49.8 (249/500) 45      (112/249) 137/249 137/500 55 
1) Number too low to support any firm conclusion  
 
Table 2: Proportion of submicroscopic gametocytemia in 5 areas of different endemicity in 
Tanzania (N denotes samples per site) 
Region Pfs25 qRT-PCR 
 
  
%         (n/N) 
LM positive in 
pfs25 positive 
 









Iringa 0.3       (1/329) 0 1/1 n.a.1)  
Dar 0.68     (3/440) 0 3/3 n.a.1) 
Tanga 6.4       (15/235) 0 15/15 100 
Bagamoyo 16.1     (51/316) 0 51/51 100 
Rufiji 43.6     (218/500) 5     (11/218) 207/218 95 
1) Number too low to support any firm conclusion 
  




Figure 1: P. falciparum prevalence by three independent diagnostic methods in 5 Tanzanian 




Figure 2: parasite load quantified by LM (log 10 parasites/µL blood) observed at 5 study sites. 
The median is shown as solid line with 25 and 75% quartiles.  
* Very few or no samples at all were detected at sites of low and moderate endemicity.  




Figure 3: Correlation of P. falciparum parasite load (expressed as Log10 18S rRNA copy 
numbers/µL blood) and gametocyte load by (expressed as Log10 pfs25 copy numbers/µL 
blood) in samples positive for both molecular assays.  r2 = 0.47. Samples from all cross 
sectional surveys were combined. 
 
 
Figure 4: Age trends in P. falciparum prevalence diagnosed by LM, RDT and qPCR for the 
combined data set from all study sites.    
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Supplementary Tables  
Supplementary Table S1: Study sites classified into different endemic settings according to 
prevalence results from the national malaria indicator survey of 2008 (THMIS 2009);N 
denotes the number of samples per study site..  
Region THMIS-Malaria 
prevalence of 2008  
Time of sampling (N) 
Dar Es Salaam 1% 2013 (440) 
Iringa 3% 2013(329) 
Coastal Bagamoyo 10% 2013(316) 
Tanga 14% 2013(235) 
Coastal Rufiji 21% 2013(500) 
 
Supplementary Table S2: P. falciparum parasite and gametocyte prevalence detected by LM, 
RDT and molecular assays per study site. 
 Parasite prevalence  
% (p/N) 
Gametocyte prevalence  
% (p/N) 
Region LM RDT 18S qPCR LM Pfs25 RT-PCR 
Iringa  0 (0/329) 0.6 (2/329) 0.6 (2/329) 0 (0/329) 0.3 (1/329) 
Dar 6.6 (29/440) 1.6 (7/440) 3.4 (15/440) 0.2 (1/440) 0.7 (3/440) 
Tanga 2.1 (5/235) 5.1 (12/325) 3.4(8/325) 0 (0/235) 6.4 (15/235) 
Bagamoyo 16.8 (53/316) 16.8 (53/316) 17.7 (56/316) 0 (0/316) 16.1 (51/316) 
Rufiji  25.8 (129/500) 47.8 (239/500) 49.8 (249/500) 2.8 (14/500) 43.6 (218/500) 
 
  





Figure S1: Mean parasite density (parasites/µL blood) by age established by LM. 
 
 
Figure S2: Percentage of submicroscopic parasitemia by age in black bars. Percentage of 
submicroscopic gametocytemia by age is shown in grey bars.  
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Planning and evaluating malaria control strategies relies on accurate definition of parasite 
prevalence in the population. A large proportion of asymptomatic parasite carriers are 
identified by surveillance with molecular methods only, yet these infections also contribute 
to onward transmission to mosquitoes. Sensitivity of molecular detection by PCR is limited 
by the abundance of the target sequence in a DNA sample, thus detection becomes 
imperfect at low densities. We aimed to increase PCR diagnostic sensitivity by targeting 
multi-copy genomic sequences for a reliable detection of low-density infections and 
investigated the impact of these tools on community prevalence data. 
 
Methods and findings 
Two qPCR assays were developed for ultra-sensitive detection of P. falciparum, targeting the 
high-copy telomere-associated repeat element 2 (TARE-2, ~250 copies/genome) and the var 
gene acidic terminal sequence (varATS, 59 copies/genome). Using parasite culture, our 
assays reached a limit of detection of 0.034 parasites/µl blood and are thus 10x more 
sensitive than standard 18S rRNA qPCR. In a cross-sectional study in Tanzania, 297/500 
samples tested positive with one or both of the ultra-sensitive assays, whereas 18S rRNA 
qPCR failed to identify 50 (17%) of these. Light microscopy missed 170 (57%) infections. To 
judge their suitability for high-throughput screens, TARE-2 and varATS assay performance 
was tested on sample pools. Both ultra-sensitive assays correctly detected all pools 
containing one low-density P. falciparum positive sample among nine negatives, which went 
undetected by 18S rRNA qPCR. 
 
Conclusions 
Malaria prevalence in communities is largely determined by the sensitivity of the diagnostic 
tool used. Prevalence in our study population was underestimated by 10% even when 
applying molecular diagnostics. Our findings highlight the need for highly sensitive tools such 
as TARE-2 and varATS qPCRs in community surveillance and for monitoring interventions to 
better describe malaria epidemiology and inform malaria elimination efforts. 




Accurate and sensitive detection of malaria parasites is a key factor in planning, targeting 
and evaluating malaria control efforts and requires different strategies at different 
elimination stages [1–3]. One major challenge is the identification of remaining reservoirs of 
human-to-mosquito transmission in asymptomatic individuals carrying low-density 
infections. The true extent of this predominantly submicroscopic reservoir became better 
defined with the wider application of molecular detection techniques in epidemiological 
studies [4,5] and its relevance to sustained malaria control has been brought into focus [1–
3]. It was recently estimated that submicroscopic but PCR-detectable infections make up 
20% of all malaria infections in high-transmission areas and as much as 70% in low-endemic 
areas, where they contribute 40% of all transmission to mosquitoes [5]. Mass drug 
administration (MDA) interventions include treatment of these undetected carriers and can 
thereby reduce parasite prevalence for several months in low-to-moderate prevalence 
settings, with even longer effects predicted at low-transmission levels [6,7]. According to 
modelling predictions, mass screening and treatment (MSAT) strategies have a lower impact 
than MDA-based interventions [7], as MSAT is limited by the sensitivity of the diagnostic tool 
used. A recent study in Burkina Faso found no sustained effect of anti-malarial treatment on 
incidence of clinical episodes nine months after MSAT using conventional rapid diagnostic 
test (RDT)-based diagnosis [8]. This finding is likely attributable to the large proportion of 
undetected low-density infections. The true parasite burden could be better defined using 
nucleic-acid based diagnostics, but even then, very low-density infections might be missed. 
Such low-density infections might be particularly prevalent in areas with a recent and drastic 
decline in P. falciparum force of infection, where high parasite densities and disease are 
controlled by residual immunity. As more countries successfully reduce malaria prevalence 
[9], the proportion of low-density infections can be expected to rise and more sensitive 
diagnostics that surpass even conventional PCR are urgently needed to detect potential 
hidden reservoirs.  
 
Of the current molecular detection methods available for malaria diagnosis (summarized in 
Table 1), RNA-based techniques such as quantitative Reverse Transcription-PCR (qRT-PCR) 
[10–12], nucleic acid-sequence based amplification (NASBA) [13–15] or ELISA-like 
hybridization assays [16] reach highest sensitivities by targeting the highly abundant 18S 
   
74 
 
small subunit ribosomal RNA (18S rRNA). However, due to the unstable nature of RNA, these 
assays require dedicated and controlled sample collection and storage and thus only have a 
limited application in field settings. DNA-based techniques are generally easier field-
adaptable and include nested PCR [17–22], quantitative PCR (qPCR) [23–31], loop-mediated 
isothermal amplification (LAMP) [32–35], isothermal recombinase polymerase amplification 
(RPA) [36], and alternative PCR-based detection methods [19,37–41]. Of the DNA-based 
assays, only qPCR allows to robustly quantify copy numbers of the template DNA in the 
reaction as a measure of parasite load in the sample. 
 
Due to the lower number of target molecules in the sample, DNA-based techniques have a 
reduced sensitivity compared to their RNA-based counterparts, but sampling for DNA-based 
diagnosis is more robust. The most prominent molecular marker is the 18S rRNA gene, 
present at 5-8 copies per genome, depending on the parasite strain [42]. Lately, several 
attempts have been made to increase DNA-based PCR sensitivity by choosing mitochondrial 
[19,27,32,43] or other nuclear multi-copy targets [40,44]. Already in 1997, Cheng et al. 
designed a nested PCR detecting the conserved region of the subtelomeric stevor gene 
group with many copies per genome [45], which had improved sensitivity over single-copy 
PCRs [46].  
 
We have taken this approach further and chose high-copy subtelomeric sequences to 
develop novel qPCR assays for highly sensitive detection and quantification of P. falciparum 
in low-density infections. The telomere associated repetitive element 2 (TARE-2) is a 1.6-kb 
long block consisting of ten to twelve 135-bp repeat units with slightly degenerate 
sequences, interspersed by two 21-bp sequences [47,48]. The TARE-2 repeat is present at 24 
of 28 subtelomeres in 3D7 [48], which amounts to ca. 250-280 copies per genome, and is 
specific to P. falciparum strains [47].  
 
The var gene family is located primarily in the subtelomere and was chosen to develop a 
second qPCR with multi-copy target. The genome of the 3D7 culture strain harbours 59 var 
genes [48], and an estimated 50-150 copies are present in other parasite lines [49,50]. Var 
genes encode the P. falciparum erythrocyte membrane protein 1 (PfEMP1) and possess a 
transmembrane domain and one intron, with exon 1 and 2 encoding for the extra- and 
intracellular parts of PfEMP1. In contrast to the highly variable extracellular domain, the 
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intracellular acidic terminal sequence (varATS) comprises some well-conserved stretches and 
can thus be targeted by qPCR [49,50]. 
 
With the aim to increase test sensitivity at least tenfold and to improve the robustness of 
parasite detection at low densities, we developed two novel qPCR assays using the multi-
copy TARE-2 and varATS sequences as targets. We then investigated the potential of both 
assays to detect ultra-low density infections that are beyond the detection limit even of 18S 
rRNA qPCR. We further hypothesized that the abundance of the PCR target in the parasite 
genome would counterbalance the diluting effect of sample pooling, and thus tested the 
suitability of our assays for application to sample pools.  
 
Methods 
Primer design and qPCR conditions 
For varATS primer design, all 59 varATS sequences per P. falciparum genome (strain 3D7; 
PlasmoDB) were aligned using ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
Within the size polymorphic varATS domain (size range 1-1.5 kb), the most conserved 
domain was selected for primer and MGB-probe design. One wobble was each inserted into 
the forward primer and probe to improve annealing, whereas the reverse varATS primer 
matched very well with all 3D7 varATS sequences. We expect that only about 40% of 3D7 
sequences match sufficiently well with the selected oligonucleotides to yield an 
amplification product. Attempts to further increase assay sensitivity by using additional 
wobbles and combinations of primers were not successful. Primer and probe sequences as 
well as qPCR reaction and cycling conditions are listed in Supplementary Table S1.  
The TARE-2 repeat region was identified in the genome of P. falciparum strains 3D7 (NCBI, 
http://www.ncbi.nlm.nih.gov/) and IT (PlasmoDB, http://plasmodb.org/plasmo/) using the 
Tandem Repeats Finder tool (http://tandem.bu.edu). TARE-2 sequences of other P. 
falciparum strains were retrieved by BLAST search using 3D7 and IT repeat units 
(http://blast.ncbi.nlm.nih.gov). All repeat units were aligned using Clustal Omega 
(http://www.ebi.ac.uk) and primers were designed on the most conserved stretches so that 
8 nucleotides prior to the 3’ end matched with the majority of repeat sequences. One 
wobble was inserted into each primer for better annealing. Owing to repeat degeneration 
and therefore difficult probe design, probe-free SYBR® Green-based real-time quantification 
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of amplicons was chosen. Primer sequences and qPCR reaction and cycling conditions are 
specified in Supplementary Table S1. Melt curves of amplicons were inspected in each 
experiment to detect false positivity. True positive samples differed clearly from primer 
dimer and unspecific PCR products based on the amplicon’s melting temperature 
(Supplementary Figure S2). 
 
Samples were quantified using a standard curve of plasmid (varATS) or parasite genomic 
DNA (gDNA, TARE-2). As varATS standard, the varATS amplicon was amplified from 3D7 
genomic DNA and inserted into the TOPO®-TA vector (Invitrogen). The purified plasmid was 
diluted to 106, 104 and 102 plasmids/µl in TE buffer. As TARE-2 standard, gDNA of a 10-fold 
dilution of ring-stage 3D7 parasite culture was used (6.8x103 to 6.8x10-2 parasites/µl, 
described in Supplementary Protocol S3).  
The reference 18S rRNA qPCR was performed as described previously [23], using a MBG-
probe (6FAM-5’-ACGGGTAGTCATGATTGAGTT-3’-NFQ-MGB) in a total volume of 12 µl. DNA 
volume matched that of varATS and TARE-2 qPCRs. The amount of target DNA in each 
sample was calculated from the Ct value using a plasmid standard curve as described above 
(18S rRNA amplicon inserted in TOPO®-TA vector, Invitrogen). 
 
Analytical specificity and sensitivity 
The analytical specificity of TARE-2 and varATS qPCRs was assessed both in silico using BLAST 
search and experimentally using human genomic DNA from a healthy malaria-free volunteer 
and P. malariae and P. ovale genomic DNA from archived anonymized diagnostic blood 
samples. No amplification from non-falciparum Plasmodium or human DNA was observed 
using the varATS and TARE-2 qPCRs.  
 
For assessment of P. vivax cross-reactivity, 14 samples with low to medium number of 
genomic P. vivax 18S rRNA copies  (22 - 393 Pv18S rRNA copies/µl, light microscopy (LM): 0 - 
219 parasites/µl) were selected from a previously analysed sample pool [11]. All 14 selected 
P. vivax DNA samples had been diagnosed P. falciparum-negative by 18S rRNA qPCR. All 14 
samples were varATS and TARE-2-negative.  
 
Analytical sensitivity and qPCR efficiency were validated on a P. falciparum dilution row of in 
vitro cultured ring stages (3D7 strain). Details on generation of the dilution row are 
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presented in Supplementary Protocol S3. TARE-2 and varATS qPCR efficiencies were 
comparable to that of 18S rRNA qPCR, however, all qPCR efficiencies were slightly outside 
the desirable efficiency range of 90-105% (Table 2). The limit of detection (LOD) was defined 
as the last dilution at which more than 50% of replicates were positive. The TARE-2 and 
varATS assays were 10x more sensitive than 18S rRNA qPCR and reached a LOD of 0.034 
parasites/µl blood (Table 3). This corresponds to 7 parasites in 200 µl whole blood, which is 
the typical volume normally processed for DNA extraction from finger prick blood samples.   
 
Field samples and DNA extraction 
Field samples used for these analyses were derived from a cohort study conducted in Maprik 
district, PNG [11] and a cross-sectional survey conducted in Rufiji, TZ, in 2013. Scientific 
approval and ethical clearance for the PNG cohort study was obtained from the Medical 
Research and Advisory Committee of the Ministry of Health in PNG (MRAC no. 09.24) and 
the Ethics Commission of Basel Land and Basel Stadt (no. 237/11). Approval for the TZ cross-
sectional study was obtained from the Institutional Review Board of the Ifakara Health 
Institute, Dar es Salaam, TZ (no. 13-2013). Informed consent was obtained from all study 
participants in PNG and TZ, for children from parents or legal guardians prior to sampling. 
The 60 DNA samples from PNG were selected from a larger pool of previously analysed 
samples   based on their positivity in 18S rRNA qPCR (33 positives, 27 negatives) and using 
18S rRNA copy numbers in theses sample to select a wide range of parasite densities [11]. 
DNA of PNG samples was extracted using the FavorPrepTM 96-well genomic DNA extraction 
kit (Favorgen) from 50-150 µl blood cell fraction, eluted in 200 µl elution buffer and stored at 
-20°C.  
 
The 500 TZ samples were age-stratified randomly selected from the larger cross-sectional 
sample set. DNA was co-extracted during RNA extraction from 50 µl whole blood in 250 µl  
RNAprotect Cell reagent (Qiagen) using the RNeasy Plus 96 kit (Qiagen). Briefly, DNA was 
recovered from the gDNA eliminator column after two washing steps according to the 
QIAamp 96 DNA blood kit protocol (500 µl AW1 buffer, 500 µl AW2 buffer) and eluted in 100 
µl AE elution buffer. After the first round of performing all three qPCRs, TZ samples positive 
in only one assay were repeated in duplicate for all assays.  TZ samples positive in two out of 
three assays were repeated in duplicate for the negative assay only. Samples were defined 
as positive if two out of three replicates were positive.  
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Generation of pooled samples  
Low-density P. falciparum positive samples (< 2 parasites/µl by TARE-2 qPCR, LM negative) 
were selected from the TZ collection and mixed with 4 or 9 P. falciparum negative blood 
samples to create pools of 5 or 10 samples. Negative samples were prepared by mixing 50µl 
blood from a malaria-negative blood donor with 250µl RNAprotect Cell reagent (Qiagen) to 
permit simultaneous DNA and RNA isolation. Per sample 100 µl of whole blood in 
RNAprotect Cell reagent were added to the pool, resulting in a total sample volume of 500 µl 
or 1 ml (for 5- and 10-sample pools, respectively). DNA was extracted from the entire 
volume of these pools using the RNeasy Plus 96 kit (Qiagen) as described above and DNA 
was eluted in 100 µl (5-sample pools) or 200 µl (10-sample pools). In total we generated 20 
pools of 5 samples, 5 of which contained a P. falciparum positive sample, and 10 pools of 10 
samples, 2 of which contained a positive sample.  
 
Results 
Detection of ultra-low density infections in Maprik area, PNG 
We compared the ability of the three qPCRs to detect low-density P. falciparum infections in 
60 DNA samples from PNG. All 33 samples that were positive in 18S rRNA qPCR were also 
positive using both ultra-sensitive assays. Out of the 27 samples negative by 18S rRNA qPCR, 
four were positive in varATS qPCR. The same four samples plus five additional samples were 
positive by TARE-2 qPCR. Since samples were not randomly selected but chosen deliberately 
to include a wide parasite density range, this result does not reflect the true P. falciparum 
prevalence in Maprik area, PNG. Nevertheless the number of additional samples positive for 
P. falciparum demonstrates that a considerable proportion of infections may persist at ultra-
low densities and remain undetected by standard qPCR.  
 
Prevalence of ultra-low density infections in Rufiji, TZ 
P. falciparum prevalence in Rufiji, TZ, was assessed on 500 samples randomly selected from 
a larger cross-sectional study conducted in 2013. P. falciparum prevalence was significantly 
higher using ultra-sensitive detection methods as compared to 18S rRNA qPCR (p < 0.05). 
Prevalence values were 58.4% (95% CI: 54.0 – 62.6) by TARE-2 qPCR, 58.0% (95% CI: 53.6 – 
62.2) by varATS qPCR and 49.4% (95% CI: 45.0 – 53.7) by 18S rRNA qPCR (Figure 1A). The 
gain in P. falciparum prevalence thus was 9% and 8.6% by TARE-2 and varATS qPCR, 
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respectively. This corresponds to roughly a fifth of P. falciparum carriers that were missed 
using standard 18S rRNA qPCR.  
 
The gain in prevalence by use of ultra-sensitive versus standard qPCR was similar across all 
age groups. We observed the highest gain in diagnosed infections in infants <1 year when 
using TARE-2 qPCR (16.7%%, p = 0.21, Figure 1B). For varATS qPCR-based prevalence the 
gain in infants was small with 5.6% (p = 0.63). Parasite densities or target copy numbers in 
the blood sample were low in infants <1 year, peaked in 2-3 year-old children and thereafter 
decreased continuously with age for all assays (Figure 1C). Parasite loads observed in infants 
were lower, equal or higher than those observed in >60 year-olds using TARE-2, varATS and 
18S rRNA qPCRs respectively. This suggests that infections carrying the lowest parasite 
densities are found in infants and were missed using varATS qPCR and even more so using 
18S rRNA qPCRs.  
 
Inter-assay agreement and correlation of P. falciparum quantification in Rufiji, TZ 
The level of agreement between assays was almost perfect with Κ = 0.86 for all assays 
(Fleiss’ Kappa) as well as in pairwise comparisons (Cohen’s Kappa Κ = 0.80-0.95) in the TZ 
sample set. 297/500 samples (59.4%) were P. falciparum positive by any assay. 50/297 
samples were not detected by 18S rRNA qPCR but were positive in either varATS or TARE-2 
qPCR (Figure 2A). 80% (40/50) of these samples were detected by both ultra-sensitive 
assays. All samples detected by 18S rRNA qPCR were also detected by varATS qPCR and all 
but two by TARE-2 qPCR.  
 
Good correlation of P. falciparum parasite quantification by 18S rRNA qPCR and microscopy 
was demonstrated previously [23]. Similarly, quantification by 18S rRNA qPCR also 
correlated very well with varATS and TARE-2 quantification in field samples from Rufiji (R2 = 
0.98 and R2 = 0.95, respectively, p < 0.001, Figure 2B). Correlation of varATS and TARE-2 
quantification was also very high with R2 = 0.97 (p < 0.001). Parasite loads by TARE-2 qPCR in 
samples negative by 18S rRNA qPCR were, except for few outliers, within the lowest quartile 
of all parasite loads by TARE-2 quantification. The same was observed for varATS copy 
numbers of 18S rRNA negative samples.  
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Performance on sample pools 
To investigate the potential of our assays for a wider application in malaria surveillance or 
epidemiological field studies, we tested the power of all three qPCR assays to identify P. 
falciparum positive samples in pools of 5 or 10 samples, each containing one low-density P. 
falciparum infection.18S rRNA qPCR failed to identify the two positive 10-sample pools and 
only identified 1 of 5 positive 5-sample pools. In contrast, varATS and TARE-2 qPCR correctly 
detected all positive 5- and 10-sample pools. No amplification was observed from negative 
control-pools. Our ultra-sensitive assays thus proved suitable for detection of low-grade 
infections after dilution in nine negative samples. These infections would be missed by 18S 
rRNA qPCR after pooling. In a setting with 2% P. falciparum prevalence as simulated here, 
the cost of sample processing and detection can therefore be reduced by at least 70% 
without loss in sensitivity if ultra-sensitive assays are applied on pools of 10 samples.  
 
Discussion 
Accurate data on parasite prevalence in the community are imperative for targeting 
antimalarial interventions and for monitoring their outcome. In this study, we provide first 
evidence of very low-grade infections in individuals who had previously been considered 
parasite-free, even after molecular diagnosis. In Rufiji, a high-endemic area in TZ, 
microscopic and submicroscopic infections each made up roughly 40% of all P. falciparum 
infections. The remaining approx. 20% were of ultra-low density and not detected by regular 
18S rRNA qPCR. Also in Maprik area in PNG, 18S rRNA qPCR failed to identify ultra-low 
density infections, which resulted in underestimation of the parasite burden.  Improved 
measures of prevalence have consequences for monitoring and evaluating malaria control 
activities as well as for assessing the potential for onward transmission from human hosts to 
mosquitoes.  In malaria-endemic areas with formerly high infection rates and recent drop in 
transmission due to successful control programmes, in particular, most P. falciparum 
infections are asymptomatic and often submicroscopic. In such areas, detection of infection 
rather than assessment of malaria-associated illness could serve as a better measure of the 
malaria burden and a better parameter for surveillance and evaluation [1].  
 
A meta-analysis of infection prevalence across the endemicity spectrum has indicated that 
submicroscopic infections are generally more prevalent in low transmission settings than in 
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high transmission areas [5], probably as a result of a recently reduced force of infection and 
the long duration of asymptomatic untreated infections [51–53]. This suggests that 
prevalence of ultra-low-density infections and, thus, underestimation of the infection 
burden may also be greatest in low-endemic areas. Few studies have investigated the 
transmission potential of submicroscopic infections. Microscopically patent infections with 
gametocyte densities below the microscopical threshold can infect mosquitoes albeit at 
lower rates than microscopically gametocyte-positive samples (13.2 vs. 2.3% infected 
mosquitoes) [54]. Similarly, data from the mid-20th century and from two recent studies 
showed that even blood from infections without any microscopically detectable parasite 
resulted in 0.2-3.2% infected mosquitoes [5,55–57]. Despite low infectivity of each individual 
infection, the relative contribution of low-density infections to forward transmission to 
mosquitoes becomes substantial in areas where these account for a large proportion of 
infections [5,54]. Accurately defining the full extent of the submicroscopic infection burden, 
including the lowest-grade infections only detectable with ultra-sensitive assays, is therefore 
a prerequisite for evaluating its relevance to maintaining malaria transmission.  
 
Our results highlight the fact that prevalence data are strongly dependent on the sensitivity 
of the diagnostic technique applied. Even if parasite prevalence is measured using standard 
qPCR protocols, many low-key infections remain undetected. Standard PCR is widely 
considered to be the gold standard of malaria diagnosis, yet our results suggest that this 
notion requires revision. It becomes increasingly clear that the volume of blood analysed and 
the use of multi-copy markers to increase representation of a PCR template in the diagnostic 
assay have great influence on the prevalence outcome. Our findings shed new light on MSAT 
strategies for interruption of transmission in elimination settings, particularly those that rely 
on RDT-based diagnosis only, as it becomes clear that the ignored proportion of 
submicroscopic infections is even larger than anticipated. Following a recent MSAT campaign 
in TZ, RDT-undetected infections were given as a plausible explanation for the short-lived 
effect on malaria episode incidence [58]. In this study, more than 45% of PCR-detectable 
infections were missed, which, given our results, is very likely a substantial underestimation. 
A major task now consists in adapting molecular methods with enhanced sensitivity to meet 
the requirements of a robust, field-compatible diagnostic assay. Such tools become 
increasingly important to determine the infection burden irrespective of endemicity level. 
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We have presented here two ultra-sensitive qPCR assays for improved detection of low-
grade P. falciparum infections and application to sample pools. The varATS qPCR is very 
robust, highly specific and allows fast and easy data analysis through the use of a sequence-
specific probe. The TARE-2 assay is more susceptibility to changes in chemical composition of 
the DNA solution and requires melt curve analysis of amplicons, which can be a potential 
draw-back, particularly when performed by less-trained personnel. Surprisingly, the TARE-2 
qPCR did not outperform the varATS assay despite substantially higher target numbers in the 
genome. This might be explained by the degenerate sequence of the TARE-2 repeat units or 
by the clustered distribution of the repeats at chromosome ends. In the 3D7 genome about 
ten TARE-2 tandem repeats are present at 24 chromosome ends and, in this arrangement, 
are unlikely to be separated during DNA extraction. The 59 varATS targets of strain 3D7 also 
localize to chromosome ends and a few intracellular loci. We assume an equal probability for 
both targets to be represented in a PCR reaction, but certainly both assays surpass that of 
18S rRNA assays with three copies on different chromosomes.  
 
Because of the need for advanced laboratory infrastructure and staff training, use of our 
TARE-2 and varATS qPCRs in their current setup is not feasible in remote field settings. 
However, they are ideally suited for use in reference laboratories, for example for quality 
assurance or for centralized processing of large sample numbers in sample pools. Several 
strategies for pooling samples for malaria surveys have been described, comprising one or 
several pooling steps before [59–61]or after [62,63] DNA extraction. Pooling is severely 
limited by its inherent diluting effect and is therefore not recommended in the malERA 
strategy [1]. In low-endemic settings, in particular, where pooling would be most cost- and 
labour-effective, submicroscopic infections are highly prevalent [5] but are most likely 
missed in pools due to their low densities. Our varATS and TARE-2 proved to be useful for 
sample pooling as they counterbalance the diluting effect through multiple marker copies 
per parasite. In our hands even the lowest-density infections diluted with nine negative 
samples were still detectable. This may be further enhanced by increasing the volume of 
blood samples and concentrating material before qPCR [64]. Availability of ultra-sensitive 
assays such as our TARE-2 and varATS qPCRs makes sample pooling without loss in sensitivity 
feasible and allows achieving higher throughput in the context of limited resources in large-
scale field studies.  
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In conclusion, we encourage employing assays with enhanced sensitivity, such as the TARE-2 
or varATS qPCRs, in any malaria survey aiming to obtain accurate prevalence data and for 
monitoring intervention success, and recommend them particularly for screening of 
community samples in areas of low endemicity. The fact that parasites are more prevalent 
than currently thought has consequences for malaria control efforts, some of which are 
based on identifying all infected individuals, and must be acknowledged by all users of 
prevalence data such as health officials, strategy planners or mathematical modellers. Until 
the infectiousness to mosquitoes of low-density infections has been clarified, applying the 
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18S rRNA, 18S small subunit ribosomal RNA 
ELISA, enzyme-linked immunosorbent assay 
LAMP, loop-mediated isothermal amplification 
LM, light microscopy 
LOD, limit of detection 
MDA, mass drug administration 
MGB, minor groove binder 
MSAT, mass screening and treatment 
NASBA, nucleic acid-sequence based amplification 
PfEMP1, P. falciparum erythrocyte membrane protein 1 
PNG, Papua New Guinea 
qPCR, quantitative PCR 
qRT-PCR, quantitative Reverse-Transcription PCR 
RDT, rapid diagnostic test 
RPA, isothermal recombinase polymerase amplification 
TARE-2, telomere associated repetitive element 2 
TZ, Tanzania 




















18S rRNA, dhfr-ts, 
28S rRNA, Stevor 
No 0.1 - 10 
[17-
22,45] 
PCR DNA mtDNA No 0.5 [43] 
qPCR DNA 
18S rRNA, Cox1, 
Cytb 
Yes 0.02 - 3 [23-31] 
PCR-based DNA 18S rRNA, Cox1 Yes/No 0.5 - 1 
[19,37-
41] 
LAMP $ DNA 18S rRNA, mtDNA No 1 - 10 [32-35] 
RPA$ DNA 18S rRNA No 4 [36] 
qRT-PCR RNA 18S rRNA Yes 0.002-0.02 [10-12] 
(QT-)NASBA$ RNA 18S rRNA Yes/No 0.02 [13-15] 
$ Isothermal amplification process 

















18S rRNA -3.63 88.5 41.09 1.0 Taqman 221 bp 3 
varATS -3.63 88.6  34.50 1.0 Taqman 65 bp <59c 
TARE-2 -3.75 84.7 32.08 0.97 
Sybr 
Green 
93 bp <250-280c 
a Intercept equals the Ct value of the DNA equivalent of 5 parasites added to the qPCR 
reaction. 
b Length of consensus sequence.  
c Polymorphism in primer binding sites likely does not permit efficient amplification of all 
genomic copies. Number of target sequences present in parasite genomes from field 
samples cannot be determined in absence of the respective genome data. Therefore this 
assay is not suitable for absolute parasite quantification. 
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Table 3: LOD of TARE-2, varATS assays and 18S rRNA qPCR determined by serial dilution of 
ring-stage parasite culture (3D7 strain) 












6800 3/3 26.3 ± 0.5 3/3 19.9 ± 0.3 3/3 16.9 ± 1.0 
680 3/3 30.4 ± 0.5 3/3 23.8 ± 0.4 3/3 21.1 ± 1.4 
68 3/3 34.1 ± 0.5 3/3 27.5 ± 0.2 3/3 24.7 ± 1.7 
6.8 3/3 37.6 ± 0.7 3/3 30.8 ± 0.1 3/3 28.6 ± 1.6 
3.4 3/3 38.7 ± 0.3 6/6 32.0 ± 0.2 6/6 29.7 ± 1.4 
0.68 3/3 40.8 ± 1.2 6/6 34.4 ± 0.3 6/6 31.9 ± 1.3 
0.34 3/3 42.7 ± 0.8 6/6 35.5 ± 0.2 6/6 32.6 ± 1.7 
0.068 1/3 - 6/6 37.3 ± 0.3 6/6 38.5 ± 2.0 
0.034 0/3 - 6/6 37.7 ± 0.5 5/6 42.0 ± 1.5 
0.0068 0/3 - 1/6 - 0/6 - 
0.0034 2/3 - 2/6 - 2/6 - 









(A) Overall P. falciparum prevalence by different diagnostic methods. Error bars represent 
95% CIs. (B) P. falciparum prevalence based on TARE-2, varATS and 18S rRNA qPCRs by age. 
Error bars represent 95% CIs. (C) P. falciparum densities based on TARE-2, varATS and 18S 
rRNA qPCRs by age. The geometric mean in each age group is marked by a diamond; the 
median is denoted by a black line. 




Figure 2: Correlation of sample positivity and quantification using varATS, TARE-2 and 
18S rRNA qPCRs.  
(A) Venn diagram of positivity by varATS, TARE-2 and 18S rRNA qPCR in samples from Rufiji, 
TZ. (B) Parasite quantities determined by ultra-sensitive assays and their correlation with 
18S rRNA quantification. Quantification was done relative to copy numbers of plasmid 
standards (18S rRNA, varATS) or a parasite dilution row (TARE-2). Quantities of samples 
negative in 18S rRNA qPCR but positive in ultra-sensitive assays are shown in the left 
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Supporting information captions 
Table S1: Oligonucleotide sequences and qPCR conditions for varATS and TARE-2 assays. 
Primers were purchased from Eurofins. The varATS-probe and all qPCR reagents were 
purchased from Applied Biosystems/Life technologies. 
 varATS TARE-2 
Oligonucleotide sequences 
 Primer-fw (5’-3’) cccatacacaaccaaytgga ctatgttgcacttacatgcayaat 
 Primer-rev (5’-3’) ttcgcacatatctctatgtctatct tgacctaagaagtavaataatgatga 
 Probe (5’-3’) 6-FAM-trttccataaatggt-NFQ-
MGB 
- 
qPCR reaction conditions (final concentration in qPCR mix) 
 Total volume 12 (25)$ 25 (25)$ 
 DNA volume 4 (5)$ 4 (5)$ 
 TaqMan® Gene 
Expression Mastermix 
1x - 
 Power SYBR® Green mix - 1x 
 Primer (each fw & rev) 800 nM 200 nM 
 Probe  400 nM - 
qPCR cycling conditions 
 Pre-incubation 2 min – 50°C 2 min – 50°C 
 Initial denaturation 10 min – 95°C 10 min – 95°C 
 Denaturation 15 sec – 95 °C 15 sec – 95 °C 
 Annealing & Elongation 1 min – 55°C 1 min – 57°C 
 Number of cycles 45 45 
 Melt Curve  - 57-95°C, 0.3°C increment 
Positivity threshold 0.07 0.07 
Standard material for 
quantification 
Plasmid gDNA of parasite dilution row 
Platform  StepOne Plus® Real-Time 
PCR System (Applied 
Biosystems) 
StepOne Plus® Real-Time PCR 
System (Applied Biosystems) 












Figure S2: Melting temperature of TARE-2 amplicons using DNA samples from 2 different 
sources (surveys in TZ and PNG).  
 
Melting temperature (Tm) of true positives (TP, as in positive control/standards) differ 
significantly from false positive signals (primer dimer, p < 0.001). Owing to the degenerate 
character of the TARE-2 repeat unit, PCR products vary in sequence composition, which is 
reflected in slight variations in the Tm of TP (TZ 68.6 – 72.2 °C; PNG 70.0 – 72.1 °C). 
Different DNA extraction kits and dilution buffers used in the PNG and TZ surveys cause 
shifts in Tm for both specific amplicons and primer dimer. The mean Tm of TP and primer 
dimer was significantly different between PNG and TZ samples (p < 0.001), while qPCR 
amplicons amplified from 3D7 DNA standard included on both the TZ and PNG qPCR plates 
showed no significant differences in their mean Tm. The Tm of specific amplicon and primer 
dimer was hence established separately for each of our two sets of field samples. 
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Protocol S3: Generation of a P. falciparum dilution row from cultured ring stages (3D7 
strain) 
After 2 rounds of synchronization (5% sorbitol), ring-stage parasites were quantified by 
microscopic examination of 15 fields of a Giemsa-stained thin film by counting parasites 
versus red blood cells (RBC). In total >2000 RBC were screened. Parasite concentration in the 
blood pellet was calculated based on RBC counts of two representative blood pellets in a 
Neubauer-counting chamber. A serial dilution of parasite culture was produced in PBS and 
diluted 1:10 in whole blood from a malaria-negative blood donor. For each dilution, DNA was 
isolated in triplicate from 100 µl blood using the QIAamp DNA Blood Kit (Qiagen), eluted in 
100 µl TE-buffer and stored at -20°C. For determination of assay sensitivity, each assay was 
performed on the extracted triplicates of all dilutions, once for high-density dilutions 












??????????????? ??? ??????? ??? ???????????? ????? ???????? ??? ????? ???? ??????????? ?????????????? ????? ?? ? ??? ????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????? ?????? ?????????? ???? ?? ??????????? ??????? ?????????? ??????????????? ??? ?????? ?????? ??????? ???
????????????????????? ????????????????? ??????????????? ??????????? ???? ?????? ???? ??????????? ??????????? ??? ?? ?????
?????????? ??????? ??? ???? ???? ??? ???? ????????? ????? ?????? ???? ???????? ???????? ???? ?????????? ???? ??????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????? ?????????? ????????? ?????????? ????????? ??? ????? ??????????? ??????????? ??? ??????? ??? ?????? ?????? ???????




??? ??????? ???? ???????? ????????? ???????? ???? ????? ????????????????? ?????????? ?????? ???????? ???? ????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

















???? ? ????????? ??? ?????????? ??????????? ??? ???????????? ??
??????????? ?????????? ??? ????????????? ?????????????? ???????
???????????????????????????????????????????????????????????????????
????????? ???? ????????????? ????? ??????? ??? ????????? ????????
?????????? ??????????? ??????? ????????????? ????? ???? ??????????
?????????? ????? ??????? ?????????? ??? ?????? ??????????? ?????
????????????????????????????? ??????????????????????????????
???????????????????????????????? ???????????????????????????????
??? ????????? ??????? ????????? ??? ???????? ??????? ??????????
????????????????????????????????????????????????????????????
?????????? ??????????????????????? ?????????????? ???? ????????????
???????
????????????????????????????????????????????????????????????
??? ????????? ??????? ???? ?? ????? ??????? ??? ???? ????? ??? ?
???? ?????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
??????? ?????????? ??? ?????? ????????? ??? ????? ??? ??????? ???????
?????????? ??????????? ???????????? ???? ??????????????? ????
??????????? ???????? ?????? ??? ?????????? ???? ???????????? ??
???????????????????????????????????????????????????????????????
??? ??????????????? ??????????????? ??? ??? ??????????? ???? ??
?????????????????????? ?????????????????????????????? ???????
??????????????????????????????????????????????????????????
?????????????? ??????????? ???????? ????????? ?????????
????????????? ?????? ??????????? ???? ???????? ????????????? ???
???????????????????????? ????????? ??????????? ????? ??????? ?????
?????????????????????????? ? ????????????????????????????????????????????
?????? ???? ????? ????? ??? ????? ?????????? ???? ?????????
????????????? ???????? ??????? ???????????? ??????? ???? ??
????????????????????????????????????
??? ????? ??? ?????? ?????? ???????? ???????? ??? ???????? ???????? ??
???? ???????? ??????????????? ??????? ????????? ??????????? ???
??????????? ??????? ???? ???????? ???? ???? ?????????? ??
???????????? ??? ???????? ??????????? ??? ????? ?????????? ???
????????? ???????? ??????????? ???????? ????????????? ??? ?????
?????? ??? ??????? ???????? ????????? ?????? ??????????????????
???????? ?????? ?????????? ?????????? ??? ????????? ???????? ??????
???????????? ?????? ???? ?????? ?????????? ???????? ??? ?????????????
????? ??????? ??????????? ???????????? ??? ????????????? ????????
????????? ???????? ????????? ????? ?????? ???? ?????????? ??
?????????????????????????????????????????????????????????????????
??????? ?????? ???? ???? ?????? ???????? ????????? ???? ???
?????????????????????????????????????????????????????????????
????? ???????? ???????? ??? ????????????????? ???? ??????????
???????? ???? ?? ? ???? ??? ??????? ?? ????? ??????? ???? ?????????
?????????????????????????????????????????????????????????????
?????? ???? ??????????? ??????????? ?????? ??????????? ??????? ??
??????? ???? ?????????????? ????????????? ????????? ??? ????????????
????????
????????????????????? ??????????? ???????????????????? ??????
????????????????????????????????????????????????????? ??? ?????????
??????????????????????????????????????????????????????????????
??? ??????? ?????? ??????? ??? ?????????? ?????? ?????????? ????????
??????????? ????? ???????? ??? ???? ??????? ???? ?????? ?????? ??????? ??
???????????? ????? ????????? ????? ?????? ?????? ???????? ????
????????? ???? ??????? ??????? ???? ?????? ???? ??????? ??? ??????
???????? ???????????? ???? ?????????????? ???? ???????? ??????? ???
?????? ??? ????? ?????? ???? ??? ???? ?????????? ?????? ????? ??? ???
?????????????????????????????????? ???????????????? ???????????
??? ?????????? ????? ????? ??? ????? ??????? ???????????? ??
??????????? ????????? ???????????? ?????? ?? ???????? ??? ??????????
?????????????????????? ?????????? ???????????????????????????
??????????? ??? ???????? ???????? ????? ?????? ???????? ????????? ?
????? ????????? ??? ???????? ??????? ??? ??????? ???????? ????????






????? ??????????? ??? ???????? ?????????? ???? ??????????? ???
??????????? ?????????? ???????? ?? ?????????? ?????????? ??? ???
????????????????????????????????????????????????????????????????
??????? ??????? ??? ????? ???????? ???? ?????????????? ?????? ????
????????? ??????? ???????? ??? ???????? ??????????? ????? ?????????
????????????? ???? ?????? ?????????????? ??? ??????????? ????????
????????? ?????? ??????????? ???? ???? ?????? ????? ???????? ???
?????????? ??? ???????? ???????????? ???? ??????????????????????
?????????????????????????????????? ???????????????????????????
???????????????????????????????????????????????????????????????
?????????? ??????? ?????????? ????????? ?????????? ??? ?????
????????? ???? ??? ???? ????? ?????????? ??? ???????????? ??? ???
???????????????????????????????????????????????????????????




???? ???? ???????????? ??????????? ???????? ????? ?? ????
?????????? ?????? ???????? ??????????? ??? ??????????????? ????????
??????????? ???? ????? ??????????? ???? ????? ?????? ?????
?????????????????????????????????????????????????????????? ???
??????????? ?????? ????? ???? ????? ???????? ?????????? ????????? ??
?????????????? ?????????????????? ????????? ??? ?????????????????
??????????????????????????????????????????????????????????





??????????????????????? ?????????????? ?????????????? ????
???? ??????? ????????????? ????????? ????? ?? ??? ?? ??????? ????
???????????????? ??????? ??????? ????? ??? ?? ?????? ??????? ?????
???????????????????????????????????????????????????????????????







????? ????? ?????? ???????????? ??????? ?????? ?????? ??? ?????





???????? ???????????? ????? ?? ?????????? ????? ??????????? ???? ??
?????? ? ???????? ?????? ?????????????? ????? ????????????? ???
??????? ??? ?????? ?????? ????????? ??? ???? ???? ?????? ??? ???
?????????? ???????????? ????? ???????? ??????? ??????? ?????? ????
??????? ??? ?????? ?????? ???? ???????????? ????? ????????? ??????




???????? ????????????? ????? ?????? ??????? ??? ?????? ?????? ???
??????????????????????????????????????????????????????????????????????
???? ??? ??? ?? ?????? ?????????? ?????? ???????????? ??? ??? ?????
?????? ???? ???????????? ????? ???? ???????????? ????? ???? ??
????????????????????????????????????????????????????????????
?????? ?????? ???????????? ????? ???? ???? ????? ???????? ??? ???
??????????????????????????????????????????????????????????
??????? ???? ???? ??????? ??????? ???????? ?????? ????? ??????????
?????????????????????????????????????????????????????
???????????????????????????????????????????????????????
???? ????? ???????????? ???? ??????? ???????? ???? ????? ????????
??????? ?????? ???? ????????? ?????? ???????????? ????????? ???? ???????
????????????????????????????????????????????? ?????????????
???????????? ???? ???????? ???? ????????? ?????????? ???? ?????? ????
???????????????????????????????????
?????????????????????????? ? ????????????????????????????????????????????




?????? ????????????? ????? ???????? ??? ?????????? ???? ??????????
?????????? ????? ???? ????? ???? ????? ????? ??? ??????????? ???? ??
??????????????
???? ???????? ???? ??????? ??????? ???? ???? ?????????? ????
?????? ?????? ???????? ??? ???????? ???? ??????? ?????
????????????????????????????????????????????????????????????????
??????? ????? ???????????? ????? ??????? ????? ???? ??? ???? ?????
??????? ??????????? ?????????????????? ???????? ???????? ????
??????????????????????????????????????????????????????????????
????? ?????? ??????????????? ???? ??? ???? ??? ??????? ???? ???????
?????? ???? ???????????? ??? ?? ????? ??? ??????? ???????? ?? ???
??????????????????????????????????? ???? ???????????????? ???????
????????? ????????? ????? ????????? ????????? ???? ???? ?????????




??????? ????????????????????? ????? ?????????????????????????
????? ??????? ???? ???? ???? ??????????? ????????? ???? ??????????
??????????????????????? ???????????????????????????????????
????????????????????????????????????????????????
?????????????????? ???????? ????????????????????????? ????
????????????????????????????????????????????????????????????
?? ??????? ?????? ???????? ???? ????? ???? ?????? ? ?????????? ????
?????????????????????????????????????????????????????????????
??????????? ????????? ??? ???????????????? ???? ????????? ???? ???
?????????? ???? ??????? ??? ????? ???????????? ?????????? ????????
??? ?? ????? ??? ??????? ??????? ???? ??? ?????????? ?????
?????????? ????? ???????? ?????????? ??? ???? ??????????????
????????????????????? ????? ???????????????????????? ????? ?????
??? ??????????? ???????????? ??? ?????? ??? ????? ??????? ??
???????????? ????????? ???? ???? ??????????? ????? ???? ?????







??? ?????? ??????? ?????? ?????? ?????? ????? ?????? ??????????
????????? ?????? ???? ???????? ????? ????? ???? ????????? ???? ????
??????? ????????? ??? ?????????? ?????? ?????????? ????? ????
????????? ???? ??????????? ????????? ?????? ?????????? ??? ???? ????













????? ????????? ?????? ???????? ??? ??????? ???? ???????? ??? ?????
??????????? ?????? ?????????? ?????? ??????????????????????????





????????????? ??? ????????? ???????? ???? ??????? ??? ???????????
??????? ?????????? ????? ????? ???? ???? ???? ????????? ???
????????????????????? ???????????? ??????????? ??? ????????????
???? ??????? ?????? ?? ????? ????????? ?????????? ????? ?????
??????????????????????????????????????????????????????????????????
???? ?????????? ?????? ???? ????????? ????? ???? ?? ?????????
?????????????????
?????????? ??????????? ???????? ??????????? ? ?????
??????????? ???? ???? ???????? ????? ??????? ??? ????? ?????????
?????? ????????? ???? ????? ??? ???????? ????????? ?????????? ??
????? ??? ?? ???????? ?????? ??????? ?? ???? ??????? ????????
????????????? ????????? ????????? ??? ?? ???????? ?????????????
???????????????????? ??????????????????????????????????????
????????? ?????????? ???? ???????? ?????????????? ???? ?????????????
?????????? ??? ???? ???? ??????? ???? ??????? ??? ?????????? ????????
????????????????????????????????????????????????????????????
??? ??????????? ?????? ????????? ??????? ???? ????? ???????????




???????? ????????? ??? ????????????????? ???????? ?????????? ??? ?
?? ????? ????????? ???? ??? ??????????? ???? ??? ??????? ???? ??? ?
??????? ????????? ???? ??? ?????? ???? ??? ?????????? ??? ???? ???
??????? ???? ??????? ??? ?????? ???? ???? ??? ???? ?????????? ??????
????????????? ?????? ??????????? ????? ?????? ?????? ???????????? ???
????? ???????????? ??? ??? ??????????? ???????? ????? ??????
????????? ????????? ??? ???? ????? ??? ???? ??? ??????? ??????
?????????? ????? ??????????? ??? ????? ????????? ?? ???? ?????? ??
???????????????? ?????????????? ????? ???????????? ????????




???? ???? ?????????? ???? ???? ???? ???? ??????????? ??? ?? ????? ??? ???
????????? ??????????? ????? ???????? ??? ???? ?????? ????? ?????
???????????????????????????????????????????????????????????
???????? ???? ??? ???????????? ??? ??????????? ??? ???????? ????????
?????????????????????????????????????????????????????????????









?????????????????? ??????????????????????????? ????????????????????? ?????????????????????????????????????????????????????





???????????? ???? ????? ?????? ????????? ??????? ????? ?????????
????? ?????? ??????? ???? ??????????????? ??? ????? ???????? ??? ????
????????
??????????????????????????????????????????????????????????
???? ???????? ????? ?????? ??????? ???? ??????????? ???? ???
???????????????????????????????????????????????????????????





???????????? ????????? ?????????? ???? ???? ???????????? ?????
???? ?????? ???????????? ????????? ?????????? ???? ??????????
???????????????????????????????????????????????????????????
?????? ?????? ???? ???? ????? ??????????? ????? ???????? ???
????????????????????? ???????????????? ???????????????????? ??
??????? ???????????? ????? ?????????? ??? ????????????????? ???
?????? ??? ?????? ???? ???? ???????????? ??? ????????? ?????? ???
??????? ????????? ???? ?????? ??? ?????? ???? ?????? ???? ?????
??? ???? ??? ????? ??? ???? ?????? ????????????????? ???? ?????
????????????????? ??????? ????? ????????? ??????? ????
???????????? ?????????? ??????????? ??? ?????????? ??? ???? ????????
?????????? ??????????? ??????????? ??? ???? ??? ?????? ?????
?????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
????????? ????????? ????? ???? ???? ??? ????? ?????????? ????? ???
???????? ???? ????????????? ??? ??????????? ?????? ???? ??????? ??
?????? ?????????????????????????????? ????? ????? ??? ???????? ???
?????????????????????????????????????????????????????????
?????????????????????????????????????????????? ??????????????
????????????????? ??? ???? ???? ?????? ??????? ???? ????? ??????




?? ????????????? ???? ?????????? ???? ????? ???????? ??? ??
????????????? ???? ???????? ??? ???????? ?????????????????? ??
???? ??? ??? ????????? ???? ??????????? ???? ????????? ???????????
?????????????? ??? ??????????????? ???? ???? ???????? ????????????
???????????????????????????????????????????????????????????
???? ??? ???????? ??????? ???? ?????? ??? ???? ???????????
?????????? ?????? ??????? ??? ???? ?? ???? ?????? ???? ??? ????? ??




????????????????? ???????? ??? ???????????? ??? ??????????????? ??
???????? ??????? ????? ???? ???? ??? ??? ????? ????? ?????? ?????? ?????
??????????????? ??? ?????????????????????????????????????????????
??????????????????????????????????????????????????????????????
??????? ???????? ?????????? ?????? ???? ??????? ????? ??????? ???
????????? ????? ??? ??????????? ??? ??????? ?????? ?????????? ????
???? ?????????? ??? ?????? ???????? ????????? ?????? ?? ??????
????????????????????????????????????????????????????????????
??? ???? ??????????? ?????? ????? ??? ?? ???????? ??????? ?????? ???
???????????????????????????????????????????????????????????????
????? ??????????? ????????????? ?????????????????????? ????????
??????????? ?????????? ?????? ?????? ?? ?????????? ?? ?????? ??????
?????????????????????????????????????????
?????? ??????????????
?????? ??????? ????? ?????? ???? ????? ??????? ????? ?????????? ??
?????????? ???? ????? ???????? ???? ????????? ???????????????? ???
??????????? ????????? ???????? ????????? ??????? ???





????????? ??????? ??? ??? ????? ??????????? ??? ??? ???????? ?
??????????? ??????? ???? ?????? ????????????? ????????? ????
?????????? ?????? ?????? ????????? ????? ????? ???? ???????
??????????? ???????????????????????????????????????????????????
??? ????? ?????? ????? ???????????? ???? ?????????? ?????????? ???
???????????? ????????? ???????????????????????? ??????? ??????????
???? ???????? ??? ???? ???????????????? ?????????? ???? ???? ??
??????????? ????? ????????? ???????????? ????????????? ????
?????????????????? ?????? ???????????????? ???????? ??? ????????????














?????????? ??? ???? ??????????? ???????? ????????? ??????? ??
????? ??? ????????? ?????????? ??? ??? ??????????? ??? ??? ?????? ???
?????????? ??????????????????????????? ?????????????????????
?????? ?????????? ????????? ???? ??????????? ?????????? ????????
????????????????????????????????????????????????????? ???
???? ???????????? ?????????? ??????? ???? ??????? ??????????? ??????
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
???? ?????? ????? ???????? ???? ??? ???? ????????? ???????? ???
????????????????? ??????? ????? ????? ?????????? ??? ???????
???????????????????????????????????????????????????????????????
???? ??? ???? ???? ?????? ??????????? ??????????????? ??????? ??????
??????????????????????????????????????????????????????????












???? ???? ??? ???? ???????? ????????? ??? ???? ???????? ??????
????? ???????? ???????????? ???????? ????????? ???????? ???????
???????????????????????????????????????????????????????????
?????????? ?????? ???? ?????????? ???????? ????? ????????? ???????





??? ????? ?????????? ??????????? ????????? ??? ????????? ?????
??????????? ????????? ???? ??????? ??????????? ????? ?????? ??????
??????????? ???? ?????? ???? ??? ???????? ???????? ????? ????????
????????? ????? ?????????????? ????? ??? ?????? ??????????? ??????





???????????????? ?????? ???????????? ????? ???????? ??? ???? ?????????
??????????? ?????? ??? ??? ??????????? ??? ?????????? ????????
????????? ??????? ??? ???? ?????????????????????????????????? ?????
??????????????????? ????????????????????????????? ???? ???? ????????
????????? ??? ???? ?????? ???????? ?????? ?????????? ???? ?????? ??? ????
??????????????????????????????????????????????????????????????
??? ????? ??????? ????????? ??? ???? ??? ??????? ??????? ?????? ????????
?????? ???? ??????????????????? ??????????? ????????? ??? ?? ??????
???? ???????? ????????? ????? ?? ?????? ??????? ??? ????? ???
?????????????? ???? ??????????? ?????????? ??? ?? ?????? ??????? ??
???????????????????????????????????????????????????????????????









??????????????? ??? ??? ???
?????????????
?????????? ????????????? ?????????????? ??????????????
??????????????????????
?????????? ???????????? ????????????? ?????????????
??????????????????? ?????????????? ?????????????? ???????????????
?????????????
??????????????????? ????????????? ????????????? ??????????????
??????????????????????????????????????
??????????????????????????????????????????????????????????????
?????????? ???? ??? ???? ????????? ?????? ?????? ????????? ??????? ??
???????????????????????????????????????? ????????????????????????
???????????? ?????????????? ???? ??????????????????? ???????????
???????????????????????????????




????? ????????? ?????? ????? ???????????? ???? ??? ??????????? ??
???????? ??? ??????? ???? ??? ???????? ????????? ?????? ????
???????????????????????????????????????????????????????????
????????????????????????? ??????????? ???????????????????????
????????? ??????????????? ??? ??? ???? ????? ??????????? ????





?????????? ?????? ????? ?????? ???? ??? ??????????? ??????? ?? ????
???????????????????????????????????? ?????????????????????????????
?????????? ??? ???? ???????? ?????? ??????????? ???? ????? ????????
???????? ???? ???????????? ???????? ???? ????????????? ???? ???
???????????? ??????? ????? ??????? ???? ??????? ???? ???????? ??
??????? ??? ???? ???????? ??? ??????? ?? ???? ???????????? ??? ???? ????
???????????????????????????????????????????????????????????????





???? ??????????? ???? ??????? ????????? ?????????? ??????????? ??
????? ??? ???????? ??????? ???? ??? ?????? ???? ?????????
?????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
????? ?????? ????? ??? ???? ??????????? ???? ????????????? ??? ???
??????????? ???????? ??????????? ??? ??? ???? ????? ??????????
?????? ????????? ??????????? ?????????? ??????????????? ???? ???
?????????????????????????????????????????????
???? ???????? ??? ????????? ???????????? ??????????? ????????
??????? ????????? ????? ?????? ????????? ???? ?? ????? ??????????
????????????? ???????? ???? ????? ???????? ???? ???????????
????????? ????????? ??????????? ???? ??? ???????????? ????? ????
????????? ?????? ???????? ??????????? ??? ?? ??????? ??????? ???? ??
????????????????????????????????????????????????????????????
??????????????????? ??????????????????????????
??? ?????????? ???? ???????? ??????????? ??? ???? ??????????
???????? ??? ??? ????? ????????? ????????? ??? ????? ????? ???????? ???
???????????????????????????????????????????????????????????
????? ???????? ???????? ????????? ??????????? ??? ???? ???? ????????
???? ??????? ??? ??????? ?? ???? ?? ???????? ???? ??? ?????????????
?????? ?????? ??????????? ????????? ??????? ??????????? ??? ??
???????????? ??? ?????? ???? ?????????? ????????? ?????? ?????? ????








?????? ????????????? ????????? ???????? ???????? ??? ???? ?????? ???
??????????? ????????? ????? ???? ??????? ??????? ????? ????? ????? ??
?????????? ????? ?????? ??? ?????????? ????? ?????? ??????? ???
??????????? ??? ???? ??????????? ???????? ??????? ???? ???????
?????????????????????????????????????????????????????????????
?????? ???? ???????? ???????? ?? ?? ?????????? ??? ????????? ??? ??
?????????? ???????? ??????? ?????????? ????????? ??? ????????? ???
?????? ????? ???????????? ???? ?????????? ??? ???? ??????? ???
???????? ??? ??????? ???????????????????? ???? ??? ??? ????? ????? ?
?? ????????????????????????????????????????????
???? ???? ?????????? ????????????? ????? ???? ?????? ???????
?????????? ??? ????? ???????????? ???????????? ???? ????????????
?????? ????? ???? ????????? ??????? ??? ???? ????????????????? ??
???? ??? ???????? ??? ??????????? ???? ??? ?????? ????????????
????????????????????????????????????????????????????????????????
??? ???? ???? ????????? ???????????? ??? ????? ????????? ???
??????????????????????????????????????????????????????????????
???? ??? ??????????? ???? ??? ?????? ???????? ???? ???????????
????????? ???????? ????? ??? ??????????? ????????? ???????? ????
?????????????????? ?? ??? ???????? ????????? ??? ????? ????????
????????????????????????????????????????????????????????????
??? ?????? ??? ?? ??????????? ??? ??????? ???????? ???????? ??? ???
???????? ??????? ??????? ????? ??? ???? ???????? ??????? ?????? ???
?????? ??? ??????????? ????????? ???????? ??? ????????? ??? ???
????????????????????????????????????????????????????????????????
??????????????? ??? ??????? ???? ??? ???? ???????? ?????? ???????? ??? ??
????????????????????????????????????????????????????????????
??? ??? ?????? ???????????? ????? ?????????? ????? ??????????? ???
????? ???????????? ???????????? ??? ?????????? ???????????
???????????????????????????????? ?????????????????????????
??? ??????????? ????? ???????? ?????????? ???????? ????? ?? ????????
???????????? ??? ????? ???? ????? ???????????? ???? ??????????
???????????????????????? ???????????????????? ????????????????
????????????????????? ????? ???? ???? ???????????????????????





???? ??????????????? ??? ???????????? ??? ?? ?????? ???????? ???
??????? ??? ????????? ???????????? ???? ??????? ??? ???? ??????????
???????? ?? ????????? ?????? ????? ???????? ????????????? ????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????






???????? ????? ??????????? ???????? ?????????? ?? ??????????
??????????????????????????????????????????????????????????????
???????????? ?????? ??? ??????????? ????? ??????? ?? ????????? ???
????????? ?????? ????? ???? ???? ?????? ??????????? ?????? ??? ???
???????? ???? ???? ????????????? ???? ?????????? ?? ??? ??? ???? ????
????????????????????????????????????????????????????????????




???????????? ???????? ??????????????????? ??? ???????? ??????? ????
??? ??? ??? ???????????? ??? ????????? ?????????? ?????????????
????????????????? ??????????????????????????????????????????????
???? ??? ???????? ????? ???????? ?????????? ????? ???? ?????? ??
??????????? ????? ???????? ??????? ????? ???????????? ????
?????????????????????????????????????????????????????????????
???????????? ??????????? ???? ?????????? ????????????? ???? ???
????????? ??? ????? ?????????? ???? ????????????? ??????????
?????????? ?????????? ??? ???? ??????????? ?????? ??? ?????? ???????????
???? ??? ???? ???? ??? ??????????? ?????? ??????????? ??????? ???
???????????? ??? ?????? ??????????? ??????? ??????? ??????????
?????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????





???? ?????? ?????? ??????????? ??? ???? ????? ????? ?????? ??
????????? ???????????? ???? ??????? ???????????? ?? ??? ????
????????? ?????? ???????? ??? ?? ??????? ??? ???? ???????
??????????????????????????????????????????????????????????????
?????? ???????? ????? ??? ????? ???? ???? ????????? ???????????????
?????????? ?????? ?? ?????? ??? ???????? ??? ?????? ???????? ???? ?????
???????? ??????? ???????????? ????? ???? ??????? ???? ???? ?????????? ??
??????????????????????????????????????????????????????????
??????????
???? ??????????? ??? ????? ??????? ?????????? ??????????
???????? ?????????????? ???????? ????? ???? ????????? ??????????? ??
???? ??????? ??? ?????????? ???? ?????????? ????? ??????????
?????????????????????????????????????????????????????????????
?????????? ??? ???? ????? ??????? ???? ?? ??????? ?????? ?????
????????????? ????????????????????????????????????????????
????? ???????????? ???? ??? ????????? ???? ?????? ???? ???? ??? ?????
??????????????????? ???????????? ???????????????????????????????
???????????????????????????????????? ????????????????????????
????????? ???? ???????? ??????????? ??? ?? ???????? ??? ?????? ?????
????????????????????????????????????????????????????????????????
??? ????????? ???????????? ?????????? ??? ???? ????????? ?????????
?????????????????????????????????????????????????????????? ???







???????? ???????? ???? ???????? ???????????????? ??????????? ????
????? ???????????? ??? ?? ?????????????? ?????? ??????? ?????? ???????
???????? ?????????? ??? ???? ??? ????????? ???????? ????? ?????????
?????????? ??? ????????? ???? ?????????? ??? ????????????? ????????
?????????????? ????????????? ???????? ??? ???? ?????????????????????
???????????????????????????????????
???????????????????????????????????????????????????????????????
??????????????? ???????????????????????????????????? ???? ????
???? ?????????????? ???? ??? ???? ???? ???????? ?? ????????? ??
???????????????????????????????????????????????????????????????
??? ???????? ?????????? ??? ????????? ??? ?????????? ???? ??????????
????????????? ???? ???????? ??? ??????????? ?????????? ???? ????
????? ?? ?????? ???? ??????????? ?????? ???? ?????? ??? ??
?????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
???????? ??? ??? ?????? ??????????? ???????? ??? ?????? ??????? ????
?????????????????????????????????????????????????? ? ??????
?????????? ??? ??????? ???????????????? ?????????? ???? ?????
????????????????? ?????????????????????? ??? ?? ???????????? ??????
??? ??? ?????? ?????? ???? ??? ????????? ??? ??????? ??????? ???? ?????
????????? ??????? ???? ???????????? ?????? ???????? ???? ??????
????????? ?????? ???????? ?????? ????????? ???? ?????? ??? ??? ????????
??????????????????????????????????????????????????????????????
??? ?????????????????????????????? ??????????????? ??? ?????????
????????






???????????? ??? ????????? ?????????? ??? ?????????? ?????????? ??? ???
?????? ??? ?????? ????? ????? ??? ?????? ????????? ?????????? ?????
???? ??? ??????????? ??????????? ?????? ????? ???? ??? ?????? ??? ?????
???????? ??????????????????????????????????????????????????????
????? ???????? ???? ??????????? ?????? ?????? ?????? ???????? ????
?????????? ???? ????????? ?????????? ???? ???????? ??? ???????
??????????????? ?????????????? ??? ??????? ??????? ??????????? ?????
??????????? ???? ??? ?????? ??????????? ?????????? ??? ????? ???????
????????????????????????????? ??? ?????????????????????????????
?????????? ???? ??????????? ????????? ????? ???????? ????????? ??
????? ??????? ????? ????????? ????? ?????? ??????? ??? ????
??????????? ????? ????????????? ???????? ??? ???? ??????????? ???
??????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
?????? ??????????????? ????????? ????? ????????? ?????????? ?????




????????? ????????????????? ??????????????????????????????? ??????
????????? ?????? ??????????? ??? ????????? ??? ???????????? ??? ?????
???????????????????????????????????????????????????? ??????????
???? ???????? ???? ??????????????????????? ???????????? ????????
?????? ??????????? ?????? ??????????????? ? ????? ???? ???? ???????? ??
???????? ????????? ???? ????? ????????? ????? ??????????????? ?????
????????????????????????????????
???????????? ?????? ? ??????????????????????? ??????????? ??
???? ?????? ??? ??????? ??????? ???? ????? ??? ????? ???? ????
??????????? ?????????? ???? ??????????????? ???? ????????? ???
?????????? ????????? ??? ?????? ????????? ????????? ??? ????? ????
??????????????????????????????????????????????????????????????
???????????? ???????? ??????? ??? ???? ?????? ???? ???? ????





???????????????????????? ?? ???????????????????? ??? ???????????
???????????? ?????? ??? ?? ?????????????? ??????????? ??? ???????
???????????????????????????????????????????????????????????????
?????????? ???? ???????????????? ???????????????????? ??????????
?????? ???????????? ????? ???? ???????? ?????? ????????? ??
???????? ???? ?????????? ??????? ??????? ????? ??? ??? ????? ????? ???
?????????????? ???? ????? ??? ????? ?????? ??????? ??????? ????? ??????
??????????????????????????????????????????????????????????????
?????? ???????? ????? ?????? ???? ??????? ???? ???????? ??????? ????? ?
??????????????????????????????????????????????????????????????






??? ?? ?????? ??? ?? ???????? ?????? ??? ????????? ?????????? ??
???????????????????????????????????????????? ???????????????????
???? ???????? ????????? ??? ?????? ?????? ?????? ????????? ????????????
??????? ???????? ???? ????? ????? ????? ?? ?????? ????? ??? ???????
????????? ????????? ??? ?????????? ????????? ???? ???????????? ??
???????? ?????? ???? ??????????? ?????????? ?????? ????????
??????????????????? ??? ??? ?? ????? ???? ?????????? ???? ?????????? ??
??????????????????????????????????????????????????????????
????????????????? ????????????????????????????????????
????????????? ??? ???????? ??????? ???????? ??????????? ???? ?????????
????? ???? ??????? ????? ?????? ???????? ??? ??????? ?????? ???????
?????????????????????????????????????????????????????????????
???????? ???? ???????? ????????? ??? ?????? ???????? ???? ??? ??? ?





???????????? ??? ?? ????????? ?????? ????? ?????????? ???????????
?????????????????????????????????????????????????????????????????
????????????? ??? ???????????????????????? ????????????????????
?????? ?????? ???????? ?????? ??????????? ????????? ????? ?????
??????????? ???????????? ???? ????? ???????? ??? ???????????? ??
?????????????????????????????????????????????????????????????????





???? ???????????? ???????????????? ?????????????????????? ???????
???????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????
???? ??????? ????????? ??? ????????????? ?????? ?????? ????????? ????
??????????? ? ?????????? ?????? ?????? ??????????? ??????????? ???
???? ??????????????????????????????????????????????????????????
?????? ??????? ????? ??? ??????????????????? ?????????? ??? ??? ???????
?????? ?????? ??????????????????? ????? ???? ???????????????????
?????
????????????? ???????????? ????? ????? ???????????????????????
???????????????????????????????????????????????????????????????
????? ????????? ???? ?????????????? ????? ???????? ???? ? ????? ??
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
????????????? ???????? ???????????? ????????????? ???? ????????
??? ???????????? ??? ??? ????????? ???? ??????????? ????????????
???????? ??? ???????????? ??? ???? ???????? ???? ????????????? ??
??????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
????? ????????? ?????? ???????? ????? ?????????? ??? ???? ??????????? ??
???????????????????????????????????????????????????????????????
??? ?????? ???? ?????????? ??????????? ??????? ??? ???? ????
???????? ??? ???? ?????????? ???????? ??? ?????????????? ???
?????????????? ???????????? ????? ?????? ??? ????? ?????????
??????????? ???? ??????????? ?????????? ???? ???????????????
????????? ????????? ???? ?????????? ??????? ???? ??? ??????????
??????? ?????? ???? ?????????? ???????????????? ???????? ???? ?????
?????? ????????? ???? ???? ?????? ???? ? ????? ??? ?????????????
????????? ??????????????? ????? ??? ??????? ?????????? ??? ??????
????????
??????????????????????
??????? ???? ? ??????????? ??? ??????????? ????????? ??????
?????? ??? ??????????? ??????? ??????? ???? ??? ?????? ??????
??????? ??????????? ?????????? ????? ?????? ????? ??????
??????????? ???? ???? ????? ????????? ??? ????? ??? ???? ????
???????????? ????????? ??? ????????? ??????? ????? ??? ????














?????? ???? ? ???????? ????????? ??????????? ???????? ????
????????? ???????? ??? ????? ???? ?????????? ?????????




????????? ???? ?????? ??? ???? ?????? ???? ???????????? ???
?????????? ???? ?????? ??????? ???? ????????? ?????????? ?????? ???
???????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????






?? ??????? ?????????? ??????????? ?????????????? ??? ????? ?? ??????????????
?????????????????????? ????????? ?? ???? ???? ?????? ???????????? ??
??????????? ???? ???? ??? ????????? ??????????????????? ???????
?????????
?? ????????????????????????????????????????????????????????????????




?? ????????? ????????????????????????????????????????????????? ??? ???
??????? ??????????? ????????? ?????????? ????? ??????????? ??????????
??????????? ???????? ???? ???? ?????? ???? ?????????? ??? ??????????? ?????? ??
??????????????????????????????????????????????????
?? ???????? ???? ???????????? ??? ?????? ??? ????? ??? ??? ????????
???????????????????????????????????????????????????????????????????????
???????????? ?????? ???????? ?????????????? ??????????? ?????? ?????????












??? ???????? ?????????????? ??????????? ?????? ?????????? ??? ?? ????? ???
??????????????????????????????????
?? ???????????????????????????????????????????????????????????? ??????
??????? ?????? ??????????? ?????????????? ??????????? ????? ???? ?????????
???????????? ????????????? ?????? ?? ???? ????? ????
???????????????????????????????????????????
?? ???????? ??? ???????????? ??? ???????????? ??? ???????? ??? ?? ??????
?? ?????????? ?????????? ??? ??????????? ?????? ???? ??????????
??????????? ???????????? ??? ????????? ????????? ??? ????????????????? ???
????? ?????? ?? ???? ????? ?????????????????????????????? ???????
?????????
??? ????????????????????????????????????????????????????????????????????
??????????????? ??? ??????????? ??????????? ???????????? ??? ????????????
??????? ??? ???????????? ??? ????????????? ???????? ????? ??????????????
??????????????? ???? ???????? ?????????? ????? ??????? ????????????
???????????????????????????????????????????
??? ????????????????????????????????????????????????????????????????????
????????????? ?????????????? ???????????????????? ???????????? ??? ?????
?? ?? ????????????? ???????? ????? ??????????????? ?????????????? ??? ????????
?????????????????????????????????????????????????????????
??? ??????????? ?????????????????????????????????????????????????????????
?????????? ??? ???????????????????? ??????????? ??? ?????? ?????? ?????? ??
????????????? ?????????? ????????????? ?????????????????????????? ??????????
???????????????????????????????????????????????
??? ??????? ?????????????????????????????????? ??????????????????????????
???????? ??? ?????? ???? ???????? ??????? ?????????? ???? ????????? ????
????????????????????????????????????????????????
??? ??????? ??? ????????? ??? ????? ???? ???? ??? ??????? ?? ??? ???? ??????? ???
????????????? ??? ???????? ??? ???? ??????? ?????? ????? ?????? ?????????
?????????????????? ??? ???????????? ???? ???????? ???????? ?????????????? ???
???????????????????????????????????????????????????????????????
??? ?????????????????????????????????????????????????????????????????????
????? ??????????? ??? ???? ????????????? ??? ???????? ??? ??????? ?????????
?????????????????????????????????????
??? ???? ???? ?????? ??? ???? ??? ??????? ??? ?????? ?? ??? ???? ??????? ???????? ???
??????????????????? ?????????????????????????? ???????????????????? ????
???????? ???????? ????? ??? ?????? ???? ???????? ?? ???? ???????? ???
?????????????????????????
??? ??? ???????????????????????????????????????????????? ?????? ???? ??????
???????????????????????????????????????????????????????????????????????
???????????? ??? ???? ???????? ?????????? ?? ???? ????? ????? ????????? ????
????????? ??????????????????????????????
??? ????? ???? ??? ??????? ??? ?????? ??? ?????????? ???? ?????? ?? ??? ???? ??????
?????????? ???? ?????????? ??? ???? ?????????????? ?????????? ???? ????
?????? ??? ?????????????????????????????????????????????????????????
??????????????????????????????????????????????
??? ?????????? ???? ?????? ??? ???? ??? ??????? ?????????? ??????????? ??
??????????? ?????? ?????????????????????? ???????? ??????????? ????? ???
??????? ???????????????????? ?? ???? ????? ?????????????????????????????
?????????????????
??? ????? ?????????????????????????????????????????????????????? ??????
????????? ???????????? ??????????? ??? ??????????? ??????????
??????????????????????????????????????????????????????????????????????
???????????????????????????????????????????
??? ??????????? ??? ??????? ???? ???????????? ???? ?????????? ??? ??????
???????????? ??? ???????? ??????????? ??????????? ???????????? ??? ?????
???????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
??? ???????? ???? ??????? ???? ?????? ???? ??????? ???? ???????? ??? ??? ???










???? ???????? ?????? ?? ??? ????? ????????????????? ???????? ?????????
????????????????????????????????????????????
??? ??????? ??? ????????? ??? ????? ???? ???? ??? ??????? ?? ??? ???? ??????? ???
????????????? ??? ???????? ??? ???? ??????? ?????? ????? ?????? ?????????
?????????????????? ??? ???????????? ???? ???????? ???????? ????????????????
???????????? ? ???????????????????????????????????????????????????
????????
??? ?? ????????????????????????????? ????????????????????????? ???????




???????????????????????????? ??????????? ??????????????? ??? ??????
??????????????????????????????????????????????? ????????????????????
??? ??? ???????????? ????? ???????????? ???? ?? ?????????? ???? ????????? ????
???????????????????????????????????????????????
??? ??????? ???? ????????? ???? ??????????? ??? ??????? ???? ????? ??? ??? ???
?????????????? ??????????????????????? ????????????????????????????????
??? ???????????? ??????????? ??????????? ??????????? ??? ???????? ?????
?????????? ?????????????????????????????????????????????????????????
???????????????????????????????
??? ?????? ???? ????????? ?????? ??? ?????? ???? ????????? ??? ??? ???? ??????




???????????? ?????????? ??????????????????? ?????? ??? ??????????????
?????????? ???? ?????????? ??? ????????????? ????????? ??? ??????????
??????????? ??? ???????? ?????? ?????? ?? ???? ???? ????
??????????????????????????????????????????
??? ???????????????????????????????????????????????????????????????





   
 112 
 
Supplementary Table S1: Primer and probe sequences.  
 
A. Generic qPCR and qRT-PCR assays (target: conserved regions in 18S rRNA)  
Species Primer Sequence (5’ -> 3’) 
Plasmodium sp. QMAL_fw TTA GAT TGC TTC CTT CAG TRC CTT ATG* 
QMAL_rev TGT TGA GTC AAA TTA AGC CGC AA 
QMAL_probe FAM-TCA ATT CTT TTA ACT TTC TCG CTT 
GCG CGA –BHQ 
 
B. Species-specific qPCRs and qRT-PCR assays 
Species Primer Sequence (5’ -> 3’) 
P. falciparum 
(DNA) 
Pf_S18S_fw TAT TGC TTT TGA GAG GTT TTG TTA CTT 
TG 
Pf_S18S_rev ACC TCT GAC ATC TGA ATA CGA ATG C 




Pf_A18S_fw TCC GAT AAC GAA CGA GAT CTT AAC 
Pf_A18S_rev ATG TAT AGT TAC CTA TGT TCA ATT TCA 
PF_A18S_probe FAM-TAG CGG CGA GTA CAC TAT A-MGB-
BHQ 
P. vivax (DNA & 
RNA) 
Pv_18S_fw GCT TTG TAA TTG GAA TGA TGG GAA T 
Pv_18S_rev ATG CGC ACA AAG TCG ATA CGA AG 
Pv_18S_probe HEX-AGC AAC GCT TCT AGC TTA -MGB-
BHQ 
P. malariae (DNA 
& RNA)  
same primers and probe as in ref. 24 
P. ovale (DNA & 
RNA) 
same primers and probe as in ref. 24  
 
C. Gametocyte-specific pfs 25 and pvs25  qRT-PCR 
Species  Primer Sequence (5’>3’) 
P. falciparum 
 
pfs25_fw GAA ATC CCG TTT CAT ACG CTT G 
pfs25_rev AGT TTT AAC AGG ATT GCT TGT ATC TAA 
pfs25_probe HEX-TGT AAG AAT GTA ACT TGT GGT AAC 
GGT-BHQ1 
P. vivax pvs25_fw ACA CTT GTG TGC TTG ATG TAT GTC 
pvs25_rev ACT TTG CCA ATA GCA CAT GAG CAA 
pvs25_probe FAM-TGC ATT GTT GAG TAC CTC TCG 
GAA-BHQ1 
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Total volume  
12  μL
 
                  
1X gene expression master mix
2
 









Stage Step Temperature Time 
Holding UDG 50°C 2 minutes 
Holding Activation of 
AmpliTaq 
polymerase 
95°C 10 minutes 
Cycling (45x) 
 
Denature 95°C 15 seconds 
Anneal/Extend 58°C 1 minute 
 
B. qRT-PCR: one-tube protocol using the TaqMan® RNA-to-CT™ 1-Step Kit
2
 
qRT-PCR Reaction mix 
1
 
Total volume 12.5  
μL
 
                  
1X  RT-to-CT master mix
2
 




2µl of RNA 
0.3 µl of Taqman RT enzyme mix (ArrayScript™ UP Reverse 





Stage Step Temperature Time 
Holding Reverse 
transcription 
48°C 15  minutes 
Holding Activation of 
AmpliTaq 
polymerase 
95°C 10 minutes 
Cycling (45x) Denature 95°C 15 seconds 
Anneal/Extend 58°C 1 minute 
 
1
 Reaction mix was prepared on a template-free bench wiped with 2.5M hypochlorite 
solution. Prepared master mix was added to the reaction plate before transfer to PCR 
cabinet for template addition. Applied Biosystems MicroAmp® 0.1ml Fast Optical 96-Well 
Reaction Plate was used for both qPCR and qRT-PCR.  
 
2
 Life Technologies Applied Biosystems, Zug, Switzerland  
 
3
The GENEX standard thermo profile of StepOnePlus Real-Time PCR system (Applied 
Biosystems) was modified for both qPCR and qRT-PCR. A maximum of 45 cycles of 
amplification was set. And all samples with Ct value ≤45 were considered positive.  
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Supplementary Table S3: Limit of detection and amplification efficiencies of all molecular 
markers determined with control plasmids. 





Generic 18S rRNA 1 96.5 
P. falciparum 18S rRNA (S-type) 1 82.5 
P. vivax 18S rRNA 3 82.2 
P. malariae 18S rRNA 1 99.9 
P. ovale 18S rRNA 1 92.8 
pfs25 1 95.2 
pvs25 0.5 92.0 
 
*
determined by serial dilution in quintuplicate of control plasmids (PCR template = insert of 
control plasmid). 
 
Supplementary Table S4. Median density of P. falciparum and P. vivax parasites/μL detected 
by microscopy, qPCR or qRT-PCR in samples from 315 children from PNG 
 Quantification method of asexual Plasmodium stages  





[1st quartile, 3rd 
quartile] 
1071 [ 285, 3839] 350 [ 24, 1898 ]  1297 [ 164, 36904 ] 
P. vivax 
quantification median 
[1st quartile, 3rd 
quartile ] 
106 [ 69, 330 ] 8 [ 6, 13 ] 
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Supplementary Table S5: Overall parasite prevalence derived from combined results of 
DNA- and RNA-based detection methods in study population (n=315) and distribution of 





The slight discrepancy to those prevalence rates given in Table 1 derives from very few 
samples positive by DNA-based detection, but negative by RNA-based detection. 
Accordingly, the summary result given here shows a slightly higher positivity.  
 
2
Eleven samples were positive for the Plasmodium genus-specific assay, but were negative in 
all species-specific assays. All but one of these 11 samples derived from RNA-based 
detection and were characterized by very low copy number (<10 transcripts). These samples 
must be considered false positive.  Due to highly abundant 18S rRNA transcripts in each cell, 
a low level of aerosol derived contamination is possible. In principle, this issues can be 
addressed by introducing a cut-off (e.g. for P. falciparum 18S rRNA qRT-PCR we in fact 
applied a cut-off of 10 copies/µl extracted RNA). But our use of the generic assay for 
screening for all parasite species did not permit application of a stringent cut-off, which 
according to the occurrence of very high parasite densities would be oriented at P. 
falciparum. Cut off application to P. vivax would lead to exclusion of some very low density 
infections. In consequence, the true parasite prevalence by our generic assay most probably 
is slightly lower, i.e. excluding the 11 potentially false positive samples and thus amounting 





Assay / marker gene Positivity
1
 
Plasmodium generic assay  171/315 (54.3%) 
Pf single infection 32/171 (18.7%) 
Pv single infection 79/171 (46.2%) 
Pm single infection 1/171 (0.6%) 
Po single infection 0/171 (0%) 
Pf + Pv infection 36/171 (21.1%) 
Pf + Pm infection 3/171 (1.8%) 
Pf + Po infection 0/171 (0%) 
 Pv + Pm infection 2/171 (1.2%) 
Pv + Po infection 0/171 (0%) 
Pf + Pv + Pm infection 1/171 (0.6%) 
Pf + Pv + Po infection 6/171 (3.5%) 
Pf + Pv + Pm + Po infection 0/171 (0%) 
missed species typing
2
 11/171 (6.4%) 
any Pf 78/171 (45.6%) 
any Pv 124/171 (72.5%) 
any Pm 7/171 (4.1%) 
any Po 6/171 (3.5%) 





Figure S1. Proportion of gametocyte carriers (gray) among P. falciparum (upper panel) and 
P. vivax (lower panel) infections separated into three copy number categories for 18S 
rDNA detected by qPCR or 18S rRNA transcripts detected by qRT-PCR. Sample size of both 
groups within a category is indicated by numbers within the bars. 
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General discussion  
The thesis aimed to gauge the extent of underestimation of P. falciparum parasite and 
gametocyte prevalence rates by routine diagnostic tools (RDT and LM) using molecular 
diagnostic assays as a gold standard. Furthermore, the study estimated the prevalence of 
submicroscopic infections and attempted to evaluate the local differences in the occurrence 
of submicroscopic infections at different endemic sites in Tanzania. Two novel qPCR assays 
for increasing test sensitivity beyond classical PCR were developed in the SwissTPH 
Molecular laboratory, a subset of the field samples from Tanzania were used to validate 
these novel assays and compared the results to the routine qPCR assay. Furthermore, the 
study utilized the gained experience and techniques from the pilot study in Papua New 
Guinea (PNG), whose aim was to evaluate and improve various methods of RNA sampling 
strategies for gametocyte detection. These methods were applied in this study to allow for 
gametocyte detection from community samples in Tanzania.  
 
Correct diagnosis of parasite infection remains a challenge in many endemic areas. Chapter 2 
of the thesis enlightens the evaluation of the performance of classical malaria diagnostic 
tools in community samples from Tanzania. In general the performance of LM in parasite 
detection of our community samples was poor. LM detected up to sevenfold lower parasite 
prevalence rates compared to our molecular assay. The detection limit of LM is known to be 
low, of about 50-100 parasites/µL blood (Moody et al. 2002). Since the study used 
community samples most of which were asymptomatic individuals harbouring low parasite 
densities explains in part the low performance of LM. Other factors such as slide preparation 
methods, loss of parasites during staining of the slides and erroneous reading of thick 
smears may also have contributed to the low performance of LM. Other studies in malaria 
endemic areas have documented similar lower prevalence rates where LM recorded almost 
2- 10 folder lower prevalence rates than PCR (Rantala 2010; Li et al. 2014). Overall, by using 
LM community prevalence rates were greatly underestimated. LM was able to identified 
identified almost half of the total infections identified by PCR. With such low performance of 
LM in P. falciparum infection detection, it is imperative to apply more sensitive diagnostics 
for quality control of LM in epidemiological surveys in order to provide most precise 
information to malaria control efforts. 
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Interestingly, our LM-determined prevalence rates in the surveyed sites are in line with the 
most recent national malaria indicator (MIS) surveys (THMIS 2013). The MIS results are 
national representative data on malaria endemicity obtained from community sampling of 
children less than five years. The use of molecular assay, revealed the poor performance of 
LM in parasite detection in community samples, and yet our data is in line with the national 
MIS data, this suggests that the data from MIS could be largely underestimated since it relies 
solely on classical diagnostics.   
 
The performance of LM in detecting other Plasmodium species was extremely low, in fact 
only 1/2046 samples collected from the 6 sites was P. malariae positive by LM. This data is 
consistent with other LM results from other field study in Tanzania were the prevalence of P. 
malariae and P. ovale was 0.3% each (Tarimo et al. 2001). By 2008 the prevalence of P. 
malariae and P. ovale was roughly, 0.5% each (Mboera et al. 2008). Molecular typing to 
confirm the presence of other Plasmodium species in our study was not performed, hence it 
is difficult to rely on LM results alone.  
 
The use of RDT in parasite detection out-performed LM in field samples. RDT detected more 
than half of all P. falciparum parasites identified by molecular tools. Despite the higher 
performance of RDT over LM, a number the RDT-positive samples were not confirmed by 
molecular tools or LM. Most of the unconfirmed RDT positives were from the high endemic 
areas (Kilombero and Rufiji) indicating the presence of circulating parasite antigens as result 
of constant exposure to infections. The histidine rich protein-2 (HRP-2) is a commonly used 
P. falciparum antigen in RDTs. The HRP-2 antigen may be detected in human blood even 
after the parasite has been cleared. Persistence of HRP-2 antigens is known to occur for as 
long as four weeks after parasite clearance (Mayxay et al. 2001). These circulating antigens 
may confound point prevalence results because it includes even individuals who have 
cleared parasitaemia. On the other hand, the ability of RDT to detect recent cleared 
infections that are no longer detectable by LM or PCR, adds to our understanding of 
transmission level of an area. The performance of RDT in the field was challenged by the lack 
of appropriate quality control during our surveys. We could only perform lot testing in 
laboratory with P. falciparum positive blood however, this was not possible during the field 
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surveys. It has been reported that most RDTs have variations even within batches, hence the 
batch testing is essential (Mouatcho and Goldring 2013). The integrity of RDTs may be 
compromised during handling and storage in high temperatures and humid conditions which 
are bound to occur in field settings (McMorrow et al. 2008; WHO 2014).  
In general LM and RDTs are sufficient for malaria diagnosis and remain the standard tools for 
the diagnosis of malaria in many health centres. In fact, Tanzania is currently scaling-up the 
use of RDTs in health centres for parasite detection before treatment. So far the use of RDT 
has shown to reduce over-treatment with antimalarial in health facilities in Tanzania 
(Masanja et al. 2012). However, the suboptimal performance of RDT and even more for LM 
in infection detection of asymptomatic community samples, urge for the use of highly 
sensitive molecular diagnostic techniques to obtain more precise prevalence data. 
 
The application of molecular qPCR assay for parasite detection in all samples from our 
community surveys yielded higher prevalence rates than those by classical diagnostics. With 
detection limit of 0.34 parasites/µL blood, the higher efficiency in parasite detection 
compared to classical diagnostic tools was expected. At sites of low and moderate endemic 
settings the molecularly determined P. falciparum prevalence rates were more or less similar 
with the classical diagnostics, suggesting that LM, RDT and PCR were equally sensitive and 
that parasite densities were high enough to be captured by LM. At higher endemic site, the 
discrepancy between the classical tools and PCR was more pronounced. LM detected less 
than half of the total infections identified by PCR. The use of molecular parasite detection 
recorded high submicroscopic prevalence of about 52.7% in Tanzania. These submicroscopic 
infections were common in adults. Higher submicroscopic prevalences were also confirmed 
by other studies conducted in Tanzania (Shekalaghe et al. 2007; Manjurano et al. 2011). 
Evidence from this study and from other studies conducted in Tanzania so far suggest that 
both microscopic-positive and submicroscopic infections were rare in low endemic areas. 
The fact that submicroscopic infection was prevalence in all endemic sites suggest that 
infections were well controlled both in low and high endemic sites, unlike the meta- analysis 
by Okell et al in 2012 which indicated that submicroscopic infections were more prevalent in 
low transmission settings. The very few parasite positive samples obtained at the low and 
moderate endemic sites impede a firm conclusion on the parasite densities and occurrence 
of submicroscopic prevalence in the low and moderate endemic sites. For instance, at the 
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low endemic site, Iringa the only 2/329 parasite-positive individuals could have recently 
been to other endemic areas where they were likely to be infected.  
 
The relevance of these submicroscopic infections in transmission remains largely unclear.  A 
few Studies on mosquito feeding experiments have indicated that submicroscopic infections 
contribute frequently to infecting mosquitoes (Schneider et al. 2006).Others studies have 
indicated submicroscopic infections can infect mosquitoes at a rate 10 times lower than 
microscopy positive blood samples (Coleman et al. 2004). These few studies suggests that 
the high submicroscopic infections of about 52.7% recorded in Tanzania have a sizeable 
contribution to mosquito infection and can play a role in propagating transmission in 
Tanzania. Moreover, other factors such as host age, asexual parasite densities and 
gametocyte maturity also seem to play a role in mosquito infections (Churcher et al. 2013). 
 
This study also aimed to detect gametocytes in Tanzanian communities using classical 
diagnostics, LM and molecular diagnostics. Gametocytes are the parasite specific stages for 
propagating transmission. Knowledge on the occurrence and quantification of gametocytes 
in Tanzania communities is essential to evaluate control efforts especially those that aim on 
transmission reduction. Our results revealed low gametocyte prevalence rates by LM. The 
general gametocyte prevalence in all 6 sites was less than 1% which is more than 15fold 
lower than that recorded by qRT-PCR. It is known that at most 1% of the asexual parasites 
commit to the sexual cycle, hence the low prevalence rate of gametocyte was expected. 
However our qRT-PCR assay revealed much higher prevalence rates compared to LM. Our 
results indicate that 96% of the identified gametocytes carriers were submicroscopic. This 
vast underestimation of gametocyte prevalence by LM is alarming since most 
epidemiological studies rely on LM, control efforts and stakeholders using such underrated 
data are greatly hampered. Moreover, the high prevalence of submicroscopic 
gametocytaemia remains a challenge to malaria control efforts since even submicroscopic 
gametocytaemia could infect mosquitoes and contribute to onwards transmission.  
 
The study evaluated the two newly developed P. falciparum DNA-based qPCR assays at the 
Swiss TTPH molecular parasitology laboratory. These TARE-2 and varATS assays were 
validated by community samples from Rufiji, a high endemic area in Tanzania. With a 
detection limit 10 times higher than the routinely used 18S rRNA qPCR, these assays 
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captured the low density infections that were missed even by our routine qPCR. The parasite 
prevalence estimates of Rufiji were greatly improved. A gain in parasite prevalence was 8.6% 
by the varATS and 9% by TARE-2 assay. This gain in prevalence suggests that the sensitivity 
of the diagnostic tool plays a major role in precision of prevalence data. In the context of 
Tanzania, these methods designed to detect low density infections are most useful in areas 
of low endemic settings such as Iringa or Zanzibar Islands. In such low endemic areas the 
prime goal is elimination and thus the priority is to capture all infections unlike in high 
endemic areas such as Rufiji where, roughly more than half the population is infected. 
RNA sampling methods were evaluated in another study from Papua New Guinea. The study 
aimed to improve blood sampling techniques for RNA preservation in the field for 
subsequent gametocyte detection. RNA for gametocyte detection was fruitful yielded from 
whole blood preserved in RNA protect reagent and from 3MM Whatman® filter paper stored 
in TRIzol® reagent. The RNA protect® sampling method detected 2-fold higher gametocyte 
prevalence than the filter paper/TRIzol® preservation method by qRT-PCR targeting 
transcripts of the gametocyte-specific expressed marker pfs25. The findings from this pilot 
project indicated the delay of RNA preservation during field sampling and further storage of 
samples for 6 months prior to extraction yielded robust RNA for gametocyte detection. 
Furthermore, the RNA was uncompromised after being stored at -80C for two years. The 
study also emphasized on the importance proper handling of RNA during extraction and 
storage in order to limit false positives results through potential aerosols (low level of signal 
caused by airborne templates).  
 
Lessons learned from this pilot study were implemented to improve sampling for 
gametocyte detection during community surveys in Tanzania. As most field studies, this 
study obtained samples from remote areas and faced storage and transport challenges. 
Despite some delay of several hours in blood sample preservation using RNA protect® 
gametocyte detection from the yielded RNA was fruitful. Since the results from the previous 
study indicated that whole blood preserved in RNAprotect® resulted in 2 fold higher 
prevalence rates, samples from all sites were collected and preserved in RNAprotect®. An 
exception was made in the Kilombero survey performed in 2011 and Dar Es Salaam survey of 
2013 where due to some technical and logistic issues we sampled blood spots onto the 3MM 
Whatman® filter paper/TRIzol® reagent. However, the study was able to detect gametocytes 
in both preservation methods.  




Study outlook  
Although the study revealed high submicroscopic prevalence rates in Tanzania, an 
unanswered question would be to what extent these submicroscopic carriers contribute to 
transmission. Studies on mosquito feeding experiments suggest from an equal chance 
between microscopic positive and submicroscopic infections in infecting mosquitoes 
(Schneider et al. 2006). Other studies have indicated young children due to their high 
parasitaemia are the most efficient transmitters (Drakeley et al. 2003). However, the 
absolute contribution of these submicroscopic infections in Tanzania, which are more 
common in adults, remains to be evaluated. Data generated from this study cannot answer 
the question. However, a future study on mosquito feeding experiments can evaluate the 
proportion of mosquito infected by submicroscopic carriers in comparison to individuals who 
are parasite carriers identified by light microscopy. Mosquito feeding assays will not only 
evaluate the extent infectious reservoir in asymptomatic humans but also will determine the 
importance of these submicroscopic infections in the current elimination era. 
 
This study used light microscopy to identify P. malariae and P. ovale in addition to identifying 
P. falciparum species in Tanzania. Only 1 P. malariae positive sample in over 2000 samples 
collected from all sites was identified by LM. Since the performance of LM in our study was 
poor, molecular techniques could be used to identify other non-falciparum species in our 
samples from Tanzania. Since the documented prevalence rates of P. malariae and P. ovale 
are very low, <1%, sample pooling experiments to save both cost and time could be done. 
This information together with P. falciparum prevalence data generated will provide more 
insightful malaria burden information on the Plasmodium species prevalence and their 
distribution in Tanzania.  
 
Study shortfalls and limitations  
Measurement of axillary temperature was not included in the study design. The WHO 
classifies a clinical episode with body temperature >37.5°C and parasitemia 
>2500parasites/µL. Due to lack of temperature records we could not define the proportion 
of symptomatic individuals in the surveyed areas.  
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Furthermore, information on geographical location of the surveyed households was not 
collected during the study surveys. Geographical positioning system (GPS) would allow 
mapping of the malaria prevalence data, spatial modelling and the prediction areas of 
increased risk of malaria also known as hot spots of transmission. Furthermore geographical 
data cold enable contact tracing studies in the surveyed areas. Other necessary information 
on bed net ownership and use was not incorporated in our surveys. These data could assist 
in multivariate analyses to predict other malaria risk factors in different communities. 
 
Sampling methods for RNA requires almost immediate preservation and refrigeration in 
order to preserve the integrity of RNA. This was difficult to attain in field settings where 
samples would stay at ambient temperatures up to 7 days before being transferred to the 
Ifakara Health Institute (IHI) laboratory for RNA preservation and refrigeration. This may 
have contributed to suboptimal yields of RNA in some samples.  
 
Conclusions 
The study has demonstrated for the first time multi-site molecular surveillance data on P. 
falciparum prevalence rates in Tanzania. This reliable data could serve a basis for planning, 
monitoring and evaluating malaria control efforts. High P. falciparum parasite and 
gametocyte prevalence rates, with high variability in endemic sites were recorded. These 
prevalence rates are higher than the currently documented national indicator surveys. This 
information has consequences for malaria control efforts, one of which is based on 
identifying all infected individuals, and must be acknowledged by all stakeholders.  
The study further shows that the use of light microscopy and rapid diagnostic tests in 
detecting P. falciparum infections in community samples greatly underestimated the 
estimates of infection burden in our study. Thus, these imperfect malaria diagnostics do not 
provide sufficient accuracy to inform control efforts and are likely to jeopardize malaria 
control efforts.  
Using molecular tools the study confirmed high submicroscopic parasitemia and 
gametocytemia in Tanzania. If our survey relied solely on LM, over 50% of parasites carriers 
and 96% gametocyte carriers would have been missed. These results justify the use 
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molecular tools even in a subset of samples to reliably estimate the infection burden 
especially in areas of high submicroscopic parasitemia. The occurrence of submicroscopic 
carriage was prevalent in all endemic settings without a pattern of predominance at low 
transmission intensity as reported elsewhere. These results can inform control strategies for 
more targeted interventions towards asymptomatic individuals, mostly adults with primarily 
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published in “Antimicrobial Agents and Chemotherapy” and “Tropical Medicine and 
International Health” the studies aimed to assess the effectiveness of intermittent 
preventive treatment during pregnancy (IPTp) in two areas with different malaria 
transmission intensities in Tanzania. The second applied PCR technique to distinguish 
between recrudescent and new infections in a study which evaluated the clinical response of 
Artemether-Lumefantrine in pregnant and non-pregnant women with uncomplicated 
Plasmodium falciparum malaria in Tanzania  
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Abstract objective To assess the effectiveness of IPTp in two areas with different malaria transmission
intensities.
methods Prospective observational study recruiting pregnant women in two health facilities in areas
with high and low malaria transmission intensities. A structured questionnaire was used for
interview. Maternal clinic cards and medical logs were assessed to determine drug intake. Placental
parasitaemia was screened using both light microscopy and real-time quantitative PCR.
results Of 350 pregnant women were recruited and screened for placental parasitaemia, 175 from
each area. Prevalence of placental parasitaemia was 16.6% (CI 11.4–22.9) in the high transmission
area and 2.3% (CI 0.6–5.7) in the low transmission area. Being primigravida and residing in a high
transmission area were significant risk factors for placental malaria (OR 2.4; CI 1.1–5.0; P = 0.025)
and (OR 9.4; CI 3.2–27.7; P < 0.001), respectively. IPTp was associated with a lower risk of placental
malaria (OR 0.3; CI 0.1–1.0; P = 0.044); the effect was more pronounced in the high transmission area
(OR 0.2; CI 0.06–0.7; P = 0.015) than in the low transmission area (OR 0.4; CI 0.04–4.5; P = 0.478).
IPTp use was not associated with reduced risk of maternal anaemia or low birthweight, regardless of
transmission intensity. The number needed to treat (NNT) was four (CI 2–6) women in the high
transmission area and 33 (20–50) in the low transmission area to prevent one case of placental malaria.
conclusion IPTp may have an effect on lowering the risk of placental malaria in areas of high
transmission, but this effect did not translate into a benefit on risks of maternal anaemia or low
birthweight. The NNT needs to be considered, and weighted against that of other protective
measures, eventually targeting areas which are above a certain threshold of malaria transmission to
maximise the benefit.
keywords IPTp-SP, placental malaria, anaemia, low birthweight
Introduction
Pregnancy-associated malaria (PAM) is an important
cause of maternal and neonatal morbidity such as severe
maternal anaemia, intrauterine growth retardation, low
birthweight (LBW), premature delivery, intra-uterine
death and stillbirth, and can lead to maternal or neonatal
mortality (Desai et al. 2007). Apart from malaria,
anaemia in pregnancy may be secondary to iron, folate
and vitamin B deficiency, sickle cell diseases, HIV or
helminthic, which may also lead to LBW (Savage et al.
2007).
The placenta is a preferred site for Plasmodium falcipa-
rum to accumulate and cause placental insufficiency due
to sequestration, with deleterious consequences for both
mother and foetus (Brabin et al. 2004). Placental para-
sitaemia, maternal anaemia and LBW are more frequent
in areas with stable than unstable malaria transmission
because of the considerably higher level of acquired
malaria immunity among women (Nosten et al. 2004).
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Use of at least two doses of sulfadoxine–pyrimeth-
amine (IPTp-SP) after quickening for intermittent
preventive treatment during pregnancy has long been rec-
ommended by WHO for malaria control (WHO 2004).
The IPTp regimen has recently been modified: it is now
suggested that the first IPTp-SP dose to be administered
as early as possible during second trimester and that
each SP dose should be given at least a month apart
until delivery (WHO 2012). There is a growing concern
that IPTp-SP effectiveness may be jeopardised by the
high degree of resistance of P. falciparum to SP, which is
a major concern in East Africa and hence questions the
viability of IPTp-SP use in this area (Menendez et al.
2008; Feng et al. 2010; Harrington et al. 2011). How-
ever, a meta-analysis by Kayentao et al. (2013) supports
the beneficial effects of three or more doses of IPTp in
reducing the risk of LBW.
With the reported significant decline of malaria in most
areas of East Africa including Tanzania (O’meara et al.
2010; D’acremont et al. 2011), it becomes essential to
evaluate the benefit of routine IPTp-SP, especially in areas
with low malaria transmission. This may assist decision-
making on the relevance of advocating universal IPTp in
areas where SP adverse reactions may outweigh the bene-
fit of the treatment. Little is known regarding effective-
ness of IPTp-SP over other preventive measures for PAM
morbidity in areas with low malaria transmission. The
aim of this study was to assess the effect of IPTp on pla-
cental malaria, PAM morbidity and birth outcomes in
areas with high and low malaria transmission intensity.
Methods
Study area
This observational study was carried out in Moshi muni-
cipal in northeastern Tanzania and in Rufiji District in
the eastern, coastal area of the country. Moshi is a low
malaria transmission area with a malaria prevalence of
1.0%, whereas Rufiji is a moderate to high malaria trans-
mission area with prevalence of 20.8% (TACAIDS
2013). The prevalence of P. falciparum dihydropteroate
synthase (Pfdhps) gene 581G mutation was 56% in
infected malaria cases, according to an evaluation con-
ducted 6 years ago in Tanga, a region adjacent to the
two study areas (Alifrangis et al. 2009). This same area
had a day 14 SP treatment failure rate as high of 68%
among children (Gesase et al. 2009). Mawenzi Hospital
in Moshi and Kibiti Health Centre (HC) in Rufiji were
involved to recruit study participants. In 2012, malaria
accounted for 4% of the total outpatient cases in Maw-
enzi Hospital and 51% in Kibiti Health Centre (MOH
2013). Both facilities are publicly owned and provide free
antenatal care and delivery services. The standard of care
and capacity to handle obstetric emergences in the two
facilities are similar.
Study design
A prospective study was conducted from July to October
2012, enrolling pregnant women who came for delivery
in Mawenzi Hospital and Kibiti HC obstetric wards. The
selection criteria for recruiting participants were as fol-
lows: residency in the study area for at least 1 year, ges-
tational age of 28 weeks and presence of up-to-date
medical information. Cases of multiple pregnancies and
severe conditions such as eclampsia were excluded. A
structured questionnaire was used to interview women.
Information from the mother’s medical registry and
Reproductive and Child Health (RCH) clinic card was
used to verify and complement the generated informa-
tion. In case of discrepancies on IPTp-SP status between
RCH log and what the participant had reported, the par-
ticipant’s information was considered the truth after fur-
ther interview to verify specifications of the reported
medicine. Other recorded information included social-
demographic characteristics, parity, ITNs use, history of
malaria illness during pregnancy, use of haematinics and
anthelmintic drugs. Gestational age was estimated based
on the date of last normal menstrual period and com-
pared with the estimated fundal height recorded during
the first RCH booking. Low birthweight was defined as
below 2500 g, preterm birth as gestational age below
37 weeks and maternal anaemia as a haemoglobin level
below 11 g/dl. Placental malaria infection was defined as
parasite positive results based on either blood slide smear
reading or polymerase chain reaction (PCR) results.
Sample collection and examination
Placental blood was collected within 1 h after delivery.
An incision was made on at least three sites of placenta
on the maternal side, where accumulated intervillous
blood was collected using a blunt syringe. About two
drops of collected blood (about 100 ll) were spotted
onto a 3MM! Whatman filter paper, air dried and
preserved in plastic zipped locked bags for PCR genotyp-
ing. Filter papers were then transferred to the laboratory,
and DNA was extracted using the Chelex! method
(Plowe et al. 1995). The DNA was stored at !20 °C
until further use. Malaria parasite positivity was
determined by quantitative real-time PCR targeting the
P. falciparum S-type gene as described by Wampfler et al.
(2013).
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Thick and thin blood smears were also prepared and
stained with Giemsa. Blood slides were examined inde-
pendently by two experienced laboratory technicians using
a light microscope. Discrepant findings were reviewed by
a third technician until consensus on positivity was
reached. Parasites in thick film fields were counted per
200 leukocytes, and the parasite count was multiplied by
a factor of 40 to give parasites per ll of blood.
Statistical analysis
Data analysis was performed using STATA! 12.0 (Stata
Corporation, College Station, TX, USA). Numerical
variables were summarised into median and range. Cate-
gorical variables were summarised using cross-tabulation
to estimate different proportion. The primary outcome
was the proportion with placental malaria. The bivariable
models included IPTp, maternal age, gravidity, transmis-
sion intensity level, history of malaria illness in preg-
nancy, HIV status and ITNs as explanatory variables.
Variables associated with the outcome having a P < 0.2
in the bivariable model were retained in the final adjusted
logistic regression model to estimate odds ratio (OR) and
95% confidence intervals (CI). The same method was
performed for secondary outcomes, that is maternal anae-
mia and LBW.
The absolute risk reduction (ARR) was calculated to
estimate difference between the risk of placental malaria
in IPTp-SP exposure and non-exposure women. Number
needed to treat (NNT) was estimated based on ARR
(Schechtman 2002).
Ethics
Ethical approval for the study was granted by the
Kilimanjaro Christian Medical University College
(KCMUCo) Research Ethics Committee. Written
informed consent was obtained from all participants.
Results
A total of 350 pregnant women were recruited and
screened for placenta parasitaemia, 175 from the high
malaria transmission area (Rufiji) and 175 from the low
malaria transmission area (Moshi). There were no early
maternal deaths or referrals to a tertiary health facility
during the study period. At the time of recruitment, the
mean maternal age was 25.2 years (standard deviation
[SD] 6.9) and the mean gestational age 37.2 (SD 2.2)
weeks. 319 (91%) recruited women reported to have
used one or more dose of IPTp. The median (interquartile
range [IQ]) gestational age when the first IPTp dose was
administered was 24 weeks (19–32), and the median (IQ)
gestational age at the second administration of IPTp dose
was 30 weeks (24–36). The participants’ main character-
istics are presented in Table 1.
Prevalence of placental malaria and associated factors
Prevalence of placental malaria was 16.6% (29/175) in
the high transmission area and 2.3% (4/175) in the low
transmission area. In high malaria transmission area,
the prevalence of placenta malaria was 8% (14/175) by
light microscopy and 15.4% (27/175) by PCR, whereas
in low transmission area, it was 1.1% (2/175) and 1.7%
(3/175), respectively.
Table 1 Characteristics of study participants from the Moshi











<20 35 (20.0) 50 (28.6) 85 (24.3)
20–35 126 (72.0) 104 (59.4) 230 (65.7)
>35 14 (8.0) 21 (12.0) 35 (10.0)
Gravidity
Primigravida 73 (41.7) 58 (33.1) 131 (37.4)
Multigravida 102 (58.3) 117 (66.9) 219 (62.6)
IPTp use
Not at all 19 (10.9) 12 (6.9) 31 (8.9)
Single dose 66 (37.7) 72 (41.1) 138 (39.4)
≥Two doses 90 (51.4) 91 (52.0) 181 (51.7)
ITNs use
Yes 161 (92.0) 170 (97.1) 331 (94.6)
No 14 (8.0) 5 (2.9) 19 (5.4)
HIV status
Positive 8 (4.6) 4 (2.3) 12 (3.4)
Negative 160 (91.4) 171 (97.7) 331 (94.6)
No results 7 (4.0) 0 (0.0) 7 (2.0)
Haemoglobin
level (g/dl)*
11.1 (1.7) 10.5 (1.4) 10.7 (1.6)
Parasite density
(count/ll)*
18 (14.1) 269.9 (336.5) 238.4 (324.9)
Pregnancy outcome
Birth outcome
Live birth 172 (98.3) 172 (98.3) 344 (98.3)
Stillbirth 3 (1.7) 3 (1.7) 6 (1.7)
Birthweight
≥2500 g 168 (96.0) 164 (93.7) 332 (94.9)
<2500 g 7 (4.0) 11 (6.3) 18 (5.1)
Gestational age at birth
Term 149 (85.1) 150 (85.7) 174 (49.7)
Preterm 26 (14.9) 25 (14.3) 176 (50.3)
*Haemoglobin level and placenta parasite density presented in
mean (SD).
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Details of variables associated with placental malaria
by bivariable and logistic regression model are shown in
Table 2. Women living in high transmission areas were
nine times more likely to have placental malaria than
those living in low transmission areas (adjusted OR 9.4;
CI 3.2–27.7; P < 0.001). Primigravidae were twice as
likely to have placental malaria as multigravidae
(adjusted OR 2.4; CI 1.1–5.0; P = 0.025). There was no
evidence of the association between placental malaria
and HIV status or history of malaria during pregnancy.
Effectiveness of IPTp on placental malaria
In the high transmission area, of the 163/175 (93.1%)
women who reported to have used at least one dose of
IPTP, twenty-four (14.7%) were found to have placental
malaria, while 139 (85.3%) had no placental malaria.
Among the 12 of 175 (6.9%) who reported not to have
used IPTp during their pregnancy, five (41.7%) were
found to have placental malaria. In the low transmission
area, of the 156/175 (89%) women who reported to have
used at least one dose of IPTp, three (2.0%) were found
to have placental malaria. Among the 19 (10.9%) who
reported not to have used IPTp, one had placental
malaria. In multivariate analysis, one dose or more of
IPTp had 80% protective efficacy against placental
malaria in the high transmission area (adjusted OR 0.2;
CI 0.06–0.7; P = 0.015), and 60% protective efficacy in
the low transmission area (adjusted OR 0.4; CI 0.04–4.5;
P = 0.478) (Table 3a,b). There was no significant rela-
tionship between the number of IPTp doses taken and
the prevalence of placental malaria in either high or low
transmission area (Figure 1).
NNT with IPTp to prevent placental malaria
In the high transmission area, 24 of 163 women who
used IPTp had placental malaria vs. five of 12 women
who did not use IPTp. This gives an ARR of 27% for
women to have placental malaria after using at least one
dose of IPTp. Thus, in the high malaria transmission
area, four (CI 2–6) pregnant women need to be treated
with IPTp to prevent one case of placental malaria
(NNT=1/0.27 = 3.7). By stratifying for gravidity, 14 of
54 primigravidae who used IPTp in the same transmis-
sion area had placental malaria vs. two of four primi-
gravidae who did not use IPTp. Among multigravidae, 10
of 109 who used IPTp had placental malaria vs. three of
eight women who did not use IPTp. The ARR in primi-
gravida in this area was 24% (0.5–0.26 9 100) and 29%












<25 14 (42) 146 (46) 0.9 (0.4–1.8) 0.860 2.5 (0.7–9.5) 0.164
≥25 19 (58) 171 (54)
Gravidity
Primigravidae 17 (52) 114 (36) 1.9 (0.9–3.9) 0.083 2.4 (1.1–5.0) 0.025
Multigravidae 16 (48) 203 (64)
Transmission
High 29 (88) 146 (46) 8.5 (2.9–24.7) <0.001 9.4 (3.2–27.7) <0.001
Low 4 (12) 171 (54)
History of malaria
Yes 6 (18) 62 (20) 0.9 (0.4–2.3) 0.849 1.1 (0.4–2.9) 0.846
No 27 (82) 255 (80)
HIV status‡
Positive 1 (3) 11 (4) 0.9 (0.1–7.0) 0.904 1.2 (0.1–11.2) 0.883
Negative 31 (97) 300 (96)
ITNs use
Yes 33 317 – – – –
No 0 0
*Adjusted for gravidity and area of malaria transmission.
†Estimated from the logistic regression model.
‡Seven women had no HIV results.
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(0.38–0.09 9 100) in multigravidae. Therefore, four (CI
2–4) primigravidae need to be treated in the high trans-
mission area with at least one dose of IPTp to prevent
one case of placental malaria (NNT = 1/0.24 = 4.2) vs.
three (CI 3–11) for multigravidae (NNT = 1/0.29 = 3.4).
In the low transmission area, three of 156 women who
used at least one dose of IPTp had placental malaria vs.
one of 19 women who did not use IPTp. This gives an
ARR of 3% (0.05–0.02 9 100). Therefore, in the low
transmission area, 33 (CI 20–50) pregnant women need
to be treated with at least a single dose of IPTp to
prevent one case of placental malaria (NNT = 1/0.03 =
33.3). One of 69 primigravidae in the same transmission
area had placental malaria, whereas there was none
among those who did not use IPTp at all. For multigravi-
dae in this transmission area, two of 87 who used IPTp
had placental malaria vs. one of 15 of who did not use
IPTp. The ARR in primigravidae in this area was less






(95% CI) P†Yes No
(a)
Placental malaria 29 (%) 146 (%)
IPTp use
Yes 24 (82.8) 139 (95.2) 0.2 (0.1–0.8) 0.023 0.2 (0.1–0.7) 0.015
No 5 (17.2) 7 (4.8)
Maternal anaemia‡ 81 (%) 53 (%)
IPTp use
Yes 76 (93.8) 49 (92.5) 1.2 (0.3–4.8) 0.756 1.2 (0.3–4.9) 0.755
No 5 (6.2) 4 (7.5)
Low birthweight 11 (%) 164 (%)
IPTp use
Yes 9 (81.8) 154 (93.9) 0.3 (0.1–1.5) 0.146 0.3 (0.1–1.5) 0.146
No 2 (18.2) 10 (6.1)
(b)
Placental malaria 4 (%) 171 (%)
IPTp use
Yes 3 (75.5) 153 (89.5) 0.4 (0.03–3.6) 0.378 0.4 (0.04–4.5) 0.478
No 1 (25.5) 18 (10.5)
Maternal anaemia§ 39 (%) 50 (%)
IPTp use
Yes 36 (92.3) 42 (84.0) 2.3 (0.7–9.3) 0.247 2.6 (0.6–10.7) 0.191
No 3 (7.7) 8 (16.0)
Low birthweight 7 (%) 168 (%)
IPTp use
Yes 6 (85.7) 150 (89.3) 0.7 (0.1–6.3) 0.767 0.7 (0.1–6.4) 0.757
No 1 (14.3) 18 (10.7)
*Adjusted for gravidity.
†Estimated from the logistic regression model.
‡No haemoglobin level information in 41 women.











HTA = High transmission area; LTA = Low transmission area
1 dose


















Figure 1 Prevalence of placental malaria in relation to IPTp
doses taken in low and high malaria transmission areas. HTA,
high transmission area; LTA, low transmission area.
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than 0 and for multigravidae, 4% (0.067–0.023 9 100).
Therefore, 25 (CI 14–50) multigravidae need to be trea-
ted in the low transmission area with at least a single
dose of IPTp to prevent one case of placental malaria
(NNT = 1/0.04 = 25).
IPTp and maternal anaemia
A total of 223/350 (63.7%) study women had their hae-
moglobin concentration measured before delivery. The
prevalence of maternal anaemia in the high transmission
area was 60.4% (81/134; CI 51.6–68.8) and 43.8% (39/
89; CI 33.3–54.7) in the low transmission area. Living in
an area of high malaria transmission was associated with
a significantly higher risk of maternal anaemia than living
in low endemic area (adjusted OR 1.8; CI 1.0–3.2;
P = 0.036) (Table 4). The prevalence of maternal anae-
mia in the high transmission area among women who
used at least one dose of IPTp was 61% (76/125), similar
to the 56% (5/9) among those who did not use IPTp
(adjusted OR 1.2; CI 0.3–4.8; P = 0.755) (Table 3a). In
the low transmission area, prevalence of anaemia was
46.2% (36/78) among women who used at least one dose
of IPTp vs. 27.3% (3/11) among those who did not
(adjusted OR 2.6; CI 0.6–10.7; P = 0.191) (Table 3b).
Among other explanatory variables, placental malaria,
gravidity, history of malaria infection during pregnancy,
HIV status, anthelminthic and use of iron and folate sup-
plementation at least a month during pregnancy period
had no statistically significant effect on maternal anaemia
(Table 4).
IPTp and low birthweight
The prevalence of LBW in the high transmission area was
6.3% (11/175; CI 3.2–11.0) vs. 4% (7/175; CI 1.6–8.1)
in low transmission area (adjusted OR 1.7; CI 0.6–4.5;
P = 0.293) (Table 5). The prevalence of LBW in the high
transmission area among women who used at least one
dose of IPTp was 5.5% (9/163) vs. 16.7% (2/12) for
those who did not (adjusted OR 0.3; CI 0.1–1.5;
P = 0.146) (Table 3a). The prevalence of LBW in the
low transmission area among women who used at least
one dose of IPTp was 3.8% (6/156) vs. 5.3% (1/19) for












Infected 20 (16.7) 10 (9.7) 1.9 (0.8–4.2) 0.133 1.5 (0.6–3.4) 0.362
Not infected 100 (83.3) 93 (90.3)
Gravidity
Primigravidae 42 (35.0) 44 (42.7) 0.7 (0.4–1.2) 0.238 0.7 (0.4–1.3) 0.261
Multigravidae 78 (65.0) 59 (57.3)
Transmission
High 81 (67.5) 53 (51.5) 2.0 (1.1–3.4) 0.015 1.8 (1.0–3.2) 0.036
Low 39 (32.5) 50 (48.5)
History of malaria
Yes 24 (20.0) 19 (18.4) 1.1 (0.6–2.1) 0.769 1.1 (0.6–2.2) 0.737
No 96 (80.0) 84 (81.6)
HIV status‡
Positive 4 (3.4) 4 (3.9) 0.9 (0.2–3.5) 0.835 0.9 (0.2–3.9) 0.912
Negative 115 (96.6) 99 (96.1)
Iron and folates§
Yes 105 (88.2) 91 (89.2) 0.8 (0.4–2.1) 0.819 0.8 (0.3–1.8) 0.552
No 14 (11.8) 11 (10.8)
Anthelminthic
Yes 108 (90.0) 89 (86.4) 0.3 (0.4–1.2) 0.406 1.1 (0.5–2.6) 0.804
No 12 (10.0) 14 (13.6)
*Adjusted for placental malaria and transmission intensity.
†Estimated from the logistic regression model.
‡One woman had no HIV result.
§Missing iron and folate use information in two women.
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those who did not (adjusted OR 0.7; CI 0.1–6.4;
P = 0.757) (Table 3b). Among other explanatory vari-
ables, placental malaria, gravidity, history of malaria
infection during pregnancy, HIV status, anthelminthic
and use of iron and folate supplementation at least a
month during pregnancy period had no statistically sig-
nificant effect on the risk of LBW (Table 5).
Discussion
To our knowledge, the present study is the first to evalu-
ate the effectiveness of IPTp in relation to placental
malaria in areas with different malaria transmission
intensities and high parasite resistance to SP. The evalua-
tion takes into account other malaria preventive measures
such as ITNs, and other preventive measures against
maternal anaemia such as routine anthelminthic, iron and
folate supplementation. The study responded to a call
from WHO that emphasised the importance of enhanced
regular monitoring of IPTp effectiveness (WHO 2012).
Overall 9% prevalence of placental malaria in this
study corresponds to 8% prevalence which was observed
9 years ago in Ifakara, another part of the country
(Kabanywanyi et al. 2008). It shows that malaria in preg-
nancy is still an important health issue in Tanzania that
needs to be addressed by effective preventive measures.
Self-reporting of ITNs use by 95% of pregnant women is
encouraging considering the reported ITNs efficacy of
23% against placental parasitaemia, 33% against miscar-
riage/stillbirth and 23% against LBW according to a
systematic reviews of randomised trials (Gamble et al.
2007). The possibility of overestimating ITNs use in the
present study cannot be excluded due to self-reporting as
the participant may try to please the interviewer. In the
present study, all women with placental malaria reported
to have used ITNs, which precludes any effectiveness cal-
culation. Our assessment of IPTp effectiveness applies
thus only in condition of full ITN coverage.
Use of IPTp was associated with protection against pla-
cental malaria in all study areas. The study findings agree
with previous studies and reviewed evidence of IPTp to
reduce the risk of placental malaria (Hommerich et al.
2007; Kayentao et al. 2013). There was no IPTp dose-
dependent relationship to reduced risk of placental
malaria. The latter is opposite to what was reported by
Kayentao et al. (2013) in a systematic review that risk of
placental infection decreases with increased number of
IPTp doses. However, our study was not powered to
determine the effect of increasing dose on placental
malaria. The time interval between the last IPTp adminis-
trated dose and screening for placental malaria may be a
stronger determinant for detecting parasitaemia rather
than the cumulative number of doses a woman received
during her pregnancy. This is essential to consider, partic-
ularly in high transmission areas, where the daily likeli-
hood for a woman to have infectious mosquito bites is
higher.
Due to the observed significant risk of having placental
malaria when living in a high transmission area, the
value for money of IPTp was much higher in areas of
high transmission intensity, with only one-eighth of the
number of women treated with at least one dose of IPTp
required to avert on case of placental malaria compared
to the low transmission area. Because of the known












Infected 3 (16.7) 30 (9.0) 2.0 (0.6–7.4) 0.290 2.1 (0.6–7.5) 0.279
Not infected 15 (83.3) 302 (91.0)
Gravidity
Primigravida 7 (38.9) 124 (37.3) 1.1 (0.4–2.8) 0.895 1.1 (0.4–3.1) 0.809
Multigravida 11 (61.1) 208 (62.7)
Transmission
High 11 (61.1) 164 (49.4) 1.6 (0.6–4.3) 0.337 1.7 (0.6–4.5) 0.293
Low 7 (38.9) 168 (50.6)
History of malaria
Yes 6 (33.3) 62 (18.7) 2.2 (0.8–6.0) 0.134 2.2 (0.8–6.1) 0.130
No 12 (66.7) 270 (81.3)
*Adjusted for history of malaria.
†Estimated from the logistic regression model.
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higher risk of placental malaria in primigravidae, we
attempted to estimate the NNT in this group vs. the mul-
tigravida ones in both areas, but the small sample size
and uneven representation of the exposure groups, both
being potential biases of the study, did not allow mean-
ingful results. In view of the importance to determine
NNT in other malaria interventions in pregnancy such as
ITN use, 18 and 50 pregnant women are the NNT with
ITN to prevent at least one placental malaria case and an
LBW case, respectively, as observed in a randomised trial
of ITN in high malaria transmission area in Kenya (ter
Kuile et al. 2003). The NNT should be more regularly
used as criterion to prioritise interventions, especially so
in moderate to low transmission areas. This estimation is
essential in an era of declining malaria.
The primary aim of malaria preventive measures in
pregnancy is to prevent deleterious effects of malaria in
woman and the baby. The usual concept is that IPTp
reduces maternal parasitaemia and hence maternal anae-
mia, placental malaria and LBW. IPTp effectiveness was
challenged by Harrington et al. (2011) who conducted a
study in Muheza, Tanzania, an area known to have high
SP resistance, where IPTp neither lowered the risk of
placental malaria nor had reduced maternal anaemia or
LBW. A further challenging finding was reported by
Gutman et al. (2013) in Malawi, which showed that
IPTp did not reduce the frequency of placental malaria
but was associated with improved birth outcomes. We
found that IPTp did reduce placental malaria, but had no
effect on maternal anaemia. For LBW, there was still a
beneficial but insignificant effect, probably due to the low
rate in both study areas. Women who delivered at home
may have had an adverse outcome, but our study had the
limitation of recruiting at delivery. However, inconsis-
tences of IPTp effectiveness on improving maternal anae-
mia and LBW have also been reported in a systematic
review by McClure et al. (2013). It is likely that malaria
is only one of the important contributors of maternal
anaemia and LBW in developing countries. Hence it will
be essential in the coming years to monitor the changes
in maternal malaria morbidity and the dynamic of LBW
rates in areas of declining malaria transmission to better
understand the roles of malaria, malnutrition, other infec-
tions and social-economic factors on maternal and baby
outcomes.
Conclusion
The study shows that IPTp was associated with a lower
rate of placental malaria, but this effect did not translate
into protection against maternal anaemia and low birth-
weight. The NNT may suggest IPTp as an appropriate
malaria control intervention, at least in areas with high
level of malaria transmission. IPTp benefit is questionable
in areas of low transmission. The NNT should be regu-
larly evaluated in different level of malaria transmission
and parasite resistance, different geographic settings and
on both mother and infant outcomes to best maximise
benefit at reasonable costs.
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Background: Artemether-Lumefantrine (AL) is the first line treatment for uncomplicated 25 
malaria in second and third trimester of pregnancy. Its efficacy has recently been challenged in 26 
pregnancy due to altered pharmacokinetic (PK) properties in this vulnerable group. The aim of 27 
this study was to determine the PK profile of AL in pregnant and non-pregnant women and 28 
assess their therapeutic outcome.  29 
Methods: Thirty-three pregnant women and 22 non-pregnant women with malaria were treated 30 
with AL (80/480mg) twice daily for 3 days. All patients provided five venous plasma samples 31 
for drug quantification at random times over 7 days. Inter- and intra-individual variability was 32 
assessed and covariates effects quantified using a nonlinear mixed-effect modeling approach 33 
(NONMEM
®
).  34 
Results: A one-compartment model with first-order absorption and elimination with linear 35 
metabolism from drug to metabolite fitted the data best for both arthemether (AM), lumefantrine 36 
(LF) and their metabolites. Pregnancy status and diarrhea showed a significant influence on LF 37 
PK. Lumefantrine relative bioavailability and metabolism rate into desmethyl-lumefantrine were 38 
respectively 34% lower and 78% higher in pregnant women than in non-pregnant patients. 39 
Overall PCR-uncorrected treatment failure was 18% in pregnant women and 5% in non-pregnant 40 
women (OR = 4.04; p value 0.22). A high median day 7 lumefantrine concentration was 41 
significantly associated with adequate clinical and parasitological response (p = 0.03). 42 
Conclusion: The observed reduction in lumefantrine relative bioavailability in pregnant women 43 
may explain the higher treatment failure in this group, mostly due to lower post-treatment 44 





Malaria in pregnancy is a major public health problem, which is associated with high maternal 48 
and perinatal mortality in tropical and subtropical regions (1). Pregnant women are at increased 49 
risk of clinical malaria compared to non-pregnant women because of the associated 50 
immunological and hormonal changes in pregnancy (2). Substantial direct risks to pregnant 51 
women include severe maternal anaemia, and those affecting the baby are intra-uterine growth 52 
retardation, intra-uterine death, stillbirth, premature delivery, low birth-weight, and perinatal and 53 
neonatal morbidity and mortality (3). Because of all this, malaria in pregnancy should be treated 54 
effectively. 55 
Artemether-lumefantrine (AL) (20mg and 120mg, respectively) is one of the most popular and 56 
efficacious fixed dose artemisinin-based combination therapies (ACT) against Plasmodium 57 
falciparum. It is currently available at a subsidized cost in most malaria endemic countries. AL 58 
has proved to be non-inferior to quinine in East Africa for the treatment of P falciparum 59 
infection in second and third trimester of pregnancy (4). ACTs are recommended by the World 60 
Health Organization (WHO) as the first line treatment for uncomplicated malaria in the second 61 
and third trimester of pregnancy (5). Unfortunately, general inter-individual variability on drug 62 
absorption, distribution to different compartments of the body and tissues, plasma binding 63 
proteins, rate of metabolism, enterohepatic recirculation, and excretion may be associated with 64 
changes in bioavailability of a drug and consequently may affect the therapeutic efficacy (6).    65 
Pregnancy has been reported to affect the efficacy of some drugs, including antimalarials. This is 66 
due to physiological changes which lower drug absorption, speed up drug clearance and increase 67 
body fluid volume of distribution (7-9). Elevation of estrogens, progesterone, cortisol and 68 
prolactin hormones during pregnancy have been linked to altered metabolic activity of several 69 
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hepatic cytochrome P450 enzymes. For instance, catalytic activity of CYP3A4, CYP2C9 and 70 
CYP2A6 enzymes increases during pregnancy (10, 11), and these enzymes are responsible for 71 
lumefantrine and artemether metabolism (12, 13). Hence, it is expected that significant alteration 72 
of the pharmacokinetics (PK) of most antimalarial drugs during pregnancy occurs, which may be 73 
associated with lower drug concentrations and lower antimalarial cure rate, especially in 74 
advanced pregnancy (14-16). A higher treatment failure rate has indeed been observed in 75 
pregnant women when compared to non-pregnant ones living in the same area (16). Several PK 76 
studies on artemether (AM), lumefantrine (LF) and their respective metabolites, 77 
dihydroartemisinin (DHA) and debutyl-lumefantrine (DLF) have demonstrated low plasma 78 
concentration of these drugs in pregnant women compared to non-pregnant adults. However, 79 
most of these studies included healthy male adult volunteers as a comparative group rather than 80 
female malaria patients (16-19). Because of various determinants of PK and therapeutic 81 
outcome, it is essential to have a comparative population of non-pregnant women of the same 82 
study area with the same disease.  83 
An important concern during the course of AL treatment is to achieve adequate residual LF level 84 
after complete elimination of AM and DHA so that it may clear all residual malaria parasite (9). 85 
Therefore, day 7 LF concentration level has been proposed as a good indicator of AL 86 
effectiveness (20, 21). Recent pharmacokinetics study of AL in Cambodia and Tanzania reported 87 
that the targeted day 7 LF concentration was also not achieved in a significant number of non-88 
pregnant adult patients. In Tanzania, 35% of samples had LF concentration below the cut-off 89 
value of 175 ng/ml at day 7 (22). In pregnancy, whereby host antiparasite immunity is somehow 90 
compromised (2), a higher day 7 venous concentration of LF may be required than what has 91 
previously been proposed in studies involving non-pregnant adult patients i.e. a cut-off values of 92 
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175 ng/ml or 280 ng/ml in order to achieve effective therapeutic outcome and 600 ng/ml for 93 
maximal efficacy (23, 24). Some predictive models have suggested that a twice-daily regimen of 94 
AL for 5 days would be preferable in later pregnancy in order to achieve sufficient drug 95 
concentration in plasma (19). Increasing the duration of AL administration is indeed expected to 96 
increase the residual LF levels in the subsequent post-treatment cycle so as to reduce chances of 97 
recrudescence (22). This should be interpreted with caution because extending the duration of 98 
treatment regimen may possibly lead to lower adherence. Doubling the dose might be another 99 
option but actually it may not be appropriate because absorption of LF is dose-limited (25). 100 
The aim of the present study was to characterize the PK profile of AL and their metabolites, to 101 
determine their variability and to identify factors that might explain variations in drugs and 102 
metabolites levels in pregnant (second and third trimester of pregnancy) and non-pregnant 103 
women of the same area, and to assess cure rate and parasitological clearance in these two 104 
groups. The model developed for lumefantrine was used to simulate day 7 concentrations under 105 
standard and alternative dosage regimens and quantify the percentages of pregnant and non-106 
pregnant women having concentrations below different proposed cut-off thresholds.  107 
Material and methods 108 
Study design and procedures 109 
This study was conducted in Rufiji district, within a Coastal region in Eastern Tanzania. The 110 
asexual parasitaemia prevalence is 14% and Plasmodium falciparum is the predominant species 111 
(26). The study was carried out at Kibiti health center from April to September 2012. Approval 112 
for the study was granted by two independent ethical review bodies; (i) Research Ethics 113 
Committee of Ifakara Health Institute (IHI) and (ii) National Institute for Medical Research 114 
(NIMR) Ethical Committee. All women signed an informed consent prior to enrolment. 115 
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Pregnant and non-pregnant women diagnosed with uncomplicated malaria were recruited from 116 
either out-patient department or Reproductive and Child Health (RCH) clinic. Inclusion criteria 117 
were women aged 18 year and above, resident of Rufiji study area, pregnant during their second 118 
and third trimester, and having signs or symptoms suggestive of uncomplicated malaria with 119 
fever (axillary temperature ? 37.50C) or history of fever for the past 24 hours, P falciparum 120 
detected by microscopy, and hemoglobin level ? 7 g/dl. Exclusion criteria were known allergy to 121 
AL or quinine, history of renal, liver or heart problem, hyperparasitaemia above 200,000/µL, 122 
reported intake of any antimalarial within the past 28 days, unable to take oral medication, and 123 
vomiting the medication within 1 hour of first dose intake. The same criteria applied to non-124 
pregnant women (control group) that were recruited concurrently during the same study period 125 
after informed consent. A full medical history including concomitant illness and concomitant 126 
medication was recorded. Clinical examination on the day of enrollment was performed by an 127 
experienced physician. Patients were also seen by the clinician during follow up visits at day 1, 128 
2, 3, 7, 14, 28 and 42 whereby axillary temperature was measured as well as evaluation of 129 
malaria related symptoms (5).  Gestational age was determined from the estimated first day of 130 
the last normal menstrual period and compared to clinical examination of a fundal height. In case 131 
of any discrepancy, gestational age was recalculated from the estimated age at first RCH visit.  132 
Drug regimen 133 
Enrolled participants received four tablets of AL (Coartem® Novartis Pharma AG, Basel; 20 mg 134 
AM and 120 mg LF) over the course of 3 days at 0, 8, 24, 36, 48 and 60 hours. Each dose was 135 
administered with 200 ml of milk containing 4.5 g of fat because of the associated increase in LF 136 
bioavailability when taken with a fat rich meal (27). All patients were asked to come back to the 137 
health center for each drug administration and observed for one hour after dose intake. None of 138 
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the patients was admitted during the course of AL treatment but one pregnant woman who 139 
developed severe malaria at day 1 was admitted and the treatment was changed to intravenous 140 
quinine. A limited number of patients were administered drug at home by the study’s clinician or 141 
field assistant, specifically for those who had difficulties to come to the clinic at scheduled times 142 
for observed drug administration. 143 
Blood samples 144 
To determine AM, DHA, LF and DLF concentration, 2 ml of venous blood sample was drawn 145 
from the patient at random times between 8 and 11 am on day 0, 1, 2, 3 and 7. The schedule for 146 
sample collections agrees with WHO recommendation for lumefantrine concentration 147 
measurement, but is suboptimal for artemether due to practical difficulties for patients to attend 148 
all requested time points (21). Day 0 blood sample was collected before starting the medication 149 
as a baseline so as to determine the presence of any antimalarial in patient’s plasma prior to 150 
treatment due to intake of non-declared drugs (28, 29). The blood samples in an EDTA 151 
vacutainer® tube were centrifuged at 2,000 x g for 5 minutes and the plasma stored in cryotubes. 152 
Samples were kept at -25
0
C for at most 6 weeks before transferred to Ifakara Health Institute 153 
(IHI) Bagamoyo clinical laboratory for temporary storage at -80
0
C. It si known that the storage 154 
of plasma samples for bioassay of artemether, lumefantrine and their metabolites at -20
0
C for 8 155 
months does not affect drug concentration (21). All samples were packed in dry ice and then 156 
shipped to clinical pharmacology laboratory of the University Hospital in Lausanne, Switzerland, 157 
to perform the drug bioassay.  158 
To estimate the parasite density and clearance rate, capillary blood from a finger prick was taken 159 
at day 0, 3, 7, 14, 28 and 42. Samples were collected on blood slide Giemsa stained thick and 160 
thin blood smear were examined by two different experienced microscopists using light 161 
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microscopy. Parasite in thick film fields were counted per 200 leukocytes and the parasite count 162 
was multiplied by a factor of 40 to give parasites per µl of blood. Approximately 50µl of finger 163 
pricked blood was spotted onto Whatman® filter paper cards (3MM). DNA was extracted from 164 
Whatman® filter paper cards by Chelex method (30). In order to differentiate between 165 
recrudescence and new infection, samples were genotyped by the most polymorphic marker the 166 
merozoite surface protein 2 (MSP 2) and the amplicons were visualized in a 2% agarose gel as 167 
described elsewhere (31). 168 
Drug assay 169 
Plasma concentrations of AM, DHA, LF and DLF were determined using a validated liquid 170 
chromatography-tandem mass spectrometry method (LC-MS/MS) (32). The presence of 10 other 171 
antimalarial drugs and metabolites i.e. artesunate, amodiaquine, N-desethyl-amodiaquine, 172 
piperaquine, pyronaridine, mefloquine, chloroquine, pyrimethamine and sulfadoxine were also 173 
assessed at the same time. This is a standard procedure on how LC-MS/MS operates and it helps 174 
to ensure that the malaria outcome that was observed was due to AL intake, and not to any other 175 
residual antimalarial. The assay is precise (3.1% - 12.6% for inter-day variation coefficient) and 176 
sensitive (0.15 – 3.0 ng/dl for lower limit quantification [LOQ] of basic or neutral antimalarial 177 
and 0.75 – 5 ng/dl for artemisinin derivatives). 178 
The bioassays were carried out at the Laboratory of clinical pharmacology of the Lausanne 179 
University Hospital, which takes part in the quality control system of the worldwide antimalarial 180 
resistance network (WWARN). 181 
Efficacy assessment 182 
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AL efficacy was determined by cure rate and parasitological clearance. The definition of 183 
treatment response was according to WHO recommendations on the methods for surveillance of 184 
antimalarial drug efficacy (33). Treatment response was thus classified into early treatment 185 
failure (ETF), late clinical failure (LCF), late parasitological failure (LPF) and adequate clinical 186 
and parasitological response (ACPR). Participants who developed either clinical or 187 
parasitological failure as defined above received quinine 10 mg/kg of body weight three times a 188 
day for 7 days, according to standard treatment guidelines (34). 189 
Pharmacokinetic analysis  190 
Drugs and their metabolites were modeled using the NONMEM computer program version 7.2 191 
(NM-TRAN version II) (35)with the PsN-Toolkit version 3.5.3 (36). The program uses mixed 192 
(fixed and random) effects regression to estimate population means and variances of the 193 
pharmacokinetic parameters and to identify factors that influence them.  194 
Structural model. One and two-compartment models with first-order absorption and elimination 195 
and linear metabolization to DLF and DHA were compared to describe, respectively, LF and AM 196 
pharmacokinetics with an additional compartment used to characterize metabolite data. 197 
Sequential and simultaneous parent-metabolite modeling methods were used for LF/DLF and 198 
AM/DHA, respectively. The final estimated parameters were drug and metabolite systemic 199 
clearances (CL and CLmet), volume of distribution of the central compartment (VC) and 200 
metabolism rate constant from the drug to the metabolite compartment (K23). Owing to 201 
identifiability problems, the volume of distributions of DLF and DHA could not be estimated 202 
and were assumed to be equal to those of LF and AM, respectively. Because of the limited 203 
number of measurements in the absorption phase, the absorption rate constants (Ka) could not be 204 
adequately estimated and were thus fixed to 0.7 and 0.54 h
-1
 to achieve AM and LF peak plasma 205 
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concentrations, respectively, 2 h and 6-8 h after drug intake (37). Finally, the known pre-206 
systemic conversion of AM into DHA was modeled estimating the fraction of the AM dose 207 
directly converted into the metabolite using 1-F1, with F1 = 1 representing AM relative 208 
bioavailability. Since the drugs were given orally, these parameters represent apparent values. In 209 
case the analysis of baseline plasma samples showed non-zero concentration of the drugs 210 
(suggesting that AL was previously taken), a factor (F0) was introduced in the model in order to 211 
estimate the residual doses from previous treatments.  212 
Statistical model. Inter-patient variability of all the PK parameters was described by exponential 213 
errors following a log-normal distribution, as illustrated by the equation ?j=?·exp(?j), where ?j is 214 
the pharmacokinetic parameter associated with the j
th
 individual, ? is the average population 215 
value, and ?j is the jth individual component of the inter-patient random effect, an independent, 216 
normally distributed variable with mean 0 and variance ?2. In order to constrain individual F1 to 217 
vary between 0 and 1, a logit function (logit F1) was used. Correlations between PK parameters 218 
were also investigated.  Finally, proportional, additive and combined proportional-additive error 219 
models were compared to describe the intrapatient (residual) variability for both drug and 220 
metabolite. The correlation between drug and metabolite concentration measurements was tested 221 
using the NONMEM
® 
L2 item.  222 
Covariate model. Available covariates were: pregnancy status, body weight, body mass index 223 
(BMI), age, gestational age and diarrhea. The covariate analysis was performed using a stepwise 224 
insertion/deletion approach. Visual inspection of the correlation between post hoc individual 225 
estimates of the PK parameters and the available patients’ characteristics was conducted at first. 226 
During the forward selection, potential covariates influencing the kinetic parameters were 227 





 (p<0.05). Backward deletion was performed once the model including all the 229 
significant factors was built. It consisted of removing the covariates one at time, starting from the 230 
most insignificant one, until no further non-significant deterioration of the model was observed 231 
(p<0.01). The typical value of the pharmacokinetic parameters ? was modeled to depend linearly 232 
on the covariate X (continuous covariates centered on the population median; dichotomous 233 
variables coded as 0 and 1) using??=?a· ?1+?b·X?, where ?a is the mean estimate and ?b is the 234 
relative deviation of the mean due to the X covariate. Body weight (BW) effect was alternatively 235 
modeled using the allometric function ?=?a· ? BWMBW??c, where MBW is the median population 236 
BW and ?c was fixed to literature values, i.e. 0.75 for CL and 1 for V. Linear and allometric 237 
functions were then compared to identify the model describing at best the relationships between 238 
BW and the pharmacokinetic parameters. 239 
Selection of the model and parameter estimation. Drugs and metabolites were fitted by use of 240 
the first-order conditional (FOCE) method with interaction using the subroutine ADVAN5. 241 
Concentrations below the quantification limit (BQL) of the assay were treated using the M3 242 
method described by Beal as implemented in the paper of Ahn et al (38, 39).  Nevertheless, when 243 
using the L2 function, BQL data were replaced by LOQ/2 and handled with the M6 approach 244 
(39). The log likelihood ratio test, based on differences in the OFV value (?OFV) provided by 245 
NONMEM
®
, was employed to discriminate between hierarchical models. Since a ?OFV 246 
between any two models approximates a ?2 distribution, a change of the objective function was 247 
considered statistically significant if it exceeded 3.84 (p < 0.05) for 1 additional parameter in 248 
model-building and covariate forward-addition steps or 6.63 (p < 0.01) in covariate backward 249 
elimination. The Akaike information criterion (AIC) was used to compare non-nested models. 250 
Shrinkage was also examined. Additional criteria for model selection were diagnostic goodness-251 
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of-fit plots, precision of pharmacokinetic parameters estimates, and the reduction of the 252 
parameters inter-patient variability. 253 
Validation of the model. The stability of the final model was assessed by means of the bootstrap 254 
method implemented in PsN, generating two-thousand datasets by re-sampling from the original 255 
dataset. Mean parameters values with their 95% confidential interval (CI95%) were derived and 256 
compared with the final pharmacokinetic model estimates. Model validation was performed by 257 







 percentiles. The observed concentrations were plotted 259 
against the 95% prediction interval (PI95%) of the simulated dataset at each time point and 260 
visually compared. Figures were generated with GraphPad Prism® (Version 6.00 for Windows, 261 
GraphPad Software, San Diego California USA, http://www.graphpad.com/).  262 
Model-based stimulation for LF.  The concentration-time profiles of LF in 1000 individuals 263 
receiving two different regimens of 6 doses over 3 days (at 0, 8, 24, 36, 48 and 60 h) and 5 days 264 
(at 0, 8, 24, 48, 72 and 96 h.) were derived by simulations based on the final model including 265 
inter-patient variability. Day 7 predicted median concentrations with their PI95% for pregnant and 266 
non-pregnant women were derived. In addition, these simulations allowed quantifying the 267 
percentages of pregnant and non-pregnant women having a day 7 concentrations below different 268 
proposed cut-off thresholds of 175 ng/ml, 280 ng/ml and 600 ng/ml associated with treatment 269 
efficacy (24, 40, 41).  270 
Other statistical analyses 271 
The relation of the outcome variable (treatment failure) and explanatory variables were tested 272 
using a t-test for continuous variables (predicted LF day 7 concentrations, gestation age, baseline 273 
13 
 
parasite count and BMI) and Pearson chi-square for categorical variable (pregnancy status, 274 
residual antimalarial and diarrhoea). A p-value below 0.05 was considered statistically 275 
significant. All the statistical analyses were performed using STATA
®
 12.0 (Stata Corporation, 276 
College Station, Texas, USA). 277 
Results 278 
Demographic and clinical parameters. Thirty-five pregnant women and 22 non-pregnant 279 
women with acute Plasmodium falciparum malaria were enrolled in the study from 23
rd
 April to 280 
5
th
 September 2012. Two of the enrolled pregnant women were withdrawn from the study at day 281 
2 and 7 because they refused to continue participating in the study. Two (9.1%) non-pregnant 282 
women were lost for follow-up at day 42. None of the pregnant women were lost for follow up. 283 
Baseline characteristics of pregnant and non-pregnant women are presented in Table 1. Two 284 
pregnant women presented with diarrhea at the day of enrollment and throughout the course of 285 
treatment. None of the study participants vomited the drug. All participants had normal physical 286 
condition on examination with no history of any chronic disease or smoking. Twenty-six women 287 
(14 pregnant and 12 non-pregnant) reported to have taken paracetamol before enrollment. The 288 
median gestational age among pregnant women was 27 (range: 14 – 37) weeks with relatively 289 
equal numbers of women in the second and third trimester of pregnancy. No participant during 290 
the study period had miscarriage or stillbirth, or any other severe adverse drug reaction.   291 
Residual antimalarial. Blood samples from all 57 recruited participants in the study were 292 
screened to determine the presence of any antimalarial drugs prior to initiation of malaria 293 
treatment. Fifty-five (96.5%) had at least one antimalarial in their plasma: 89.5% (29 pregnant 294 
and 22 non-pregnant) of participants had plasma LF above the LOQ but the drug concentration 295 
was generally low with the average of 37.3 ng/ml. Other antimalarial drugs which were detected 296 
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were DLF 8 (14.0%), AM 4 (7%), DHA 0 (0.0%), sulfadoxine 14 (24.6%), pyrimethamine 11 297 
(19.3%) and quinine 1 (1.8%).  Summarized statistics are shown in Table 2. Out of 14 298 
participants detected with sulfadoxine, 13 were pregnant with a median baseline parasitaemia of 299 
72086 (range 3920 – 198080) counts/µL [Figure 1]. Sulfadoxine concentration persisted at 300 
relatively constant concentration throughout the first 7 days of monitoring plasma drug levels.  301 
Population pharmacokinetic analysis 302 
A total of 265 LF, 263 DLF, 146 AM, and 98 DHA plasma concentrations were included in the 303 
analysis. Twenty-five percent (n=37) AM, 7% (n=7) DHA and 2% (n=4) DLF concentrations 304 
were below the respective LOQs. The median (range) of samples available per study subject was 305 
5 (4 – 5) for LF, 4 (3 – 5) for DLF, 3 (1 – 5) for AM and 2 (1 – 4) for DHA.  306 
Artemether 307 
AM and DHA pharmacokinetics were best described using a one-compartment model with first-308 
order absorption from the gastrointestinal tract and linear metabolism to DHA, including pre-309 
systemic conversion into the metabolite. Elimination of both compounds was modeled using a 310 
first-order process. The few basal AM concentrations did not allow estimating a residual dose 311 
from previous treatments. Inclusion of an inter-patient variability on Vc, CLM, K23 or F1 in 312 
addition to AM CL did not improve description of the data (?OFV ? -1.9, p ? 0.17). A mixed 313 
error model best described residual intra-patient variability for AM and a proportional one for 314 
DHA. No correlations between the drug and the metabolite concentrations could be identified. 315 
Structural model shrinkages lower than 15% were found for all the inter- and intra-individual 316 
variability. Our results show that 21% of the AM dose is converted pre-systemically into DHA. 317 
None of the available covariates significantly affected AM or DHA pharmacokinetics (?OFV ? 318 
3.0, p ? 0.08). Although non-significant, an increase of 37% in drug CL in pregnant women 319 
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compared to non-pregnant ones was however observed (?OFV = -1, p = 0.32). The final model 320 
parameters’ estimates and bootstrap evaluations are given in Table 3. The model was considered 321 
reliable since the obtained parameter estimates laid within the bootstrap CI95%. VPC graphs of 322 
AM and DHA are shown in Figure 2A.            323 
Lumefantrine 324 
A one-compartment model with first-order absorption and elimination was retained to depict LF 325 
data. A two-compartment model did not improve the model fit (?OFV = -0.1, p = 0.75). Average 326 
dose from previous treatment (F0) was estimated to be 3.2 mg with a large inter-individual 327 
variability (?OFV = -40, p = 2.5·10-10). In addition to CL, an inter-patient variability on Vc 328 
(?OFV = -23, p = 1.6·10-6) and a correlation between CL and Vc improved significantly the fit 329 
(?OFV = -117, p = 2.9·10-27). The assignment of an inter-patient variability on LF bioavailability 330 
F1 (fixed to 1) accounting for the correlation between CL and Vc and their variability resulted in 331 
additional improvement of the model fit (?OFV = -9.5, p = 8.7·10-3). Metabolite concentrations 332 
were included in the model using a supplementary compartment with linear metabolism from the 333 
LF central compartment. The addition of an inter-individual variability on K23 improved 334 
significantly the description of the data (?OFV = -41, p = 1.5·10-10), while no enhancement was 335 
observed when assigning variability on CLM (?OFV = -0.02, p = 0.89). Residual intra-patient 336 
variability was best described using a proportional and mixed error model for LF and DLF, 337 
respectively. The model was further improved by including a correlation between drug and 338 
metabolite concentrations (?OFV = -85, p = 3.0·10-20). Structural model shrinkages for the inter- 339 
and intra-individual variability were all estimated to be lower than 15%. 340 
In univariable analyses, pregnancy and diarrhea were identified as significant covariates for both 341 
F1 (?OFV = -5.1, p = 0.024 and ?OFV = -15, p = 1.1·10-4) and K23 (?OFV = -13, p = 3.1·10-4 342 
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and ?OFV = -4, p = 0.045). None of the remaining covariates influenced LF and DLF 343 
pharmacokinetics (?OFV ? -1.4, p ? 0.24). Multivariable combination of the significant 344 
covariates showed an additive influence of pregnancy and diarrhea on F1 and pregnancy on K23 345 
(?OFV = -33, p = 3.2·10-7 with respect to the model without covariates). Our results show that 346 
relative bioavailability is 34% lower and metabolism rate 78% higher in pregnant women 347 
compared to non-pregnant patients. A decrease of 83% in F1 was observed in women with 348 
diarrhea as compared to those who had no diarrhea. Table 3 illustrates the final model 349 
parameters’ estimates together with their bootstrap evaluations. The model was considered 350 
reliable since the obtained parameter estimates laid within the bootstrap CI95%. Figure 2B shows 351 
the concentration time-plots of LF and DLF for pregnant and non-pregnant women included in 352 
the analysis with average population predictions and 95% intervals.  353 
Concentration-time simulation of lumefantrine 354 
The day 7 predicted median concentrations of LF after administration of a 6-dose regimen over 3 355 
days were 908 (PI95% : 217 – 3256) ng/ml for pregnant women and 1382 (PI95%: 386 – 5135) 356 
ng/ml for non-pregnant women (p = 0.10). While considering the large inter-patient variability in 357 
the kinetics of LF, 3% of the pregnant women would have day 7 concentrations below the cut-off 358 
value of 175 ng/ml, 9% below 280 ng/ml and 31% below 600 ng/ml. For non-pregnant women, 359 
1% would exhibit day 7 concentrations below the cut-off value of 170 ng/ml, 2% below 280 360 
ng/ml and 15 % below 600 ng/ml. Prolonging the time of drug administration over 5 days among 361 
pregnant women would provide median concentrations of 1374 (PI95% 367 – 5536) ng/ml, with 362 
0.1%, 2% and 16% of patients with concentrations below the cut-off value of 175 ng/ml, 280 363 
ng/ml and 600 ng/ml, respectively [Figure 3]. 364 
Pharmacodynamics  365 
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There were a total of 7 therapeutic failures in the study, 6 (18.2%) pregnant women and 1 (4.5%) 366 
non-pregnant woman (OR = 4.04; p = 0.22). Among pregnant women, one developed ETF at day 367 
1. She presented with signs and symptoms suggestive of severe malaria, was admitted and kept 368 
on full dose of intravenous quinine. One pregnant women had LCF, presented with fever (body 369 
temperature = 38.7
0
C) at day 20, blood slide confirmed to have parasitaemia of 10,750 370 
counts/µL. The remaining four pregnant women had LPF, one at day 28 and three at day 42. One 371 
non-pregnant woman had LPF at day 28. Hence, the overall PCR uncorrected efficacy of AL in 372 
the study was 87%, 82% (6/33) in pregnant women and 95% (1/22) in non-pregnant women. 373 
PCR investigation confirmed recrudescent infection in two women, one with ETF and the other 374 
with LCF, both pregnant; the remaining 5 (71%) had new infections.   375 
Analysis of day 7 LF concentration was done irrespective of the nature of the failure (new 376 
infection or a recrudescence). The mean day 7 plasma concentration was 971 (726 – 1216) ng/ml 377 
in pregnant and 1261 (999 – 1522) ng/ml in non-pregnant women (p = 0.109) [Figure 4A]. Day 7 378 
LF concentration was significantly lower among women with therapeutic failure than those with 379 
ACPR. The mean LF concentration among women with ACPR was 1154 (967 – 1341) ng/ml 380 
whereas, for the women with LCF and LPF it was 507 (95 – 919) ng/ml (p = 0.029) [Figure 4B]. 381 
Twenty percent of study participants had day 7 LF concentrations below 600 ng/ml. Only two 382 
patients (33%) out of six among the ones who developed LCF and LPF had day 7 LF 383 
concentrations below 600 ng/ml and all were pregnant. Potential predictors of treatment failure 384 
in addition to day 7 LF concentration were pregnancy status, gestational age, baseline parasite 385 




The study describes the pharmacokinetic properties of AM, LF and their active metabolites DHA 388 
and DLF in pregnant and non-pregnant women with malaria. The role of different covariates that 389 
could influence AL bioavailability, distribution and clearance in the two groups were carefully 390 
analyzed. The study differs from previous reports of population pharmacokinetics of AM and LF 391 
in pregnancy (16, 18, 19) by having a comparative group of non-pregnant women with malaria 392 
from the same population with relatively similar characteristics.  393 
Prior treatment. Detectable residual antimalarial among recruited participants was 394 
unexpectedly high. This might be explained by uncontrolled prescription of AL, a first line 395 
malaria treatment, which is highly available and easily accessible from both private and public 396 
facilities (42, 43). Prevalence of residual antimalarial among participants was higher than what 397 
was reported five years ago from in vivo studies in Ifakara (Tanzania) and Praeh Vihear 398 
(Cambodia) which was 74.3% and 50%, respectively (28, 29). Such high prevalence of residual 399 
antimalarial levels in this population, particularly LF, is alarming because it can promote 400 
emergence and spread of drug resistance parasite. Also, the high residual prevalence of LF, 401 
irrespective of pregnancy trimester suggests a considerable AL exposure in the first trimester. 402 
There is an urgent need to monitor closely the implementation of standard malaria treatment 403 
guideline and discourage self-treatment by not acquiring antimalarial from drug venders without 404 
attended and screened for presence of malaria parasitaemia. Significant levels of detected 405 
sulfadoxine among pregnant women were probably the result of SP received from RCH clinic for 406 
Intermittent Preventive Treatment (IPTp).  407 
Pharmacokinetics. LF pharmacokinetics is known to exhibit a multi-compartment disposition. 408 
The short sampling duration in the present study, however, prevented an appropriate 409 
characterization of the drug profound disposition. A simple one-compartment model was thus 410 
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employed to describe LF concentration-time profile. The important study finding was the lower 411 
LF plasma concentration among pregnant patients compared to non-pregnant ones. This is 412 
similar to what has been observed in a Thailand study in which the concentration of LF was 413 
approximately half that of non-pregnant patients from historical data in the same population (16). 414 
The reason for low LF concentration may be due to physiological changes related to pregnancy 415 
status which accounts for reduced absorption, expanded volume of distribution, elevated drug 416 
metabolism and clearance rate (6). The observed increase in LF metabolism rate among pregnant 417 
women is explained by hormonal changes in pregnancy which increases catalytic activity of   418 
hepatic enzymes such as CYP3A4, an important enzyme for LF metabolism (11). The design of 419 
the study did not allow displaying the effect of reduced absorption on LF bioavailability. 420 
Altered bowel condition such as having diarrhea during malaria treatment has a significant effect 421 
on drug absorption and consequently lowers drug bioavailability. Increase of gastro-intestinal 422 
motility due to diarrhea reduces intestinal transit time of a drug, and this time is important to 423 
maximize drug absorption (44). The latter explains why LF concentration, a high lipophilic 424 
compound, was 83% lower in women with diarrhea compared to the ones with no diarrhea. It is 425 
therefore important to assess for presence of diarrhea in patients and correct dosage regimens 426 
accordingly. 427 
It is important to study concentration levels of a slowly eliminated partner antimalarial drug such 428 
as LF so as to determine minimum parasiticidal concentration (MPC) and minimum inhibitory 429 
concentration (MIC) of malaria parasite (20). The observed day 7 median concentration of LF 430 
was lower in pregnant than in non-pregnant women. However, the concentration among pregnant 431 
women was twofold higher compared to what had been observed in Thai pregnant patients (19). 432 
It is also higher than the concentrations previously reported in non-pregnant adults and paediatric 433 
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patients in Ifakara-Tanzania, Thailand, Cambodia and the Lao People’s Democratic Republic 434 
(22, 24, 45, 46). Higher day 7 LF levels in the present study may be due to the administration of 435 
a standard recommended adult dose of AL with food (5) to all patients regardless of the patient’s 436 
body weight.  437 
The observed higher AM clearance in pregnant as opposed to non-pregnant women, although not 438 
statistically significant, could explain the differences in the therapeutic outcome. Little has been 439 
done on AM bioassay in relation to its specific role on therapeutic efficacy in pregnancy as 440 
opposed to LF. AM can better explain ETF and hence, further studies are encouraged with 441 
detailed assessment on AM pharmacokinetics despite of its shorter half-life.  442 
The simulations under the standard 6 dose of AL over 3 days schedule show that a non-443 
negligible number of pregnant women would have LF concentrations below various proposed 444 
therapeutic threshold targets at day 7. Splitting the same recommended total dose over a 5 day 445 
regimen would greatly improve the probability of exhibiting therapeutic drug concentrations. 446 
The latter has already been shown in other pharmacokinetics studies (22, 23, 47), but the benefit 447 
might be jeopardized by poor adherence to treatment in the prolonged regimen. Hence, a formal 448 
assessment of feasibility should be performed.   449 
Pharmacodynamics. The observed cure rate and parasite clearance in pregnant women was 450 
lower compared to that of non-pregnant patients despite having the same median baseline 451 
parasitaemia. The observed lower LF concentration at day 7 among the patients with therapeutic 452 
failure could be one of the reasons explaining this difference. In order to improve therapeutic 453 
efficacy, it is therefore important to consider dose increase or modifying treatment regimen to 454 
allow higher day 7 LF concentrations. Day 7 LF concentration above 600 ng/dl was associated 455 
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with 100% efficacy among pregnant patients in Thailand (40). The latter was not observed in our 456 
study; indeed 3 out of the 5 (60%) pregnant women with LCF or LTF had day 7 LF 457 
concentration above 600 ng/ml. This observation suggests that the proposed 600 ng/dl cut-off 458 
value better predicts parasite clearance of ongoing infection, rather than occurrence of new 459 
infection in the follow-up period. 600 ng/dl LF concentration at day 7 is not high enough to 460 
ensure post-treatment prophylaxis effect up to day 42.  Indeed, reinfections were not all 461 
prevented with a day 7 LF concentration of 600 ng/ml. Partner drugs with longer half-life might 462 
offer better protection (20). 463 
Baseline parasitaemia was not an important factor to determine therapeutic response among 464 
study participants. Indeed mean baseline parasite count in patients with ACPR was twofold 465 
higher compared to the ones with therapeutic failure. This is contrary to what has been reported 466 
in previous studies involving pregnant and non-pregnant patients in which patients with higher 467 
baseline parasitaemia were more likely to fail treatment (40, 47). However, baseline peripheral 468 
parasitaemia in pregnant women usually does not tell much about the actual picture of parasite 469 
level that a pregnant woman might have because of parasite sequestration in the placenta (48). 470 
Therapeutic failure rate among pregnant women in our study was much lower than that observed 471 
in Thailand in recent AL pharmacodynamics studies whereby therapeutic failure among pregnant 472 
patients was more than 30% (19, 40). We have reason to believe that AL is more efficacious in 473 
Africa than in Southeast Asia where resistance to other antimalarial drugs such as quinine, 474 




The current AL treatment regimen in pregnancy is challenged by having low post-treatment 477 
prophylactic effect. Pregnancy is an important associated factor for low plasma concentration of 478 
LF probably due to reduced drug absorption, elevated drug metabolism and rapid clearance rate. 479 
It is therefore important to evaluate new treatment regimens of AL in this vulnerable group that 480 
would target higher day 7 LF concentration levels.  481 
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Tables and figures 670 





Pregnant women (n=33) Non-pregnant women (n=22) 
Median (range) Median (range) 
Age (years) 25 (18 -41) 21.5 (18 -35) 
Body weight (Kg) 52 (40 – 80) 48.5 (41 – 79) 
Height (cm) 158 (147 – 169) 157 (150 – 174) 
BMI 21.8 (16.5 – 30.1) 20.3 (16.4 – 33.3) 
Haemoglobin (g/dl) 10.2 (7.1 – 13.3) 13.4 (8 – 15.5) 
Temperature (
0
C) 37.1 (36.0 – 39) 37.2 (36.0 – 39.6) 
Parasitaemia (counts/µL) 25,280 (560 – 198,080) 22,280 (560 – 195,680) 
Gestation age (weeks) 27 (14 – 37) NA 
*Pregnancy – trimesters   
Second trimester (%) 17 (52) NA 
Third trimesters (%) 16 (48) NA 
*Trimester presented in number (%). NA means not applicable 672 
Table 2: Plasma concentration of residual antimalarial drugs detected prior to treatment with AL 673 







Plasma concentration [ng/ml] 
Mean Median Minimum Maximum 
Lumefantrine 51 (89.5)  37.3 24.9 5.4 205.5 
Desbutyl-
limefantrine 
8 (14.0)  2.5 1.5 0.3 6 
Artemether 4 (7)  26.4 2.9 0.4 157.3 
Sulfadoxine 14 (24.6)  1,334.3 1,298.1 5.3 3,615.6 
Pyrimethamine 11 (19.6)  6.9 5.3 1.7 18 




Table 3: Final population parameter estimates of artemether, lumefantrine and their metabolites 676 
and their bootstrap evaluations in 2000 replicates 677 
Population pharmacokinetics analysis Bootstrap evaluation 



















CL (L/h) 98 24 99 65 102 69-140 93 66-120 
Vc (L) 373 16   354 225-492   
LogitF1 1.4 27   1.5 0.7-2.6   
Ka (h
-1) Fixed to 0.70       
VM (L) Fixed to Vc       
K23 (h
-1) 0.084    0.088 0.05-0.16   
CLM(L/h) 71 46   69 38-136   
?prop,AM (CV%) 72 26   69 49-87   
?add,AM 
(?mol/L) 
0.13 7   0.13 0.03-0.20   
?prop,DHA (CV%) 53 14   51 44-59   
Lumefantrine         
CL (L/h) 2.8 12   2.8 2.2-3.6   
Vc (L) 134 14   134 101-174   
F1 Fixed to 1 65 50    61 43-77 
?PregF1 -0.33 37   -0.31 -(0.52-0.05)   
?diarrF1 -0.84 15   -0.78 -(0.95-0.44)   
Ka (h
-1) Fixed to 0.54       
VM (L) Fixed to Vc        
F0 (mg) 2.7 18 87 46 2.95 1.9-4.4 116 70-164 
K23 (h
-1) 1.6·10-4  46 54 1.6·10-4 (1.2-2.0)·10-4 44 31-57 
?PregK23 0.80 32   0.80 0.4-1.3   
CLM(L/h) 2.6 15   2.6 1.9-3.5   
?prop,LF (CV%) 51 32c   51 45-56   
?prop,DLF(CV%) 39 40c   38 32-44   
Correlation 
LF/DLF 
68 18   67 63-69   
?add,DLF(?mol/L) 4.4·10-3 17c   4.9·10-3 (3.8-6.1)·10-3   
29 
 
Abbreviations: CL: clearance, VC: central volume of distribution, logitF1: logit F1 678 
expressed as a logit function, ka: first-order absorption rate constant, VM: volume of 679 
distribution of the metabolite, F0: residual amount from the previous treatment, k23: 680 
metabolism rate constant, CLmet: metabolite clearance, ?prop: exponential residual error, 681 
?add: additive residual error, ?X PAR: effect of the X covariate on the parameter PAR 682 
expressed as (1- ?X PAR X). 683 
a
 Standard error (S.E.) of the estimate ?i defined as S.E estimate/estimate, expressed as a 684 
percentage  685 
b
 Inter-individual variability  686 
c
 Standard error (S.E.) of the coefficient of variation or the additive component of the 687 
residual error defined as ?S.E estimate/estimate, expressed as a percentage 688 
d
 95% confidence interval (C.I.)  689 
 690 
Figure 1: Relationship between parasite density at enrollment and plasma residual levels of 691 
sulfadoxine prior treatment in 14 pregnant women  692 
   693 


























Figure 2A:  Observed AM (left panel) and DHA plasma concentrations (right panel). Filled and 694 
empty circles represent pregnant and non-pregnant women, respectively. The solid line 695 
represents the average predicted concentrations and the dashed lines the 95
th
 prediction intervals. 696 
697 
Figure 2B: Observed LF (upper panels) and DLF plasma concentrations (lower panels) in 698 
pregnant and non-pregnant women. Triangles residual plasma concentrations of LF and DLF 699 
found prior treatment initiation. The solid lines represent the mean population prediction and the 700 






Figure 3: Predicted median concentration of lumefantrine (LF) after administration of 704 
6·480 mg regimen over 3 (continuous line) and 5 days (dotted line) in pregnant women. 705 
Day 7 (168h) median predicted concentrations (circles) with their PI95% are shown for the 706 
two dosage regimens.  707 
 708 
 709 
Figure 4A: Day 7 plasma concentration of lumefantrine in pregnant (n = 32) and non-pregnant 710 
(n = 22) study women 711 






































Figure 4B: Day 7 plasma concentration of lumefantrine in women with ACPR (n = 48) and 713 
those with treatment failure (n = 6) * 714 
 715 
* Day 7 lumefantrine concentration could not be assessed in one woman since a rescue treatment 716 
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